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  of	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  of	  the	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Ka:	  Absorption	  rate	  constant	  
K12,	  K21:	  Micro-­‐rate	  constants	  of	  distribution	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xvi 
Peff:	  Effective	  permeability	  
P-­‐gp:	  P-­‐glycoprotein	  
PHT1/2:	  peptide	  histidine	  transporters	  1	  and	  2	  
PK:	  Pharmacokinetics	  
PEPT1:	  Peptide	  transporter	  1	  
PEPT2:	  Peptide	  transporter	  2	  
POT:	  Proton-­‐coupled	  oligopeptide	  transporter	  
Pw:	  Permeability	  at	  the	  intestinal	  wall	  
Tmax:	  Time	  at	  which	  the	  maximum	  concentration	  is	  observed	  
Vc:	  Volume	  of	  distribution	  in	  the	  central	  compartment	  
Vdss:	  Volume	  of	  distribution	  steady	  state	  
Vp:	  Volume	  of	  distribution	  in	  the	  peripheral	  compartment	  
Vmax:	  Maximal	  uptake	  rate	  
	   	  
xvii 
ABSTRACT	  
Although	  PEPT1	  is	  the	  most	  important	  pathway	  in	  the	  absorption	  of	  di-­‐	  and	  tri-­‐
peptides	  in	  the	  small	  intestine,	  its	  in	  vivo	  relevance	  in	  the	  absorption,	  tissue	  
distribution,	  and	  disposition	  of	  pharmacologically	  active	  compounds	  is	  still	  not	  well	  
understood.	  Hence,	  we	  decided	  to	  study	  the	  role	  of	  PEPT1	  in	  the	  following:	  1)	  the	  
intestinal	  permeability	  of	  cefadroxil,	  2)	  the	  in	  vivo	  pharmacokinetics	  of	  cefadroxil,	  
and	  finally	  3)	  the	  in	  silico	  absorption	  and	  pharmacokinetics	  of	  cefadroxil	  using	  the	  
advanced	  compartmental	  absorption	  and	  transit	  (ACAT)	  model	  built	  into	  
Gastroplus®.	  Cefadroxil	  was	  chosen	  as	  a	  model	  drug	  to	  study	  PEPT1	  because	  of	  its	  
good	  metabolic	  stability	  and	  commercial	  availability	  as	  a	  radiolabeled	  compound.	  
The	  findings	  show	  that	  PEPT1	  was	  responsible	  for	  90%	  of	  the	  effective	  permeability	  
(Peff)	  of	  cefadroxil.	  PEPT1	  transport	  of	  cefadroxil	  in	  the	  jejunum	  of	  wild-­‐type	  mice	  
had	  a	  Km	  of	  3.8	  mM	  and	  a	  Vmax	  of	  4.75	  nmol/cm2/s.	  Also,	  the	  Peff	  in	  the	  duodenum,	  
jejunum,	  and	  ileum	  were	  significantly	  higher	  in	  wild-­‐type	  than	  in	  PEPT1	  knockout	  
mice,	  but	  not	  in	  colon	  where	  the	  Peff	  was	  very	  low	  in	  both	  genotypes.	  After	  oral	  
administration,	  the	  Cmax	  and	  AUC0-­‐120	  across	  all	  doses	  were	  lower	  in	  knockout	  mice	  
than	  in	  wild-­‐type	  animals.	  There	  was	  also	  an	  “apparent”	  linearity	  in	  the	  Cmax	  and	  
AUC0-­‐120	  for	  both	  genotypes.	  However,	  the	  analysis	  of	  the	  intravenous	  data	  showed	  
no	  difference	  in	  disposition	  between	  genotypes.	  The	  third	  specific	  aim	  was	  an	  effort	  
to	  integrate	  the	  experimental	  results	  and	  to	  retrospectively	  model	  the	  absorption	  
and	  pharmacokinetics	  of	  cefadroxil	  using	  an	  ACAT	  model.	  In	  the	  knockout	  mice,	  a	  
good	  prediction	  of	  plasma	  concentration-­‐time	  profiles	  was	  obtained	  for	  all	  doses	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studied.	  In	  the	  wild-­‐type	  mice,	  the	  plasma	  concentration-­‐time	  profiles	  for	  the	  lower	  
doses	  were	  reproduced.	  The	  model	  predicts	  saturation	  of	  the	  intestinal	  PEPT1	  at	  
higher	  concentrations	  in	  wild-­‐type	  mice	  that	  was	  not	  seen	  experimentally,	  probably	  
due	  to	  a	  simultaneous	  saturation	  of	  the	  active	  tubular	  secretion	  and	  reabsorption,	  
resulting	  in	  an	  apparent	  linearity	  of	  the	  plasma	  concentration-­‐time	  profiles	  as	  a	  
function	  of	  dose.	  A	  physiologically-­‐based	  pharmacokinetic	  model	  will	  need	  to	  be	  
developed	  to	  take	  into	  account	  the	  saturation	  in	  cefadroxil	  renal	  clearance.	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CHAPTER	  1	  	  
	  
INTRODUCTION	  AND	  RESEARCH	  OBJECTIVES	  
	  
	  
Proton-­‐coupled	  oligopeptide	  transporters,	  also	  known	  as	  peptide	  
transporters,	  are	  a	  family	  of	  membrane	  transport	  proteins	  present	  in	  a	  broad	  range	  
of	  species,	  from	  bacteria	  to	  mammals.	  These	  proteins	  transport	  di-­‐	  and	  tri-­‐
peptides—themselves	  products	  of	  protein	  degradation—and	  other	  peptide-­‐like	  
molecules	  across	  different	  membranes	  in	  the	  body.	  These	  transporters	  are	  usually	  
located	  in	  the	  brush	  border	  membrane	  (apical	  side)	  of	  epithelial	  cells.	  They	  co-­‐
transport	  peptides	  and	  protons	  into	  the	  cell	  cytosol,	  down	  an	  inwardly-­‐directed	  
proton	  gradient	  and	  negative	  membrane	  potential.	  	  
Proton-­‐coupled	  oligopeptide	  transporters	  have	  been	  found	  in	  many	  species.	  
In	  humans	  four	  types	  have	  been	  cloned	  and	  identified:	  PEPT1,	  PEPT2,	  PHT1	  and	  
PHT2.	  The	  first	  two,	  PEPT1	  and	  PEPT2,	  can	  transport	  di-­‐	  and	  tri-­‐peptides	  with	  
different	  sequences	  and	  charges,	  but	  not	  single	  amino	  acids	  or	  peptides	  longer	  than	  
4	  amino	  acid	  residues.	  The	  last	  two,	  PHT1	  and	  PHT2,	  can	  transport	  histidine,	  along	  
with	  some	  di-­‐	  and	  tri-­‐peptides.	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PEPT1	  is	  a	  high-­‐capacity	  and	  low-­‐affinity	  transporter,	  expressed	  
predominantly	  in	  the	  small	  intestine,	  and	  to	  a	  lesser	  extent	  in	  the	  kidney,	  pancreas,	  
and	  liver.	  PEPT2	  is	  a	  high-­‐affinity	  and	  low-­‐capacity	  transporter	  expressed	  in	  the	  
kidney,	  mammary	  gland	  epithelium,	  brain	  and	  choroid	  plexus,	  lungs,	  and	  enteric	  
nervous	  system,	  but	  not	  in	  the	  intestinal	  epithelium.	  	  
Understanding	  the	  importance	  of	  PEPT1	  contribution	  to	  the	  absorption,	  
tissue	  distribution,	  and/or	  disposition	  of	  peptides	  and	  peptide–like	  drugs	  has	  been	  a	  
goal	  of	  several	  research	  groups	  for	  the	  past	  30	  years.	  This	  transporter	  has	  been	  
shown	  to	  be	  relevant	  in	  the	  in	  vitro	  uptake	  of	  di-­‐	  and	  tri-­‐peptides	  and	  certain	  
peptide-­‐like	  drugs,	  such	  as	  beta-­‐lactam	  antibiotics,	  angiotensin-­‐converting	  enzyme	  
and	  renin	  inhibitors,	  and	  some	  anticancer	  drugs	  like	  bestatin.	  It	  also	  has	  been	  shown	  
to	  be	  relevant	  in	  the	  absorption	  of	  di-­‐peptides,	  such	  as	  Gly-­‐Sar,	  though	  to	  date	  
nobody	  has	  actually	  shown	  its	  relevance	  and	  contribution	  to	  the	  in	  vivo	  and	  in	  situ	  
absorption,	  tissue	  distribution	  and	  disposition	  of	  pharmacologically	  relevant	  
molecules.	  	  
When	  it	  comes	  to	  studying	  drug	  transport,	  Caco-­‐2	  cells	  are	  convenient,	  
inexpensive,	  and	  ideal	  for	  screening	  and	  preliminary	  experiments.	  It	  is	  widely	  
known	  that	  experimental	  results	  obtained	  with	  these	  cells	  do	  not	  always	  correlate	  
with	  human	  ones	  due	  to	  the	  over	  or	  lack	  of	  expression	  of	  several	  transport	  proteins	  
in	  these	  cells.	  On	  the	  other	  hand,	  ex	  vivo	  experiments	  give	  results	  that	  are	  closer	  to	  
natural	  conditions,	  but	  still	  lack	  the	  intact	  blood	  and	  nerve	  supply.	  Finally,	  in	  situ	  
and	  in	  vivo	  experiments	  require	  the	  most	  time	  and	  resources,	  but	  they	  best	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resemble	  the	  real	  anatomical	  and	  physiological	  conditions,	  giving	  more	  precise	  
results.	  	  
For	  drug	  delivery,	  peptide	  transporters,	  especially	  PEPT1,	  have	  been	  of	  great	  
interest	  to	  researchers	  and	  pharmaceutical	  companies	  because	  of	  their	  broad	  
substrate	  specificity.	  Recent	  research	  activities	  have	  applied	  pro-­‐drug	  strategies	  to	  
target	  this	  transporter	  to	  improve	  drug	  bioavailability	  after	  oral	  dosing.	  One	  
example	  is	  L-­‐Dopa-­‐L-­‐Phe,	  a	  prodrug	  of	  L-­‐Dopa,	  which	  is	  effectively	  absorbed	  in	  the	  
small	  intestine,	  and	  is	  used	  in	  the	  treatment	  of	  Parkinson’s	  disease.	  
In	  the	  proposed	  study,	  cefadroxil	  has	  been	  chosen	  as	  a	  model	  drug	  to	  
investigate	  the	  role	  of	  PEPT1	  in	  drug	  absorption	  because	  it	  has	  several	  advantages.	  
For	  example,	  it	  has	  been	  shown	  to	  be	  a	  substrate	  for	  PEPT1.	  Also,	  since	  this	  
antibiotic	  is	  very	  stable,	  quantification	  strategies	  are	  less	  demanding.	  Cefadroxil	  is	  
excreted	  unchanged	  in	  the	  urine;	  it	  is	  not	  hydrolyzed	  in	  the	  acidic	  environment	  of	  
the	  stomach	  or	  degraded	  by	  intra-­‐	  or	  extracellular	  enzymes.	  Moreover,	  cefadroxil	  is	  
commercially	  available	  as	  a	  radiolabeled	  compound,	  allowing	  its	  detection	  and	  
quantification	  in	  very	  small	  quantities	  of	  blood,	  body	  fluids,	  tissues	  and	  organs.	  	  
Due	  to	  its	  chemical	  structure	  and	  its	  high	  steric	  resemblance	  to	  physiological	  
occurring	  tri-­‐peptides,	  cefadroxil	  has	  a	  high	  affinity	  for	  PEPT1,	  allowing	  us	  to	  
hypothesize	  that	  its	  absorption	  will	  be	  affected	  by	  the	  deletion	  of	  this	  protein.	  	  
Different	  from	  other	  di-­‐	  and	  tri-­‐peptides	  previously	  used	  in	  PEPT1	  research	  (e.g.	  
Gly-­‐Sar),	  cefadroxil	  is	  pharmaceutically	  relevant,	  since	  it	  has	  been	  widely	  used	  to	  
treat	  several	  bacterial	  infections	  in	  the	  skin,	  urinary	  tract,	  and	  upper	  respiratory	  
airways.	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In	  order	  to	  better	  comprehend	  the	  transporter’s	  contribution	  to	  the	  
absorption,	  distribution	  and	  disposition	  of	  cefadroxil,	  it	  is	  necessary	  to	  compare	  the	  
drug’s	  behavior	  in	  systems	  where	  the	  transporter	  is	  present	  to	  those	  where	  the	  
transporter	  is	  not.	  In	  our	  laboratory,	  viable	  PEPT1	  knockout	  mice	  were	  developed	  
and	  have	  been	  proven	  to	  be	  a	  useful	  tool	  for	  the	  study	  of	  this	  protein.	  Having	  PEPT1	  
knockout	  mice	  as	  an	  experimental	  tool	  provides	  a	  unique	  opportunity	  to	  study	  the	  
importance	  of	  PEPT1	  in	  the	  kinetics	  of	  cefadroxil	  oral	  absorption,	  as	  well	  as	  the	  
kinetics	  of	  cefadroxil	  distribution	  and	  elimination	  from	  the	  body.	  In	  this	  project,	  I	  
studied	  the	  contribution	  of	  PEPT1	  in	  the	  absorption	  and	  pharmacokinetics	  of	  
cefadroxil	  by	  doing	  the	  following:	  	  
1)	  Measuring	  the	  contribution	  of	  PEPT1	  to	  the	  intestinal	  permeability	  of	  
cefadroxil	  and	  the	  influence	  of	  pH,	  sodium,	  substrate	  concentration,	  and	  intestinal	  
segment	  on	  drug	  uptake,	  using	  an	  in	  situ	  single-­‐pass	  perfusion	  technique	  in	  wild	  
type	  and	  PEPT1	  knockout	  mice.	  	  
2)	  Determining	  the	  contribution	  of	  PEPT1	  to	  the	  in	  vivo	  absorption,	  tissue	  
distribution,	  and	  disposition	  of	  cefadroxil	  using	  wild	  type	  and	  PEPT1	  knockout	  mice.	  
3)	  Establishing	  an	  in	  silico	  model	  of	  the	  absorption	  and	  pharmacokinetics	  of	  
cefadroxil	  in	  wild	  type	  and	  PEPT1	  knockout	  mice	  using	  an	  advanced	  compartmental	  
absorption	  and	  transit	  (ACAT)	  model.	  
	   	  
 




CHAPTER	  2	  	  
	  
BACKGROUND	  AND	  LITERATURE	  REVIEW	  
	  
Anatomy	  and	  Physiology	  of	  the	  Small	  Intestine	  
The	  small	  intestine	  is	  the	  longest	  part	  of	  the	  gastrointestinal	  tract	  and	  is	  
located	  between	  the	  stomach	  and	  the	  large	  intestine.	  It	  consists	  of	  3	  parts	  that	  look	  
very	  similar	  to	  the	  naked	  eye,	  but	  differ	  at	  the	  microscopic	  level	  [1].	  The	  first	  part	  of	  
the	  small	  intestine	  is	  called	  the	  duodenum.	  In	  adult	  humans	  the	  duodenum	  is	  
approximately	  25	  cm	  and	  has	  a	  pH	  between	  1-­‐2	  at	  fasted	  conditions.	  The	  
subsequent	  segment	  of	  the	  small	  intestine	  is	  called	  the	  jejunum.	  It	  is	  about	  250	  cm	  
long	  and	  has	  an	  approximate	  pH	  of	  6.5.	  The	  final	  part	  of	  the	  small	  intestine	  is	  called	  
the	  ileum	  and,	  like	  the	  jejunum,	  but	  unlike	  the	  duodenum,	  is	  attached	  to	  the	  body	  by	  
the	  mesentery.	  The	  ileum	  is	  between	  200	  and	  400	  cm	  long	  and	  has	  an	  approximate	  
pH	  of	  6.6	  during	  fasting	  conditions	  [1].	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The	  absorption	  of	  most	  nutrients	  and	  orally	  administered	  drugs	  takes	  part	  in	  
the	  small	  intestine.	  This	  is	  mostly	  due	  to	  its	  vast	  surface	  area,	  given	  the	  arrangement	  
of	  the	  intestinal	  wall	  [1]	  (Figure	  2.1)The	  surface	  of	  the	  intestinal	  wall	  contains:	  1)	  
circular	  folds	  (plicae	  circularis),	  2)	  small	  projections	  called	  villi,	  and	  3)	  tiny	  
projections	  called	  microvilli.	  	  
The	  circular	  folds	  form	  creases	  and	  ridges	  that	  do	  not	  disappear	  when	  the	  
intestine	  is	  extended,	  and	  can	  be	  seen	  with	  the	  naked	  eye.	  Villi	  are	  microscopic	  
structures	  that	  have	  a	  hair-­‐like	  shape	  and	  measures	  around	  0.5	  to	  1.5	  mm	  in	  height	  
depending	  on	  the	  intestinal	  segment.	  Each	  villus	  plays	  an	  important	  role	  in	  the	  
exchange	  of	  nutrients	  and	  drugs	  because	  it	  contains	  a	  capillary	  network	  and	  a	  lymph	  
vessel	  [1].	  Microvilli	  are	  cytoplasmic	  protrusions	  or	  extensions	  of	  the	  plasma	  
membrane	  on	  the	  apical	  (luminal)	  side	  of	  the	  intestinal	  columnar	  epithelial	  cells,	  
also	  known	  as	  enterocytes	  or	  absorptive	  cells.	  It	  is	  because	  of	  these	  hair-­‐like	  
microstructures	  that	  the	  apical	  membrane	  is	  also	  known	  as	  the	  brush-­‐border	  
membrane.	  Each	  absorptive	  cell	  can	  have	  as	  many	  as	  3000	  of	  these	  structures	  in	  its	  
apical	  membrane,	  and	  each	  one	  can	  be	  up	  to	  1	  µm	  in	  length	  [1,	  2].	  	  
The	  intestinal	  wall	  is	  a	  thick	  barrier	  that	  consists	  of	  four	  broad	  concentric	  
layers:	  1)	  the	  mucosa,	  2)	  the	  submucosa,	  3)	  the	  muscularis	  externa,	  and	  4)	  the	  
serosa	  or	  adventitia	  [1,	  2].	  The	  mucosa	  faces	  the	  luminal	  side	  of	  the	  intestine	  and	  is	  
composed	  of	  the	  simple	  columnar	  epithelium,	  the	  lamina	  propia,	  and	  the	  muscularis	  
mucosae.	  The	  epithelium	  is	  a	  monolayer	  made	  up	  of	  4	  different	  types	  of	  cells:	  
absorptive,	  goblet,	  APUD,	  and	  M	  cells.	  The	  absorptive	  cells	  are	  the	  most	  numerous	  
ones	  in	  the	  epithelium	  and	  are	  located	  on	  the	  tips	  of	  the	  villi.	  The	  two	  principal	  
 
  7 
functions	  of	  these	  cells	  are	  to	  produce	  and	  secrete	  enzymes,	  and	  to	  absorb	  nutrients.	  
The	  goblet	  cells	  produce	  and	  secrete	  mucus,	  and	  are	  also	  located	  on	  the	  tips	  of	  the	  
villi.	  Both	  the	  absorptive	  and	  the	  goblet	  cells	  are	  generated	  from	  undifferentiated	  
cells	  in	  the	  crypts	  of	  Lieberkuhn.	  They	  then	  differentiate	  and	  migrate	  to	  the	  tips	  of	  
the	  villi.	  APUD	  cells,	  which	  stand	  for	  amine	  precursor	  uptake	  and	  decarboxylation	  
cells,	  produce	  hormones	  that	  regulate	  different	  functions	  in	  the	  intestine,	  such	  as	  
mobility	  and	  secretion.	  M	  cells,	  also	  known	  as	  microfold	  cells,	  specialize	  in	  sampling,	  
phagocyting,	  and	  transporting	  antigens	  from	  the	  intestinal	  lumen.	  These	  last	  two	  
types	  of	  cells	  are	  produced	  in	  the	  crypts	  of	  Lieberkuhn	  and	  do	  not	  migrate	  to	  the	  top	  
of	  the	  villi	  [2].	  
The	  next	  sublayer	  of	  the	  mucosa,	  the	  lamina	  propia,	  is	  the	  connective	  tissue	  
that	  holds	  the	  epithelium.	  It	  contains	  collagen	  fibers,	  elastic	  fibers,	  blood	  and	  lymph	  
capillaries,	  and	  lymph	  cells.	  The	  blood	  and	  lymph	  vessels	  are	  located	  close	  to	  the	  
epithelium	  to	  facilitate	  absorption	  [2].	  	  
The	  layer	  above	  the	  lamina	  propia	  is	  called	  the	  muscularis	  mucosae.	  This	  
stratum	  consists	  of	  two	  thin	  layers	  of	  smooth	  muscle.	  The	  fibers	  of	  the	  internal	  layer	  
are	  arranged	  in	  a	  circular	  manner,	  while	  those	  of	  the	  external	  layer	  are	  arranged	  
longitudinally.	  Both	  of	  these	  layers	  are	  responsible	  for	  the	  contraction	  of	  the	  villi	  
during	  digestion	  [1].	  	  
The	  submucosa	  is	  the	  tissue	  section	  above	  the	  muscularis	  mucosae.	  It	  has	  a	  
rich	  and	  well-­‐developed	  network	  of	  blood	  and	  capillary	  vessels,	  and	  is	  highly	  
innervated	  with	  parasympathetic	  nerves.	  The	  submucosa	  of	  the	  duodenum	  has	  an	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unusual	  type	  of	  gland,	  the	  Brunner’s	  Glands.	  These	  duodenal	  glands	  produce	  
mucous,	  epidermal	  growth	  factor,	  and	  bicarbonate	  rich	  fluid	  [1].	  	  
The	  muscularis	  externa	  is	  the	  outer	  most	  level	  of	  the	  intestine,	  and	  is	  
responsible	  for	  peristaltic	  movements.	  It	  is	  composed	  of	  two	  layers	  of	  smooth	  
muscle—i.e.	  an	  inner	  circular	  layer,	  and	  an	  outer	  longitudinal	  one—and	  a	  middle	  
layer	  of	  nerve	  fibers	  [1].	  	  
As	  mentioned	  above	  the	  intestinal	  wall	  is	  highly	  perfused	  with	  blood	  vessels.	  
The	  arterial	  blood	  that	  reaches	  the	  jejunum	  and	  the	  ileum	  comes	  from	  the	  superior	  
mesenteric	  artery,	  while	  the	  venous	  blood	  is	  transported	  to	  the	  portal	  vein	  and	  
eventually	  to	  the	  liver	  [2].	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Absorption	  and	  Transport	  Mechanisms	  
Most	  of	  the	  absorption	  of	  electrolytes,	  nutrients,	  water	  and	  drugs	  occurs	  in	  
the	  proximal	  segment	  of	  the	  small	  intestine,	  which	  is	  facilitated	  by	  its	  vast	  surface	  
area.	  For	  a	  molecule	  to	  go	  from	  the	  lumen	  of	  the	  intestine	  to	  the	  lumen	  of	  the	  blood	  
vessel	  it	  needs	  to	  go	  through	  several	  barriers,	  including	  the	  unstirred	  water	  layer	  in	  
the	  lumen	  of	  the	  intestine,	  the	  apical	  and	  the	  basolateral	  membranes	  of	  the	  
epithelial	  cells,	  the	  intercellular	  space,	  and	  the	  apical	  and	  basolateral	  membranes	  of	  
the	  endothelial	  cells	  [1].	  	  
There	  are	  different	  pathways	  molecules	  can	  cross	  a	  cellular	  membrane,	  
including	  the	  paracellular	  and	  transcellular	  routes.	  Transcellular	  refers	  to	  the	  traffic	  
of	  molecules	  across	  the	  interior	  of	  a	  cell,	  while	  paracellular	  means	  the	  traffic	  in	  	  
Probetween	  the	  cells.	  Transcellular	  transport	  includes	  passive	  diffusion,	  active	  and	  
facilitated	  transport,	  and	  transcytocis	  [3]	  (Figure	  2.2)	  
Different	  physicochemical	  and	  structural	  factors	  influence	  the	  route	  a	  
molecule	  takes	  to	  reach	  the	  blood	  stream.	  Water	  and	  some	  small	  ions,	  like	  chloride	  
and	  potassium,	  are	  transported	  via	  paracellular	  channels,	  a	  process	  driven	  by	  
osmotic	  and	  electrochemical	  gradients	  [3].	  	  
Some	  molecules	  can	  passively	  diffuse	  through	  the	  membrane.	  Passive	  
diffusion	  is	  a	  process	  that	  does	  not	  require	  energy	  because	  the	  movement	  of	  
molecules	  is	  driven	  by	  a	  concentration	  and/or	  an	  electrochemical	  gradient	  [3].	  In	  
passive	  diffusion	  the	  transport	  of	  a	  solute	  across	  a	  membrane	  is	  a	  non-­‐saturable	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process.	  The	  rate	  of	  transport	  or	  flux	  is	  proportional	  to	  the	  solute	  concentration	  
gradient,	  and	  can	  be	  described	  using	  Fick’s	  first	  law	  of	  diffusion,	  according	  to	  the	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X
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2.1)	  
where	  dM/dt	  is	  the	  rate	  of	  transport	  (µg/sec),	  A	  is	  the	  surface	  area	  of	  the	  
membrane	  (cm2),	  D	  is	  the	  diffusion	  coefficient	  (cm2/sec),	  X	  is	  the	  thickness	  of	  the	  
membrane	  (cm),	  and	  Ci-­‐Co	  is	  the	  difference	  of	  solute	  concentration	  between	  the	  two	  
sides	  separated	  by	  the	  membrane	  (µg/mL).	  The	  diffusion	  coefficient	  D	  is	  a	  
parameter	  related	  to	  the	  lipophilicity	  and	  the	  size	  of	  the	  molecule,	  and	  to	  the	  
viscosity	  of	  the	  membrane.	  Usually	  small	  lipophilic	  drugs	  can	  cross	  membranes	  
easier	  than	  large	  hydrophilic	  ones	  [1,	  3,	  4].	  
Large	  hydrophilic	  molecules	  usually	  need	  the	  help	  of	  membrane	  transport	  
proteins	  to	  get	  into	  the	  cytosol.	  There	  are	  two	  types	  of	  membrane	  transport	  
proteins:	  transporters	  and	  channels.	  Channels	  form	  aqueous	  pores	  in	  the	  cell	  
membrane,	  that	  allow	  small	  ions	  and	  water	  to	  go	  through	  it	  without	  binding	  to	  it[3].	  
Transporters	  are	  proteins	  that	  bind	  the	  solute	  and	  after	  a	  series	  of	  conformational	  
changes,	  transfer	  it	  across	  the	  cell	  membrane.	  Some	  transporters,	  but	  no	  channels,	  
can	  transport	  a	  solute	  against	  its	  concentration	  gradient	  or	  electrochemical	  gradient.	  
This	  process	  is	  called	  active	  transport	  because	  it	  uses	  energy,	  e.g.	  from	  ATP	  
hydrolysis,	  to	  pump	  molecules	  across	  the	  membrane	  [3]	  (Figure	  2.3)	  
There	  are	  several	  types	  of	  transporters	  and	  they	  can	  be	  classified	  according	  
to	  the	  source	  of	  energy	  that	  they	  use	  to	  move	  solutes.	  ATP-­‐driven	  pumps	  use	  the	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energy	  that	  results	  from	  the	  hydrolysis	  of	  ATP	  to	  move	  solutes	  uphill	  (against	  a	  
concentration	  gradient)	  [3].	  Coupled	  transporters	  combine	  the	  downhill	  transport	  
of	  a	  molecule	  to	  the	  uphill	  transport	  of	  another.	  These	  can	  either	  be	  symporters,	  in	  
which	  both	  molecules	  go	  in	  the	  same	  direction,	  or	  antiporters,	  in	  which	  they	  move	  
in	  opposite	  ones.	  Na+	  and	  H+	  are	  some	  of	  the	  most	  utilized	  molecules	  by	  coupled	  
transporters	  [3].	  	  
When	  proteins	  are	  ingested,	  they	  get	  degraded	  into	  oligopeptides	  by	  
different	  types	  of	  enzymes.	  Once	  the	  products	  of	  the	  degradation	  of	  these	  proteins	  
reach	  the	  small	  intestine,	  they	  get	  further	  cleaved	  by	  peptidases	  located	  in	  the	  brush	  
border	  membrane	  and	  then	  get	  absorbed,	  mainly	  as	  di-­‐	  and	  tripeptides	  [5].	  Due	  to	  
the	  hydrophilicity	  and	  the	  presence	  of	  charged	  groups,	  it	  has	  been	  shown	  that	  these	  
peptides	  need	  a	  transporter	  protein	  to	  reach	  the	  cytosol	  of	  the	  enterocytes.	  This	  
transporter	  has	  been	  identified	  as	  PEPT1.	  Di-­‐	  and	  tri-­‐peptides	  that	  reach	  the	  cytosol	  
get	  further	  hydrolyzed	  into	  amino	  acids	  by	  intracellular	  peptidases,	  and	  are	  either	  
used	  in	  the	  cell	  or	  get	  released	  by	  amino	  acid	  transporters	  in	  the	  basolateral	  
membrane.	  Some	  peptide-­‐like	  molecules	  do	  not	  undergo	  degradation	  and	  are	  
potentially	  transported	  by	  still	  unknown	  peptide	  transporters	  in	  the	  basolateral	  
membrane	  [6].	  
The	  interaction	  of	  a	  transporter	  and	  its	  substrate	  follows	  the	  Michaelis-­‐
Menten	  kinetics.	  The	  rate	  of	  transport	  (v)	  increases	  with	  the	  drug	  concentration,	  but	  
it	  reaches	  a	  maximum,	  called	  Vmax,	  when	  the	  transporter	  gets	  saturated	  [7]	  (	  Figure	  
2.3).	  The	  concentration	  at	  half	  of	  the	  maximum	  rate	  of	  transport	  (Vmax)	  is	  called	  the	  
Michaelis-­‐Menten	  constant	  (Km)	  and	  is	  a	  good	  indicator	  of	  the	  affinity	  of	  the	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transporter	  for	  the	  substrate.	  	  A	  substrate	  with	  low	  Km	  has	  a	  higher	  affinity	  for	  the	  
transporter	  than	  one	  with	  a	  higher	  Km	  [7].	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2.2)	  
Some	  compounds	  can	  competitively	  inhibit	  the	  protein	  without	  being	  
transported	  by	  it,	  and	  are	  therefore	  called	  inhibitors.	  The	  affinity	  of	  the	  inhibitor	  for	  
the	  transporter	  can	  be	  expressed	  by	  the	  inhibition	  constant	  Ki,	  and	  is	  usually	  
calculated	  using	  IC50	  of	  the	  competitive	  inhibitor	  and	  the	  concentration	  and	  Km	  of	  
the	  substrate	  as	  shown	  in	  equation	  2.3	  [7].	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2.3)	  
	   	  











  13 
	  
Modeling	  and	  Simulation	  of	  Absorption	  Behavior	  	  
The	  prediction	  of	  the	  rate	  and	  extent	  of	  absorption	  and	  pharmacokinetics	  of	  
orally	  dosed	  drugs	  is	  a	  task	  many	  research	  groups	  have	  pursued	  in	  the	  last	  few	  
decades,	  however	  it	  is	  still	  a	  difficult	  venture.	  This	  task	  has	  been	  proven	  to	  be	  not	  
easy	  due	  to	  the	  several	  factors	  that	  affect	  the	  absorption	  process.	  Those	  factors	  can	  
be	  divided	  into	  3	  categories:	  1)	  Physiological	  factors	  of	  the	  GI	  tract,	  2)	  
Physicochemical	  characteristics	  of	  the	  drug,	  and	  3)	  Dosage	  form	  factors[8].	  In	  the	  
first	  category,	  one	  can	  find	  that	  several	  physiological	  aspects	  of	  the	  gastrointestinal	  
tract	  may	  affect	  drug	  absorption,	  including	  and	  not	  limited	  to	  pH,	  transit	  time,	  blood	  
flow,	  gastric	  emptying,	  membrane	  porosity,	  surface	  area	  of	  the	  GI	  tract,	  and	  
absorption	  mechanisms.	  In	  the	  second	  category	  some	  of	  the	  most	  common	  factors	  
that	  affect	  absorption	  are	  solubility,	  pKa,	  stability,	  lipophilicity,	  and	  salt	  form.	  From	  
the	  dosage	  form	  stand	  point,	  one	  should	  consider	  if	  the	  drug	  is	  administered	  as	  a	  
solution,	  suspension,	  capsule,	  tablet	  or	  as	  a	  sustained	  release	  form[8,	  9]	  [10].	  
A	  variety	  of	  models	  are	  available	  for	  the	  prediction	  of	  absorption	  of	  drugs	  in	  
the	  intestine,	  from	  very	  simple	  ones	  such	  as	  the	  mixing	  tank	  model,	  to	  the	  more	  
complex	  ones,	  such	  as	  the	  advanced	  compartmental	  absorption	  and	  transit	  model	  
(ACAT)	  developed	  by	  Simulations	  Plus	  (Figure	  2.4)[9].	  	  
The	  ACAT	  model	  was	  developed	  based	  on	  the	  compartmental	  absorption	  
model	  developed	  (CAT)	  by	  Yu	  and	  Amidon	  in	  1996	  [11].	  The	  original	  CAT	  model	  
divides	  the	  gastrointestinal	  tract	  into	  7	  segments,	  but	  doesn’t	  take	  into	  account	  the	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absorption	  of	  drugs	  in	  the	  stomach	  or	  colon.	  It	  also	  needs	  the	  measured	  drug’s	  
effective	  permeability	  [8].	  The	  ACAT	  model	  used	  in	  Gastroplus®	  was	  developed	  by	  
Simulations	  Plus	  model	  and	  divides	  the	  gastrointestinal	  tract	  into	  9	  compartments,	  
in	  all	  of	  which	  absorption	  can	  occur.	  The	  ACAT	  defines	  one	  compartment	  for	  
stomach,	  one	  for	  the	  duodenum,	  2	  compartments	  for	  the	  jejunum,	  3	  for	  the	  ileum,	  1	  
for	  the	  ceacum,	  and	  finally	  1	  compartment	  for	  the	  ascending	  colon.	  Those	  9	  
compartments	  are	  then	  sub-­‐divided	  into	  the	  following	  4	  sub-­‐compartments:	  
unreleased	  drug,	  undissolved	  drug,	  dissolved	  drug,	  and	  the	  enterocyte	  [8].	  The	  
ACAT	  model	  uses	  a	  series	  of	  differential	  equations,	  around	  80	  of	  them,	  to	  describe	  
the	  transfer	  of	  drug	  along	  the	  GI	  tract	  and	  across	  the	  different	  sub-­‐compartments.	  	  
Different	  from	  the	  CAT	  model,	  the	  ACAT	  model	  allows	  drug	  absorption	  in	  the	  
stomach	  and	  colon,	  and	  also	  can	  predict	  in	  silico	  the	  effective	  permeability	  of	  
different	  drugs	  based	  on	  their	  chemical	  structure	  using	  the	  ADMET	  prediction	  
module[8].	  The	  ACAT	  model	  also	  allows	  the	  addition	  of	  paracellular	  absorption	  
through	  out	  the	  gastrointestinal	  tract.	  	  It	  also	  allows	  the	  incorporation	  of	  
transporter	  and	  metabolism	  processes	  in	  the	  small	  intestine,	  colon	  and	  liver,	  by	  
using	  Michaelis-­‐Menten	  kinetics	  differential	  equations	  [8,	  12,	  13].	  	  
One	  of	  the	  most	  interesting	  features	  of	  the	  ACAT	  model	  is	  its	  ability	  to	  
extrapolate	  in	  vitro	  and	  pre-­‐clinical	  data	  in	  order	  to	  predict	  a	  drug’s	  absorption	  
behavior	  and	  its	  pharmacokinetics	  and	  establish	  first	  in	  human	  doses.	  Abuasal	  et	  al	  
[14]	  published	  recently	  a	  paper	  about	  the	  successful	  prediction	  of	  human	  
pharmacokinetics,	  from	  in	  vitro	  and	  rat	  in	  situ	  and	  in	  vivo	  data	  for	  a	  compound	  that	  
was	  a	  substrate	  of	  CYP3A4	  and	  P-­‐gp	  [12-­‐14].	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Proton-­‐coupled	  Oligopeptide	  Transporters	  
Peptide	  transporters	  are	  plasma	  membrane	  proteins	  that	  belong	  to	  the	  
SoLute	  Carrier	  family	  15	  (SLC15).	  The	  SLC15	  family	  is	  a	  phylogenetically	  conserved	  
family	  comprised	  by	  four	  proton-­‐dependent	  membrane	  transporters:	  SLC15A1	  
(PEPT1),	  SLC15A2	  (PEPT2),	  SLC15A3	  (PHT2),	  and	  SLC15A4	  (PHT1)	  [15-­‐17].	  
Peptide	  transporters	  have	  been	  identified	  in	  a	  wide	  variety	  of	  species,	  both	  in	  
prokaryote	  and	  eukaryote	  organisms,	  where	  they	  have	  been	  reported	  to	  have	  
similar	  structural	  features	  and	  functions.	  PEPT1	  was	  the	  first	  member	  of	  the	  SLC15	  
family	  to	  be	  identified.	  First,	  it	  was	  cloned	  and	  characterized	  in	  the	  rabbit	  small	  
intestine	  in	  1994	  by	  Fei	  et	  al	  and	  Boll	  et	  al	  [18,	  19],	  and	  later	  found	  in	  mouse,	  rat,	  
and	  human.	  	  Peptide	  transporters	  have	  been	  found	  to	  be	  highly	  homologous	  across	  
different	  species,	  with	  around	  90%	  amino	  acid	  identity	  between	  mammal	  species.	  	  
[20]	  [21].	  Though,	  there	  is	  only	  50%	  amino	  acid	  identity	  between	  PEPT1	  and	  PEPT2,	  
and	  only	  20%	  between	  PHT1	  and	  PEPT2	  [22].	  
PEPT1	  is	  highly	  expressed	  in	  the	  apical	  border	  of	  the	  small	  intestinal	  
epithelial	  cells.	  It	  is	  mainly	  located	  at	  the	  tip	  of	  the	  villi	  of	  the	  duodenum,	  the	  
jejunum,	  and	  the	  ileum.	  In	  healthy	  patients	  PEPT1	  is	  not	  expressed	  in	  the	  colon,	  but	  
it	  has	  been	  found	  in	  the	  colon	  of	  patients	  with	  chronic	  diseases,	  such	  as	  Crohn’s	  
disease	  and	  ulcerative	  colitis	  (for	  references	  see	  Table	  2.1).	  PEPT1	  has	  also	  been	  
found	  to	  a	  lesser	  extent	  in	  other	  organs	  of	  the	  healthy	  human	  body,	  such	  as	  the	  
kidney,	  liver,	  and	  pancreas.	  In	  the	  kidney,	  PEPT1	  has	  been	  found	  in	  the	  apical	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membrane	  of	  epithelial	  cells	  in	  the	  S1	  segment	  of	  the	  proximal	  tubule,	  where	  it	  
reabsorbs	  a	  very	  small	  percentage	  of	  the	  di-­‐	  and	  tripeptides	  from	  the	  urine	  back	  into	  
the	  blood	  prolonging	  their	  half-­‐life	  [21].	  	  
PEPT2	  is	  expressed	  in	  different	  parts	  of	  the	  body,	  including	  the	  kidney,	  the	  
lung,	  the	  enteric	  nervous	  system,	  the	  choroid	  plexus,	  astrocytes,	  cerebral	  cortex,	  and	  
neurons	  (for	  more	  details	  see	  Table	  2.1.	  Localization	  of	  peptide	  transporters.)	  [23-­‐
26].	  In	  the	  kidney,	  PEPT2	  is	  mostly	  expressed	  on	  the	  apical	  membrane	  of	  the	  
epithelial	  cells	  in	  the	  S3	  segments	  of	  the	  in	  proximal	  tubules,	  where	  it	  does	  most	  of	  
the	  reabsorption	  of	  di-­‐and	  tri-­‐peptides	  and	  peptide-­‐like	  drugs.	  PEPT2	  is	  expressed	  
on	  the	  apical	  membrane	  of	  the	  choroid	  plexus,	  where	  it	  has	  been	  shown	  to	  remove	  
neuropeptides	  and	  peptide-­‐like	  drugs	  from	  the	  cerebrospinal	  fluid	  (CSF)[27-­‐30].	  	  
While	  PEPT1	  is	  a	  low	  affinity	  and	  high	  capacity	  transporter,	  its	  isoform	  
PEPT2	  is	  a	  low	  capacity	  and	  high	  affinity	  one	  [31].	  Peptide	  transporters	  can	  move	  
substrates	  against	  a	  concentration	  gradient	  thanks	  to	  an	  inwardly	  directed	  proton	  
gradient	  and	  a	  negative	  membrane	  potential	  [32].	  The	  proton	  gradient	  is	  caused	  by	  
the	  pH	  difference	  between	  the	  acidic	  microclimate	  (pH=6.6)	  at	  the	  brush	  border	  
membrane	  of	  the	  intestine	  and	  the	  neutral	  cytoplasm	  (pH=7.35).	  This	  acidic	  micro-­‐
climate	  is	  maintained	  by	  the	  sodium	  hydrogen	  exchanger	  (NHE3),	  which	  is	  a	  
transporter	  located	  in	  the	  apical	  membrane	  of	  the	  cell,	  and	  responsible	  for	  
catalyzing	  the	  exchange	  of	  an	  exiting	  H+	  and	  an	  incoming	  Na+	  [6,	  33]	  (see	  Figure	  2.5).	  
The	  movement	  of	  substrates	  involves	  the	  binding	  and	  co-­‐transport	  of	  a	  
proton,	  or	  two,	  from	  the	  intestinal	  lumen	  to	  the	  cell	  cytosol,	  the	  excretion	  of	  a	  
proton	  back	  to	  the	  lumen	  via	  the	  sodium-­‐proton	  exchanger	  (NHE3),	  and	  the	  efflux	  of	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sodium	  to	  the	  blood	  by	  a	  sodium	  potassium	  exchanger	  in	  the	  basolateral	  membrane.	  
This	  sodium	  potassium	  exchanger	  is	  a	  transporter	  that	  uses	  the	  energy	  generated	  by	  
the	  hydrolysis	  of	  ATP	  to	  exchange	  3	  sodium	  ions	  for	  2	  potassium	  ions	  [3]	  [33]	  [6].	  
While	  mammalian	  peptide	  transporters	  PEPT1	  and	  PEPT2	  can	  transport	  almost	  all	  
possible	  di-­‐	  and	  tri-­‐peptide	  combinations,	  and	  some	  peptide-­‐like	  drugs,	  they	  cannot	  
move	  single	  amino	  acids	  or	  oligopeptides	  with	  4	  or	  more	  amino	  acid	  residues	  [34]	  
(Table	  2.2	  ).	  
Little	  is	  known	  about	  the	  other	  2	  members	  of	  the	  SLC15	  family,	  the	  
peptide/histidine	  transporters	  PHT1	  and	  PHT2.	  These	  transporters,	  different	  from	  
PEPT1	  and	  PEPT2,	  can	  transport	  the	  amino	  acid	  L-­‐histidine.	  Although	  it	  has	  been	  
shown	  that	  they	  transport	  peptides,	  it	  is	  still	  unknown	  to	  what	  extent	  they	  can	  
transport	  all	  di-­‐	  and	  tripeptide	  combinations	  [35]	  [36].	  	  
Although	  the	  three	  dimensional	  structure	  of	  human	  PEPT1	  has	  not	  been	  
completely	  elucidated,	  some	  structural	  features	  have	  been	  proven	  to	  be	  key	  for	  
substrate	  recognition	  and	  transport.	  This	  human	  protein	  contains	  708	  amino	  acid	  
residues,	  and	  is	  predicted	  to	  have	  12	  putative	  transmembrane	  domains,	  with	  both	  
the	  amino-­‐	  and	  carboxy-­‐termini	  facing	  the	  cytosolic	  side	  of	  the	  membrane	  [20].	  It	  
also	  has	  a	  large	  extracellular	  loop	  between	  the	  9th	  and	  10th	  transmembrane	  domain	  
with	  several	  glycosilation	  points	  [20]	  (Figure	  2.6).	  
Several	  studies	  with	  chimeric	  transporters	  have	  shown	  that	  the	  
transmembrane	  domains	  TM1-­‐TM4	  and	  TM7-­‐TM	  are	  relevant	  for	  substrate	  affinity	  
and	  binding	  [37-­‐39].	  Mutational	  studies	  proved	  that	  the	  extracellular	  histidine	  H57	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is	  involved	  in	  the	  binding	  of	  the	  proton,	  and	  tyrosines	  Y12,	  Y56,	  Y64,	  Y91,	  and	  Y167	  
play	  a	  key	  role	  in	  the	  binding	  and	  translocation	  of	  the	  substrate	  [40-­‐42].	  	  
Although	  PEPT1	  has	  a	  preference	  for	  compounds	  with	  no	  net	  charge,	  it	  can	  
transport	  both	  positively	  and	  negatively	  charged	  molecules	  [43,	  44].	  The	  transport	  
of	  molecules	  with	  zero	  net	  charge	  is	  optimal	  at	  the	  pH	  of	  the	  brush	  border	  
microclimate	  (around	  6.5),	  but	  the	  optimal	  pH	  for	  the	  transport	  of	  ionic	  species	  
shifts	  up	  or	  down	  according	  to	  their	  net	  charge.	  Neutral	  and	  cationic	  species	  are	  
transported	  in	  a	  1:1	  stoichiometry	  in	  relation	  to	  protons.	  Acidic	  peptides,	  like	  the	  
ones	  containing	  aspartic	  or	  glutamic	  acid	  are	  moved	  in	  a	  1:2	  relation,	  where	  the	  
second	  proton	  is	  attached	  to	  the	  peptide	  side	  chain	  [44-­‐46].	  	  
Water	  plays	  an	  important	  role	  in	  the	  active	  transport	  of	  the	  differently	  
charged	  peptides.	  It	  interacts	  with	  the	  charged	  amino	  acid	  residues,	  acting	  as	  a	  
shield.	  	  It	  also	  fills	  void	  spaces	  in	  the	  transporter	  to	  allow	  a	  better	  docking	  of	  the	  
peptide	  [47,	  48].	  	  
Different	  authors	  have	  shown	  that	  certain	  features	  in	  the	  substrate	  are	  
required	  for	  its	  ability	  to	  bind	  to	  the	  transporter,	  such	  as	  two	  oppositely	  charged	  
groups	  separated	  by	  carbon	  backbone	  with	  a	  distance	  of	  5.5	  to	  6.3	  Angstrom,	  along	  
with	  the	  presence	  of	  at	  least	  one	  L-­‐enantiomer	  amino	  acid	  residue	  in	  the	  molecule	  
[49].	  	  
The	  alpha-­‐amino	  group	  and	  the	  peptide	  bond	  have	  been	  shown	  not	  to	  be	  
necessary	  for	  binding	  to	  the	  transporter,	  although	  their	  presence	  in	  the	  substrate	  
increases	  the	  affinity	  [50].	  Another	  important	  feature	  that	  helps	  increase	  the	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bonding	  affinity	  is	  the	  carbonyl	  oxygen	  in	  the	  peptide	  bond,	  since	  it	  binds	  to	  the	  
substrate-­‐binding	  domain	  by	  a	  hydrogen	  bond	  [51].	  
Competition	  and	  electrophysiological	  experiments	  have	  helped	  measure	  Km	  
constants	  for	  different	  compounds	  and	  identified	  some	  substrates	  and	  inhibitors	  of	  
the	  PEPT1	  transporter.	  Peptides	  that	  have	  3	  amino	  acid	  residues	  as	  L-­‐enantiomers	  
have	  a	  higher	  affinity	  than	  those	  with	  only	  two	  or	  just	  one	  [50].	  Also,	  compounds	  in	  
which	  the	  peptide	  bond	  has	  a	  trans	  conformation	  also	  have	  a	  higher	  affinity	  for	  
PEPT1	  [52].	  Molecules	  that	  have	  hydrophobic	  side	  chains	  expel	  water	  from	  the	  
binding	  pockets	  and	  therefore	  have	  a	  higher	  affinity	  for	  the	  protein,	  acting	  as	  
inhibitors	  [53].	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Pharmacological	  Importance	  of	  Peptide	  Transporters	  	  
As	  mentioned	  above,	  PEPT1	  is	  a	  high-­‐capacity	  and	  low-­‐affinity	  peptide	  
transporter	  capable	  of	  carrying	  all	  natural	  di-­‐	  and	  tripeptides,	  and	  some	  peptide-­‐like	  
drugs	  [20]	  [19].	  Some	  of	  these	  drugs	  include	  betalactam	  antibiotics	  like	  cephalexin	  
and	  cefadroxil,	  antiviral	  drugs	  like	  valacyclovir	  and	  valgancyclovir,	  peptidomimetic	  
anticancer	  compounds	  like	  bestatin,	  and	  inhibitors	  of	  the	  angiotensin-­‐converting	  
enzyme	  (ACE)	  like	  enalapril	  [54-­‐60]	  (Figure	  2.8).	  	  	  
For	  several	  years	  researchers	  have	  experimented	  with	  drug	  chemical	  
structures	  to	  improve	  undesirable	  pharmaceutical	  and	  pharmacokinetic	  
characteristics	  without	  diminishing	  their	  therapeutic	  capabilities	  [61].	  Several	  
approaches	  are	  available,	  and	  attaching	  moieties	  to	  molecules	  to	  improve	  their	  
characteristics	  is	  a	  widely	  used	  technique.	  The	  modified	  drug,	  also	  known	  as	  
prodrug,	  is	  then	  later	  converted	  to	  the	  active	  drug	  in	  the	  body	  usually	  by	  enzymes.	  	  
Prodrugs	  can	  be	  design	  specifically	  to	  target	  specific	  membrane	  transporters	  or	  
enzymes	  in	  order	  to	  control	  their	  uptake	  into	  certain	  tissues	  [61].	  	  
Designing	  a	  prodrug	  to	  target	  PEPT1	  is	  a	  strategy	  that	  has	  been	  used	  with	  
hydrophilic	  drugs	  to	  improve	  their	  permeability	  through	  the	  intestine.	  Since	  PEPT1	  
has	  high	  capacity	  and	  broad	  substrate	  specificity	  it	  has	  been	  used	  as	  a	  target	  for	  
improving	  drug	  delivery.	  Drugs	  with	  low	  permeability	  can	  be	  modified	  into	  
prodrugs	  that	  can	  by	  recognized	  and	  transported	  by	  PEPT1,	  improving	  then	  the	  
drug’s	  bioavailability.	  There	  are	  already	  numerous	  prodrugs	  in	  the	  market	  that	  are	  
bound	  and	  transported	  by	  PEPT1.	  L-­‐valacyclovir	  is	  the	  ester	  prodrug	  of	  acyclovir,	  an	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antiviral	  drug	  with	  low	  permeability.	  In	  this	  case	  the	  prodrug	  has	  3	  to	  5	  times	  higher	  
oral	  bioavailability	  than	  the	  original	  nucleoside	  [62].	  	  
Another	  successful	  case	  in	  target-­‐designed	  prodrugs	  is	  the	  one	  involving	  α-­‐
methyl-­‐dopa,	  an	  antihypertensive	  drug	  with	  low	  permeability	  in	  the	  intestine.	  By	  
modifying	  the	  parent	  drug	  with	  peptidic	  moieties,	  like	  Phe-­‐α-­‐methyl-­‐dopa,	  α-­‐
methyl-­‐dopa-­‐Phe,	  and	  p-­‐Glu-­‐L-­‐Dopa-­‐Pro	  its	  permeability	  and	  therefore	  its	  
bioavailability	  increased	  significantly	  [63,	  64].	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Genetic	  Variation	  of	  PEPT1	  
Similar	  to	  metabolizing	  enzymes,	  transporters	  also	  have	  genetic	  
polymorphisms	  that	  have	  been	  linked	  to	  important	  changes	  in	  the	  pharmacokinetics	  
of	  drugs,	  and	  potentially	  significant	  consequences	  on	  their	  pharmacodynamics	  and	  
toxicity.	  	  For	  example,	  genetic	  variations	  in	  p-­‐glycoprotein	  have	  been	  associated	  
with	  changes	  in	  the	  disposition	  of	  some	  of	  its	  substrates,	  such	  as	  digoxin	  [65]	  and	  
fexofenadine	  [66].	  Also,	  genetic	  variants	  of	  OATP-­‐C	  and	  OAT3	  have	  been	  implicated	  
with	  changes	  in	  the	  disposition	  of	  pravastatin	  in	  humans	  [67].	  	  
Interestingly	  enough,	  three	  independent	  studies	  found	  that	  PEPT1	  has	  well	  
conserved	  substrate	  recognition	  and	  very	  few	  genetic	  polymorphisms	  that	  actually	  
affect	  the	  uptake	  of	  its	  substrates	  [68-­‐70].	  For	  the	  study	  done	  by	  Zhang	  et	  al	  the	  9	  
non-­‐synonymous	  SNPs,	  and	  their	  relative	  frequencies,	  were:	  S117N	  (22.7%),	  G419A	  
(6.8%),	  T451N	  (3.4%),	  V416L	  (1.1%),	  V450I	  (1.1%),	  R459C	  (1.1%),	  T114I	  (1.1%),	  
V122M	  (1.1%),	  and	  P586L	  (1.1%)	  (see	  Figure	  2.7).	  The	  latter	  two	  non-­‐synonymous	  
polymorphisms	  are	  located	  in	  the	  transmembrane	  domains,	  while	  the	  other	  seven	  
are	  located	  in	  the	  extracellular	  loops.	  When	  the	  variants	  were	  transfected	  into	  HeLa	  
cells	  and	  their	  transport	  capacity	  was	  tested	  using	  Gly-­‐Sar,	  the	  results	  showed	  that	  
none	  of	  the	  non-­‐synonymous	  polymorphisms	  had	  reduced	  affinity	  for	  the	  substrate	  
(i.e.	  significant	  changes	  in	  the	  Km).	  The	  only	  significant	  difference	  was	  seen	  with	  the	  
P586L	  variant,	  which	  showed	  reduced	  maximal	  uptake	  of	  Gly-­‐Sar	  (Vmax	  was	  10-­‐fold	  
lower)	  [69].	  	  
In	  their	  second	  study,	  Anderle	  et	  al	  [70]	  show	  that,	  although	  the	  non-­‐
synonymous	  polymorphism	  F28Y	  has	  reduced	  Gly-­‐Sar	  uptake	  (Km	  is	  3.5-­‐fold	  higher)	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when	  transfected	  into	  HeLa	  cells.	  They	  also	  showed	  its	  frequency	  is	  rare	  (0.002),	  
and	  interestingly	  enough	  it	  was	  only	  detected	  in	  the	  African-­‐American	  population.	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Regulation	  of	  PEPT1	  
The	  expression	  level	  and	  function	  of	  PEPT1	  can	  be	  regulated	  by	  a	  variety	  of	  
factors,	  and	  several	  studies	  have	  reported	  changes	  in	  mRNA	  and	  protein	  levels	  both	  
in	  vivo	  and	  in	  vitro	  under	  different	  conditions.	  
For	  example,	  fasting	  and	  type	  of	  diet	  are	  some	  of	  the	  most	  reported	  factors	  
affecting	  the	  levels	  of	  PEPT1.	  For	  example,	  it	  has	  been	  shown	  that	  the	  expression	  of	  
PEPT1	  is	  subject	  to	  the	  influence	  of	  the	  diurnal	  rhythm,	  and	  that	  the	  amount	  of	  
transporter	  is	  higher	  at	  night	  when	  the	  rats	  are	  awake	  and	  eating,	  than	  during	  the	  
day	  when	  they	  are	  sleeping	  [71,	  72].	  Pan	  et	  al	  revealed	  that	  in	  rats	  PEPT1	  levels	  
were	  dependent	  on	  food	  intake	  and	  that	  its	  functionality	  was	  higher	  at	  8pm	  than	  at	  
8am,	  which	  indicates	  that	  the	  levels	  of	  the	  protein	  were	  higher	  after	  a	  few	  hours	  of	  
fasting	  [72,	  73].	  Also,	  Ferraris	  et	  al	  showed	  that	  RNA	  and	  protein	  levels	  of	  PEPT1	  in	  
rats	  increased	  after	  fasting	  for	  periods	  of	  24	  hours	  [74,	  75].	  	  Finally,	  Ma	  et	  al	  [76]	  
demonstrated	  that	  in	  wild-­‐type	  mice,	  PEPT1	  protein	  levels	  in	  the	  small	  intestine	  
increase	  with	  fasting	  periods	  of	  over	  16	  hours.	  This	  protein	  up	  regulation	  resulted	  in	  
an	  increase	  of	  Gly-­‐Sar	  absorption	  after	  oral	  administration	  to	  wild-­‐type	  mice.	  No	  
effect	  was	  seen	  in	  PEPT1	  knockout	  mice,	  demonstrating	  that	  the	  increase	  in	  Gly-­‐Sar	  
exposure	  was	  due	  solely	  to	  increase	  in	  PEPT1	  expression,	  and	  not	  in	  other	  
transporters[76].	  	  
Experiments	  in	  Caco-­‐2	  cells	  have	  proven	  that	  an	  increased	  concentration	  of	  
peptides	  in	  the	  growth	  medium	  increases	  the	  Vmax	  of	  the	  PEPT1-­‐mediated	  transport	  
by	  increasing	  the	  number	  of	  transporters	  present	  in	  the	  apical	  membrane	  of	  the	  
cells	  [77].	  This	  increase	  in	  protein	  levels	  was	  caused	  by	  an	  enhanced	  gene	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transcription	  [77,	  78].	  Other	  experiments	  in	  rats	  showed	  that	  high	  protein	  diets	  and	  
therefore	  high	  concentration	  of	  peptides	  in	  the	  intestinal	  lumen	  increase	  the	  amount	  
of	  PEPT1	  in	  the	  apical	  membrane	  by	  increasing	  the	  gene	  expression	  [79].	  
Several	  reports	  reveal	  the	  effect	  of	  disease	  state	  on	  PEPT1	  levels.	  For	  
example,	  there	  is	  some	  in	  vivo	  and	  in	  vitro	  evidence	  that	  intestinal	  PEPT1	  is	  up	  
regulated	  in	  patients	  that	  have	  damaged	  intestinal	  mucosa	  due	  to	  infections	  with	  
cryptosporidium	  parvum,	  a	  common	  cause	  of	  diarrhea.	  It	  is	  hypothesized	  that	  the	  
damage	  to	  the	  mucosa	  causes	  a	  decrease	  in	  the	  absorption	  of	  peptides,	  which	  in	  turn	  
causes	  an	  increase	  in	  the	  amount	  of	  PEPT1	  mRNA	  being	  transcribed	  [80].	  	  
Also,	  PEPT1	  has	  been	  reported	  to	  be	  aberrantly	  present	  in	  the	  colon	  of	  
patients	  with	  Crohn’s	  disease	  and	  ulcerative	  colitis,	  the	  two	  forms	  of	  the	  
inflammatory	  bowel	  disease	  (IBD).	  Although	  no	  conclusions	  have	  yet	  been	  reached	  
about	  the	  role	  of	  PEPT1	  in	  the	  mechanism	  of	  the	  disease,	  some	  in	  vitro	  experiments	  
have	  suggested	  that	  this	  transporter	  is	  in	  charge	  of	  the	  movement	  of	  the	  peptide	  
neutrophil	  chemotactic	  factors	  such	  as	  fML	  (N-­‐formyl-­‐Met-­‐Leu-­‐Phe)	  and	  muramyl	  
dipeptide	  [81-­‐83].	  New	  evidence	  suggest	  that	  in	  IBD	  patients	  the	  colonic	  PEPT1	  acts	  
as	  a	  gate	  into	  the	  enterocyte	  for	  bacterial	  di-­‐	  and	  tri-­‐peptides,	  which	  trigger	  an	  
immunologic	  response	  by	  producing	  of	  cytokines	  and	  chemokines	  that	  induce	  
neutrophil	  migration	  into	  the	  inflammation	  site	  [81-­‐85].	  
Hormonal	  regulation	  of	  PEPT1	  is	  another	  well-­‐described	  phenomenon	  in	  this	  
field.	  Experiments	  in	  Caco-­‐2	  cells	  and	  jejunal	  brush	  border	  vesicles	  show	  that	  when	  
Insulin	  and	  EGF	  bind	  to	  their	  extracellular	  receptors,	  the	  Vmax	  of	  the	  PEPT1	  
mediated	  transport	  increases	  transiently	  but	  the	  mRNA	  levels	  do	  not,	  indicating	  that	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the	  increase	  in	  transport	  is	  caused	  by	  an	  increased	  stability	  of	  the	  RNA	  and	  not	  an	  
increase	  on	  the	  transcription	  of	  it	  [86]	  [87].	  When	  physiological	  concentrations	  of	  
EGF	  were	  added	  to	  the	  basolateral	  compartment	  of	  Caco-­‐2	  cells	  cultures	  for	  
different	  periods	  of	  time,	  the	  transport	  of	  dipeptides	  was	  first	  increased,	  without	  an	  
increase	  in	  the	  RNA	  levels	  [88],	  and	  then	  after	  several	  days	  of	  exposure	  the	  
transport	  was	  inhibited	  due	  an	  inhibition	  of	  PEPT1	  transcription	  [89].	  	  
On	  the	  other	  hand,	  research	  with	  leptin	  has	  revealed	  receptors	  for	  this	  
hormone	  in	  the	  small	  intestine	  of	  rats,	  especially	  in	  the	  jejunum.	  	  An	  increase	  in	  
peptide	  transport	  is	  noted	  when	  leptin	  is	  added	  in	  perfusion	  experiments	  [90].	  
Experiments	  with	  Caco-­‐2	  cells	  have	  also	  revealed	  that	  the	  transport	  of	  some	  
betalactam	  antibiotics	  can	  be	  enhanced	  when	  this	  hormone	  is	  added	  to	  the	  medium	  
on	  the	  apical	  side	  of	  the	  chamber,	  but	  not	  on	  the	  basolateral	  side	  [90].	  Although	  
more	  research	  needs	  to	  be	  done,	  it	  is	  believed	  that	  the	  increased	  transport	  is	  due	  to	  
translocation	  of	  the	  peptide	  transporter	  from	  the	  cytoplasm	  to	  the	  apical	  membrane,	  
and	  not	  to	  enhanced	  transcription	  [90,	  91].	  	  
Other	  hormones	  like	  triiodothyronine	  (T3),	  recombinant	  human	  growth	  
hormone	  (rhGH),	  and	  progesterone	  have	  been	  investigated	  to	  a	  lesser	  extent.	  When	  
T3	  is	  added	  to	  Caco-­‐2	  cell	  cultures	  it	  decreases	  the	  amount	  of	  membrane	  PEPT1,	  and	  
therefore	  the	  uptake	  of	  dipeptides	  [92].	  The	  mechanism	  by	  which	  the	  increase	  in	  
transcription	  and/or	  stability	  of	  the	  transporter	  is	  induced	  is	  not	  yet	  known.	  
However,	  in	  vivo	  experiments	  have	  shown	  that	  rats	  with	  hypothyroidism	  have	  a	  
decrease	  in	  PEPT1	  expression	  and	  activity	  in	  the	  small	  intestine	  [93].	  When	  rhGH	  
was	  added	  over	  four	  days	  to	  Caco-­‐2	  cell	  cultures	  the	  uptake	  of	  cephalexin,	  a	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betalactam	  antibiotic,	  was	  enhanced	  due	  to	  the	  increase	  of	  PEPT1	  mRNA	  in	  the	  cells	  
[94].	  Other	  experiments	  in	  Caco-­‐2	  cells	  have	  shown	  that	  when	  progesterone	  and	  
norethisterone	  were	  added	  to	  the	  medium,	  the	  uptake	  and	  transport	  of	  cephalexin	  
decreased	  with	  both	  hormones	  because	  of	  a	  decrease	  in	  the	  expression	  of	  PEPT1	  
[95,	  96].	  	  
It	  has	  been	  shown	  in	  vitro	  and	  in	  vivo	  that	  some	  drugs	  affect	  the	  expression	  of	  
PEPT1	  by	  either	  increasing	  or	  decreasing	  the	  protein	  levels	  at	  the	  apical	  membrane	  
or	  the	  mRNA	  levels	  of	  it.	  Drugs	  like	  5-­‐fluorouracil	  and	  clonidine	  have	  been	  reported	  
to	  increase	  the	  transporter’s	  level	  both	  in	  vivo	  and	  in	  vitro,	  though	  the	  exact	  
mechanism	  is	  not	  yet	  known	  [97,	  98].	  Nifedipine,	  a	  calcium	  channel	  blocker,	  was	  
shown	  to	  boost	  the	  activity	  of	  PEPT1	  and	  increase	  the	  bioavailability	  of	  orally	  
administered	  amoxicillin	  in	  humans.	  The	  mechanism	  of	  this	  enhancement	  relies	  on	  
the	  decrease	  of	  intracellular	  calcium,	  which	  stimulates	  the	  sodium-­‐proton	  
exchanger	  and	  resulting	  in	  an	  increase	  of	  extracellular	  protons	  available	  for	  
PEPT1[99].	  The	  opposite	  effect	  is	  shown	  with	  amiloride,	  which	  is	  a	  blocker	  of	  the	  
sodium-­‐proton	  exchanger.	  When	  amiloride	  was	  given	  concomitantly	  with	  oral	  
amoxicillin,	  the	  bioavailability	  of	  the	  latter	  one	  was	  reduced	  significantly[99].	  Some	  
immunosuppressive	  agents	  have	  been	  shown	  to	  reduce	  the	  transport	  rate	  of	  Gly-­‐Sar	  
in	  vitro	  [100].	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Cefadroxil	  
The	  IUPAC	  chemical	  name	  for	  cefadroxil	  is	  (6R,	  7R)-­‐7-­‐[(R)-­‐2-­‐amino-­‐2-­‐(p-­‐
hydroxyphenyl)acetamido]-­‐3-­‐methy-­‐8-­‐oxo-­‐5-­‐thia-­‐1-­‐azabicyclo[4.2.0]oct-­‐2-­‐ene-­‐2-­‐
carboxylic	  acid	  (See	  structure	  in	  Figure	  2.9).	  	  Its	  molecular	  weight	  is	  363.39	  and	  its	  
molecular	  formula	  is	  C16H17N3O5S.	  It	  is	  soluble	  in	  water	  (Intrinsic	  solubility	  =	  17.4	  
mg/mL)	  and	  slightly	  soluble	  in	  alcohol.	  Its	  apparent	  pKa’s	  are:	  2.64,	  7.30	  and	  9.69	  at	  
35	  °C	  and	  its	  isoelectric	  point	  is	  4.9	  [101]	  .	  	  
Cefadroxil	  is	  a	  semi-­‐synthetic	  betalactam	  antibiotic	  that	  belongs	  to	  the	  first	  
generation	  of	  cephalosporins.	  It	  is	  used	  to	  treat	  different	  kinds	  of	  infections	  in	  the	  
ear,	  skin,	  urinary	  tract,	  and	  upper	  and	  lower	  respiratory	  tract.	  It	  has	  been	  widely	  
used	  to	  treat	  community-­‐acquired	  pneumonia	  and	  infections	  in	  patients	  with	  known	  
allergies	  to	  penicillins	  [102,	  103].	  	  	  
Cefadroxil	  is	  effective	  against	  most	  Gram-­‐positive	  cocci,	  but	  not	  against	  
methicillin-­‐resistant	  Staphilococci	  and	  Enterococci.	  It	  is	  also	  active	  against	  certain	  
Gram-­‐negative	  bacteria	  like	  Klebsiella	  pneumoniae,	  Proteus	  mirabilis	  and	  Escherichia	  
coli	  [104].	  	  
Cefadroxil	  binds	  to	  transpeptidases,	  which	  are	  specific	  penicillin-­‐binding	  
proteins	  (PBP’s)	  inside	  the	  bacterial	  cell	  wall.	  This	  binding	  causes	  the	  inhibition	  of	  
cross-­‐linking	  of	  peptydoglycan,	  a	  basic	  step	  in	  the	  synthesis	  of	  the	  bacterial	  wall.	  
The	  inhibition	  of	  this	  step	  breaks	  the	  equilibrium	  between	  the	  degradation	  and	  
formation	  of	  new	  bonds,	  allowing	  the	  bacterial	  autolysins	  to	  degrade	  the	  entire	  
bacterial	  wall	  [105].	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Cefadroxil	  adverse	  reactions	  are	  usually	  mild	  and	  can	  be	  reversed	  easily	  
[103].	  The	  antibiotic	  can	  cause	  nausea,	  vomiting,	  diarrhea,	  and	  hypersensitivity	  
reactions	  like	  skin	  rashes	  and	  dermatitis.	  It	  is	  contraindicated	  in	  patients	  with	  
known	  allergies	  to	  other	  cephalosporins	  [104].	  	  
Cefadroxil	  has	  a	  high	  oral	  bioavailability	  and	  food	  does	  not	  alter	  its	  
absorption.	  Its	  half-­‐life	  in	  humans	  is	  around	  95	  minutes,	  which	  is	  longer	  than	  that	  of	  
other	  cephalosporins	  of	  the	  same	  generation.	  It	  is	  extensively	  distributed	  to	  several	  
tissues,	  including	  the	  lung,	  tonsils,	  placenta,	  bone,	  muscle,	  and	  prostate	  and	  is	  
approximately	  20%	  bound	  to	  plasma	  proteins	  [103,	  104].	  Cefadroxil,	  like	  some	  
other	  cephalosporins,	  is	  not	  metabolized	  and	  about	  90%	  can	  be	  recovered	  
unchanged	  in	  urine	  in	  the	  first	  24	  hours	  after	  oral	  administration	  [104].	  Table	  2.4	  
shows	  the	  pharmacokinetic	  parameters	  of	  cefadroxil	  in	  humans.	  	  
The	  absorption	  of	  cefadroxil	  from	  the	  small	  intestine	  has	  been	  attributed	  to	  
transporters,	  due	  to	  the	  antibiotic’s	  physicochemical	  characteristics	  and	  the	  
saturable	  kinetics	  of	  this	  process	  [106].	  Cefadroxil,	  being	  a	  hydrophilic	  drug	  with	  
two	  oppositely	  charged	  groups	  at	  the	  physiological	  pH,	  is	  most	  likely	  to	  be	  
transferred	  across	  membranes	  by	  different	  transporters	  than	  by	  passive	  diffusion.	  
However,	  the	  contribution	  of	  each	  of	  these	  mechanisms	  to	  the	  total	  mass	  transfer	  
process	  is	  still	  not	  known	  [107].	  	  	  
As	  mentioned	  previously,	  cefadroxil	  chemical	  structure	  resembles	  that	  of	  a	  
tri-­‐peptide	  (see	  Figure	  2.10),	  and	  its	  proton-­‐dependent	  transport	  is	  inhibited	  by	  
other	  amino-­‐cephalosporins	  and	  di-­‐	  and	  tri-­‐peptides	  [56,	  107-­‐110].	  Several	  authors	  
have	  shown	  that	  peptide	  transporters,	  like	  PEPT1,	  play	  a	  critical	  role	  in	  the	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absorption	  of	  cefadroxil	  from	  the	  small	  intestine	  [107,	  109].	  Cefadroxil	  has	  been	  
widely	  used	  as	  a	  substrate	  to	  study	  PEPT1	  and	  PEPT2	  because	  of	  its	  
pharmacological	  activity,	  high	  affinity	  for	  peptide	  transporters,	  and	  its	  lack	  of	  
degradation	  or	  metabolism	  by	  enzymes	  in	  the	  body.	  	  
PEPT2	  has	  been	  shown	  to	  be	  responsible	  for	  most	  of	  the	  reabsorption	  of	  
cefadroxil	  from	  the	  urine	  back	  to	  the	  blood,	  increasing	  the	  half-­‐life	  of	  the	  drug	  and	  
therefore	  increasing	  the	  exposure	  of	  different	  tissues	  to	  the	  antibiotic	  [111].	  	  On	  the	  
other	  hand,	  PEPT2	  has	  also	  been	  shown	  to	  act	  as	  an	  efflux	  transporter	  of	  cefadroxil	  
from	  the	  cerebrospinal	  fluid	  (CSF)	  in	  the	  choroid	  plexus,	  decreasing	  the	  
concentration	  of	  this	  drug	  in	  the	  brain.	  Previous	  studies	  have	  shown	  that	  when	  
PEPT2	  null	  mice	  where	  treated	  with	  cefadroxil,	  the	  ratio	  of	  the	  CSF	  to	  plasma	  drug	  
concentration	  was	  higher	  as	  compared	  to	  wild	  type	  mice	  [28,	  29].	  	  
Since	  cefadroxil	  has	  a	  negative	  charge	  at	  the	  physiological	  pH,	  it	  can	  bind	  to	  
organic	  anion	  transporters	  (OATs).	  These	  transporters	  are	  present	  in	  the	  
basolateral	  membrane	  of	  the	  epithelial	  cells	  in	  the	  proximal	  renal	  tubules,	  and	  are	  
thought	  to	  be	  responsible	  for	  the	  active	  secretion	  from	  blood	  to	  tubular	  fluid	  of	  
several	  negatively	  charged	  endogenous	  and	  exogenous	  compounds,	  like	  cefadroxil.	  
This	  family	  of	  transporters	  includes	  OAT1,	  OAT2	  and	  OAT3	  and	  it	  was	  shown	  
recently	  that	  from	  these	  three	  proteins	  present	  in	  the	  human	  kidney,	  OAT3	  plays	  a	  
stronger	  role	  than	  OAT1	  in	  the	  active	  secretion	  of	  cephalosporins	  [112].	  
Experiments	  using	  Xenopous	  oocytes	  expressing	  OATP2B1,	  the	  organic	  anion	  
transporting	  polypeptide-­‐2	  A	  1	  expressed	  in	  the	  liver,	  show	  that	  cefadroxil	  is	  also	  a	  
substrate	  for	  this	  transporter	  [113].	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It	  has	  been	  shown	  that	  in	  mice	  where	  the	  multidrug	  resistance-­‐associated	  
protein	  4	  was	  removed,	  there	  is	  an	  increase	  in	  the	  blood	  concentration	  of	  
ceftizoxime	  and	  cefazolin	  [114].	  MRP4	  is	  located	  in	  the	  basolateral	  membrane	  of	  the	  
epithelial	  cells	  in	  the	  kidneys	  where	  it	  is	  involved	  in	  the	  tubular	  active	  secretion	  of	  
some	  cephalosporins	  from	  the	  blood	  to	  the	  urine	  [114].	  	  Also,	  de	  Waart	  et	  al	  [115]	  
showed	  that	  MRP3	  and	  MRP4	  located	  on	  the	  basolateral	  membrane	  of	  the	  
enterocytes	  could	  be	  involved	  in	  the	  transport	  of	  cefadroxil	  across	  the	  basolateral	  
membrane	  (from	  the	  enterocyte	  into	  the	  blood)	  in	  mice.	  
The	  human	  multidrug	  and	  toxin	  extrusion/H(+)-­‐organic	  cation	  antiporters	  
(MATE1)	  have	  been	  shown	  to	  be	  capable	  of	  transporting	  some	  cephalosporin	  
antibiotics.	  This	  transporter	  is	  expressed	  in	  the	  basolateral	  membrane	  of	  the	  
kidneys	  [116-­‐118].	  
	   	  
 




Figure	  2.1.	  Layers	  of	  the	  small	  intestine.	  Extracted	  from	  Gastrointestinal	  Physiology,	  The	  
McGraw-­‐Hill	  Companies,	  Inc.	  2008	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Figure	  2.2.	  Cellular	  transport	  pathways.	  Paracellular	  transport	  happens	  between	  two	  
adjacent	  cells,	  through	  the	  tight	  junctions.	  	  Drug	  transport	  occurs	  through	  the	  cell,	  and	  can	  
happen	  through	  different	  mechanisms,	  such	  as	  A)	  passive	  diffusion	  and	  B)	  active	  transport.	  
Source	  Goodman	  and	  Gilman,	  12th	  edition,	  The	  McGraw-­‐Hill	  Companies,	  2010.	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Figure	  2.5.	  Model	  of	  peptide	  transport	  in	  the	  enterocyte.	  PEPT1	  is	  located	  in	  the	  apical	  
membrane	  of	  the	  cell	  and	  facilitates	  the	  transport	  of	  di-­‐	  and	  tri-­‐peptides	  across	  the	  brush	  
border	  membrane.	  Once	  the	  peptides	  reach	  the	  cell	  they	  get	  degraded	  into	  amino	  acids	  and	  
get	  exported	  out	  of	  the	  cell	  into	  the	  blood	  stream	  through	  the	  amino	  acid	  transporters	  
present	  on	  the	  basolateral	  membrane.	  Extracted	  from:	  Hannelore	  Daniel.	  Molecular	  and	  
integrative	  physiology	  of	  intestinal	  peptide	  transport.	  Annu.	  Rev.	  Physiol.	  2004.	  66:361–84.	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Figure	  2.6.	  Topology	  of	  PEPT1.	  Analyses	  indicate	  that	  the	  transporter	  has	  12	  putative	  
transmembrane	  domains.	  It	  also	  contains	  a	  large	  extracellular	  loop	  between	  the	  9th	  and	  10th	  
transmembrane	  domain,	  1	  protein	  kinase	  A	  site,	  and	  1	  protein	  kinase	  C	  site.	  Both	  the	  amino	  
and	  carboxy	  termini	  are	  facing	  the	  cytosol.	  Extracted	  from:	  Rubio	  I.	  and	  Daniel	  H.	  Trends	  in	  
Pharmacological	  Sciences,	  Volume	  23,	  Issue	  9,	  434-­‐440,	  1	  September	  2002.	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Figure	  2.7.	  Representation	  of	  most	  common	  cSNPs	  of	  PEPT1	  in	  humans.	  The	  9	  non-­‐
synonymous	  amino	  acid	  changes	  are	  in	  bold	  and	  numbered.	  Synonymous	  amino	  acid	  
changes	  are	  depicted	  in	  grey.	  Figure	  extracted	  from	  Zhang	  et	  al	  2004	  [69].	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Figure	  2.8.	  Some	  known	  substrates	  of	  the	  peptide	  transporter	  1	  (PEPT1).	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Figure	  2.9.	  Structure	  of	  cefadroxil.	  This	  first	  generation	  amino-­‐cephalosporin	  has	  a	  
molecular	  weight	  of	  363,	  a	  cLogP	  of	  -­‐2.51,	  and	  pKa’s	  of	  2.70,	  7.22,	  and	  9.62	  (shown	  in	  
parenthesis).	  Its	  intrinsic	  solubility	  is	  17.4	  mg/mL	  (pH	  =	  4.9),	  and	  its	  Log	  D	  (4.8)	  =	  -­‐2.11.	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Figure	  2.10.	  Structural	  similarities	  between	  a	  tri-­‐peptide	  and	  cefadroxil.	  Both	  molecules	  
have	  carboxylic	  groups	  and	  amino	  terminal	  groups	  separated	  by	  a	  carbon	  backbone	  of	  
similar	  length.	  They	  also	  have	  the	  peptide	  bond	  in	  the	  L-­‐conformation.	  Extracted	  from:	  
Rubio	  I.	  and	  Daniel	  H.	  Trends	  in	  Pharmacological	  Sciences,	  Volume	  23,	  Issue	  9,	  434-­‐440,	  1	  
September	  2002.	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Figure	  2.11.	  Some	  of	  the	  transporter	  proteins	  involved	  in	  the	  uptake	  of	  cefadroxil	  in	  
different	  tissues	  of	  the	  body.	  PEPT1	  is	  expressed	  mainly	  on	  the	  apical	  membrane	  of	  the	  
enterocyte,	  but	  also	  at	  lower	  levels	  on	  the	  apical	  membrane	  of	  the	  kidney	  tubular	  cells	  (S1).	  
PEPT2	  is	  responsible	  for	  most	  of	  the	  reabsorption	  of	  cefadroxil	  in	  the	  kidney.	  It	  is	  expressed	  
on	  the	  apical	  membrane	  of	  the	  renal	  tubular	  cells	  in	  the	  S2	  and	  S3	  segments	  of	  the	  proximal	  
tubule.	  The	  organic	  anion	  transporters	  1,	  2,	  and	  3	  (OAT	  1/2/3)	  have	  been	  shown	  to	  be	  
responsible	  for	  the	  active	  secretion	  of	  cefadroxil	  in	  the	  kidney	  tubular	  cells.	  OATP2B1	  
expressed	  in	  the	  liver	  has	  been	  shown	  to	  uptake	  cefadroxil	  into	  the	  hepatocytes	  from	  the	  
basolateral	  membrane.	  Extracted	  from:	  Zair	  et	  al.	  Pharmacogenomics	  2008	  9(5).	  
 
  43 
Tables	  
TRANSPOTER	   SITE	  OF	  EXPRESSION	   REFERENCES	  
PEPT1	  
(SLC15A1)	  
Small	  Intestine	  	  




(apical	  membrane	  of	  epithelial	  cells)	  
[37]	  
Pancreas	  	  
(lysosomes	  of	  acinar	  cells)	  
[121]	  
Bile	  Duct	  











(apical	  membrane	  epithelial	  cells)	  
[125-­‐127]	  
Brain	  








(epithelial	  cells	  in	  glands	  and	  ducts	  
[130]	  
Macrophages	  and	  glial	  cells	  of	  enteric	  nervous	  system	   [23]	  
PHT1	  
(SLC15A4)	  
Brain	   [35]	  
Eye	   [35]	  
PHT2	  
(SLC	  15A3)	  
Brain	   [36]	  
Thymus	  and	  lymphatic	  system	   [36]	  
Lung	   [36]	  
Spleen	   [36]	  
Table	  2.1.	  Localization	  of	  peptide	  transporters.	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PROPERTY	   PEPT1	   PEPT2	   PHT1	   PHT2	  
Gene	   SLC15A1	   SLC15A2	   SLC15A4	   SLC15A3	  
Amino	  Acids	   707	  -­‐	  710	   729	   572	   582	  
Transmembrane	  
Domains	  
12	   12	   12	   12	  
AA	  identity	   80	  –	  90	  %	  
(species)	  
80	  –	  90	  %	  
(species)	  
50%	  (PEPT1)	  
<	  20%	  (PEPT1)	   50%	  (PHT1)	  
<	  20%	  (PEPT1)	  
Amino	  Acids	  in	  
Substrate	  
2-­‐3	   2-­‐3	   2-­‐3	   2-­‐3	  
L-­‐Histidine	   No	   No	   Yes	   Yes	  
Substrate	  Affinity	   Low	   High	   High	   ?	  
Km	  range	   mM	   μM	   μM	   ?	  








Table	  2.2	  Molecular	  and	  functional	  features	  of	  the	  4	  identified	  human	  peptide	  transporters.	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TRANSPORTER	   LOCATION	   SYSTEM	  USED	   REFERENCE	  
PEPT1	   Small	  intestine	  
	  




[45,	  55,	  131]	  
	  
[55,	  132]	  
PEPT2	   Kidney	  (AP)	  
	  
CSF	  
KO	  mice,	  cells,	  
BBMV	  
Cells,	  KO	  mice	  
[132]	  [21]	  [111]	  
[55]	  
[21,	  28,	  29,	  55,	  111]	  
OAT3	   Kidney	  (BL)	   S2	  cells	  
(transfected)	  
[133]	  [112,	  134]	  
OAT1	   Kidney	  (BL)	   S2	  cells	  
(transfected)	  
[112,	  133,	  134]	  
OAT2	  (rat)	   Kidney	  (BL)	   S2	  cells	  
(transfected)	  
[133,	  134]	  
OAT4	   Kidney	  (BL)	   S2	  cells	  
(transfected)	  
[133,	  134]	  
OATP2	   Liver	  rat	  (BL)	   Oocytes	   [113]	  
MRP3/4	   Intestine	   Oocytes	   [115]	  
Table	  2.3.	  Transporters	  involved	  in	  the	  transport	  of	  cefadroxil.	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PHARMACOKINETIC	  PARAMETER	   VALUE	   REFERENCE	  
Clearance	  (mL/min)	   181.5	   [135]	  
Vdss	  (L)	   17.05	   [135]	  
%	  Excreted	  after	  24	  hours	  (I.V.)	   93	   [135]	  
F	  (%)	   90.1	   [135]	  
T1/2	  (min)	   115	   [136]	  
Cmax	  (ug/mL)	  
	  (500	  mg)	  





Tmax	  (min)	   50	   [136]	  
Cl/F	  (mL/min)	   145	  -­‐	  200	   [136]	  
Table	  2.4.	  Pharmacokinetic	  parameters	  of	  cefadroxil	  in	  adult	  humans.	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  INTESTINAL	  PERMEABILITY	  OF	  CEFADROXIL	  	  
IN	  WILD-­‐TYPE	  AND	  PEPT1	  KNOCKOUT	  MICE	  
Abstract	  
The	  purpose	  of	  this	  study	  was	  to	  determine	  the	  contribution	  of	  PEPT1	  on	  
cefadroxil	  intestinal	  permeability	  and	  the	  influence	  of	  concentration,	  segment,	  
potential	  inhibitors,	  and	  pH	  on	  drug	  uptake.	  The	  effective	  permeability	  (Peff)	  of	  
cefadroxil	  was	  measured	  using	  single	  pass	  perfusion	  in	  the	  duodenum,	  jejunum,	  
ileum	  and	  colon	  of	  wild-­‐type	  and	  PEPT1	  knockout	  mice.	  	  The	  Peff	  values	  (cm/s)	  of	  
cefadroxil	  in	  wild-­‐type	  mice	  were:	  4.94*10-­‐5	  in	  duodenum,	  8.01*10-­‐5	  in	  jejunum,	  
8.81*10-­‐5	  in	  ileum	  and	  6.36	  10-­‐6	  in	  colon,	  and	  in	  knockout	  mice	  were:	  2.87*10-­‐7,	  
8.97*10-­‐6,	  4.19*10-­‐6	  and	  3.15*10-­‐6	  cm/s,	  respectively.	  The	  Peff	  values	  for	  the	  small	  
intestine	  were	  significantly	  different	  between	  both	  genotypes	  (p<0.05),	  but	  there	  
was	  no	  difference	  in	  colon.	  The	  uptake	  of	  cefadroxil	  was	  a	  saturable	  process,	  with	  a	  
K’mof	  3.8	  mM	  and	  a	  V’max	  of	  4.75	  nmol/cm2/s.	  	  The	  bulk	  pH	  had	  no	  significant	  effect	  
on	  the	  drug	  uptake.	  There	  was	  a	  significant	  reduction	  in	  the	  Peff	  when	  PEPT1	  
 
  57 
substrates,	  such	  as	  Gly-­‐Pro	  and	  Gly-­‐Sar,	  were	  co-­‐perfused,	  but	  high	  concentrations	  
of	  amino	  acids,	  as	  well	  as	  an	  organic	  acid	  and	  base	  did	  not	  affect	  the	  permeability.	  
The	  findings	  show	  that	  PEPT1	  is	  the	  major	  transporter	  involved	  in	  the	  uptake	  of	  
cefadroxil	  in	  the	  small	  intestine,	  accounting	  for	  about	  90%	  of	  the	  Peff	  of	  this	  
antibiotic.	  
Key	  Words	  
Cefadroxil,	  PEPT1,	  Single	  Pass	  Intestinal	  Perfusion,	  Effective	  permeability,	  
Knockout	  Mice,	  Intestinal	  Permeability.	  	   	  
 
  58 
Introduction	  
Proton	  oligopeptide	  transporters	  (POT’s)	  are	  a	  family	  of	  membrane	  
transport	  proteins	  present	  in	  a	  broad	  range	  of	  species,	  from	  bacteria	  to	  mammals,	  
that	  transport	  proteins	  transport	  di-­‐	  and	  tripeptides—themselves	  products	  of	  
protein	  degradation—and	  other	  peptide-­‐like	  molecules.	  This	  uptake	  process	  occurs	  
with	  the	  co-­‐transport	  of	  protons	  into	  the	  cytosol,	  against	  a	  peptide	  concentration	  
gradient	  and	  down	  an	  inwardly	  directed	  proton	  gradient	  and	  a	  negative	  membrane	  
potential	  [1]	  [2-­‐4].	  
Four	  types	  of	  peptide	  transporters	  have	  been	  cloned	  and	  identified:	  PEPT1,	  
PEPT2,	  PHT1	  and	  PHT2	  [4-­‐6].	  PEPT1	  is	  a	  high-­‐capacity	  and	  low-­‐affinity	  transporter	  
that	  moves	  di-­‐	  and	  tripeptides	  with	  different	  sequences	  and	  charges,	  but	  not	  single	  
amino	  acids	  or	  peptides	  longer	  than	  3	  amino	  acid	  residues.	  [4,	  7,	  8]	  [9].	  It	  is	  
expressed	  predominantly	  in	  the	  small	  intestine,	  and	  to	  a	  lesser	  extent	  in	  the	  kidney,	  
pancreas,	  and	  liver	  [10-­‐12].	  Previous	  studies	  from	  our	  group	  showed	  that	  PEPT1	  is	  
expressed	  at	  the	  apical	  membrane	  of	  enterocytes	  in	  the	  duodenum,	  jejunum	  and	  
ileum	  of	  mice,	  but	  not	  in	  colon[8,	  13].	  These	  studies	  also	  demonstrated	  that	  in	  
PEPT1	  knockout	  mice,	  a	  mouse	  model	  also	  developed	  by	  our	  group,	  the	  effective	  
permeability	  of	  Gly-­‐Sar	  was	  significantly	  reduced	  in	  the	  small	  intestine	  (<10-­‐fold)	  
compared	  to	  wild-­‐type	  mice	  [13].	  Furthermore,	  it	  was	  also	  shown	  that	  the	  
concomitant	  administration	  of	  cefadroxil	  at	  high	  concentrations	  reduced	  
significantly	  the	  effective	  permeability	  of	  Gly-­‐Sar	  in	  the	  small	  intestine	  [8].	  	  
Understanding	  the	  importance	  of	  PEPT1	  contribution	  to	  the	  absorption	  and	  
disposition	  of	  drugs	  has	  been	  a	  goal	  of	  several	  research	  groups	  for	  the	  past	  couple	  of	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decades.	  This	  transporter	  has	  been	  shown	  to	  be	  involved	  in	  the	  pharmacokinetics	  of	  
many	  drugs	  that	  resemble	  di-­‐	  and	  tripeptides,	  such	  as	  betalactam	  antibiotics,	  ACE	  
inhibitors,	  and	  some	  anticancer	  drugs	  like	  bestatin,	  but	  little	  is	  known	  about	  the	  
actual	  contribution	  and	  relevance	  of	  PEPT1	  to	  the	  absorption	  of	  cefadroxil	  [14-­‐20].	  
Cefadroxil	  is	  a	  first	  generation	  cephalosporin,	  use	  to	  treat	  a	  diverse	  range	  of	  
bacterial	  infections,	  such	  as	  urinary	  tract	  infections	  cause	  by	  E.	  coli	  and	  P.	  mirabilis,	  
and	  pneumonia	  caused	  by	  S.	  pyogenes	  [21].	  This	  broad-­‐spectrum	  amino-­‐
cephalosporin	  has	  a	  high	  bioavailability,	  despite	  its	  charge	  and	  poor	  lipophilicity	  at	  
intestinal	  pH.	  Cefadroxil	  is	  very	  stable,	  doesn’t	  hydrolyze	  in	  the	  acidic	  environment	  
of	  the	  stomach	  or	  degraded	  by	  intra-­‐	  or	  extracellular	  enzymes	  and	  is	  eliminated	  
almost	  completely	  intact	  in	  urine	  (>90%)	  in	  24	  hours.	  The	  absorption	  of	  cefadroxil	  
isn’t	  affected	  by	  food,	  and	  this	  drug’s	  half-­‐life	  is	  around	  95	  minutes,	  which	  is	  longer	  
than	  that	  of	  other	  cephalosporins	  of	  the	  same	  generation.	  It	  is	  extensively	  
distributed	  to	  several	  tissues,	  including	  the	  lung,	  tonsils,	  placenta,	  bone,	  muscle,	  and	  
prostate	  and	  is	  approximately	  20%	  bound	  to	  plasma	  proteins	  [21,	  22].	  
	  The	  absorption	  of	  cefadroxil	  from	  the	  small	  intestine	  it’s	  a	  process	  that	  has	  
been	  shown	  to	  have	  Michaelis-­‐Menten	  kinetics.	  [23-­‐25]	  [26,	  27].	  It	  has	  also	  been	  
demonstrated	  that	  due	  to	  its	  chemical	  structure	  resemblance	  to	  physiological	  
occurring	  peptides,	  such	  as	  an	  alpha	  amino	  group,	  a	  carboxylic	  end,	  and	  a	  peptide	  
bond,	  cefadroxil	  is	  a	  substrate	  of	  PEPT1	  [14,	  28].	  However,	  other	  transporters	  also	  
have	  been	  implicated	  in	  the	  transport	  of	  cefadroxil.	  For	  example,	  PEPT2	  has	  been	  
shown	  to	  be	  responsible	  for	  most	  of	  the	  reabsorption	  of	  cefadroxil	  from	  the	  urine	  
back	  to	  the	  blood,	  increasing	  the	  half-­‐life	  of	  the	  drug	  and	  therefore	  increasing	  the	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exposure	  of	  different	  tissues	  to	  the	  antibiotic	  [29].	  	  On	  the	  other	  hand,	  PEPT2	  has	  
also	  been	  shown	  to	  act	  as	  an	  efflux	  transporter	  of	  cefadroxil	  from	  the	  cerebro-­‐spinal	  
fluid	  (CSF)	  in	  the	  choroid	  plexus,	  decreasing	  the	  concentration	  of	  this	  drug	  in	  the	  
brain	  [30,	  31].	  	  
Since	  Cefadroxil	  has	  a	  negative	  charge	  at	  the	  physiological	  pH,	  it	  can	  bind	  to	  
organic	  anion	  transporters	  (OAT).	  These	  transporters	  are	  present	  in	  the	  basolateral	  
membrane	  of	  the	  epithelial	  cells	  in	  the	  proximal	  renal	  tubules,	  and	  are	  thought	  to	  be	  
responsible	  for	  the	  active	  secretion	  into	  the	  blood	  of	  several	  negatively	  charged	  
endogenous	  and	  exogenous	  compounds,	  such	  as	  cefadroxil.	  Although,	  OAT1	  and	  
OAT3	  are	  present	  in	  human	  kidney,	  OAT3	  plays	  a	  stronger	  role	  than	  OAT1	  in	  the	  
active	  secretion	  of	  cephalosporins	  [32-­‐34].	  Also,	  experiments	  using	  Xenopous	  
oocytes	  expressing	  OATP2,	  the	  organic	  anion	  transporting	  polypeptide-­‐2,	  show	  that	  
cefadroxil	  is	  also	  a	  substrate	  for	  this	  transporter	  [35].	  	  	  
Though	  we	  know	  that	  cefadroxil	  is	  a	  substrate	  for	  several	  transporting	  
proteins,	  it	  is	  still	  unknown	  the	  importance	  of	  the	  contribution	  of	  these	  and	  passive	  
diffusion	  to	  the	  total	  mass	  transfer	  process	  in	  the	  small	  intestine.	  Therefore	  the	  aim	  
of	  this	  study	  is	  to	  evaluate	  the	  role	  of	  PEPT1	  in	  the	  absorption	  process	  of	  cefadroxil	  
in	  the	  different	  segments	  of	  the	  intestine,	  and	  also	  to	  evaluate	  the	  factors	  that	  affect	  
it.	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Materials	  and	  Methods	  	  
Chemicals	  
All	  chemicals	  were	  purchased	  from	  Sigma-­‐Aldrich	  (St.	  Louis,	  MO).	  	  
Animals	  
All	  studies	  were	  done	  in	  8-­‐10	  week	  old	  gender-­‐matched	  wild-­‐type	  
(PEPT1+/+)	  and	  PEPT1	  knockout	  	  (PEPT1-­‐/-­‐)	  mice.	  The	  animals	  were	  kept	  in	  a	  
controlled	  temperature	  room	  with	  12-­‐hour	  light,	  12-­‐hour	  dark	  cycle,	  and	  had	  
standard	  diet	  and	  water	  ad	  libitum.	  All	  of	  the	  procedures	  were	  approved	  by	  the	  
University	  of	  Michigan	  Committee	  on	  Use	  and	  Care	  of	  Animals	  (UCUCA),	  and	  were	  
carried	  out	  in	  accordance	  with	  the	  Guide	  for	  Use	  of	  Laboratory	  Animals	  as	  adopted	  
and	  promulgated	  by	  the	  US	  National	  Institutes	  of	  Health	  (NIH	  publication	  No.	  85-­‐23,	  
revised	  in	  1985).	  
In	  Situ	  Single-­‐Pass	  Intestinal	  Perfusion	  	  
Gender-­‐matched	  wild-­‐type	  (PEPT1+/+)	  and	  PEPT1	  knockout	  (PEPT1-­‐/-­‐)	  
mice	  were	  fasted	  overnight.	  Following	  anesthesia	  using	  sodium	  pentobarbital	  (40	  
mg/kg	  ip)	  the	  mice	  were	  placed	  on	  a	  heated	  pad	  to	  maintain	  body	  temperature	  and	  
isopropyl	  alcohol	  was	  used	  to	  sterilize	  the	  abdomen.	  The	  abdomen	  was	  opened	  
through	  a	  midline	  incision	  to	  expose	  the	  abdominal	  cavity	  and	  the	  small	  intestine.	  
An	  8	  cm	  segment	  of	  the	  jejunum	  (proximal	  jejunum)	  was	  isolated	  by	  partially	  
cutting	  the	  intestinal	  segment	  at	  the	  proximal	  and	  distal	  ends	  (2	  cm	  distal	  from	  the	  
Treitz	  ligament).	  Then,	  the	  intestinal	  segment	  was	  rinsed	  and	  cleaned	  with	  isotonic	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saline	  solution,	  and	  two	  glass	  cannulas	  (1.9	  mm	  in	  diameter)	  were	  inserted	  and	  
fixed	  firmly	  at	  place	  with	  silk	  suture	  at	  both	  ends	  of	  it.	  	  
Subsequently,	  animals	  were	  transferred	  to	  a	  temperature-­‐controlled	  
chamber	  (31°C)	  to	  control	  body	  temperature,	  where	  the	  inlet	  cannula	  was	  
connected	  to	  a	  10	  mL	  syringe	  containing	  0.01	  0M	  cefadroxil	  in	  perfusion	  buffer	  at	  
pH	  6.5.	  The	  perfusion	  buffer	  contains	  10	  mM	  2-­‐(N-­‐morpholino)-­‐ethanesulfonic	  acid	  
(MES),	  135	  mM	  sodium	  chloride	  (NaCl),	  and	  5	  mM	  of	  potassium	  chloride	  (KCl).	  The	  
intestinal	  segment	  was	  perfused	  at	  a	  rate	  of	  0.1	  mL/min	  for	  90	  minutes	  using	  a	  
syringe	  pump	  (Harvard	  Apparatus,	  South	  Natick,	  MA).	  Water	  flux	  was	  measured	  
using	  a	  gravimetric	  method.	  Animals	  were	  sacrificed	  at	  the	  end	  of	  the	  experiments	  
before	  recovering	  from	  anesthesia.	  	  
Regional	  Permeability	  Experiments	  
The	  effective	  permeability	  of	  cefadroxil	  was	  measured	  in	  all	  the	  three	  
segments	  of	  the	  small	  intestine	  and	  in	  the	  colon.	  For	  duodenal	  permeability	  an	  
intestinal	  segment	  of	  approximately	  2	  cm	  in	  length	  were	  isolated,	  starting	  at	  the	  end	  
of	  the	  stomach	  and	  ending	  at	  the	  ligament	  of	  Treitz.	  For	  jejunal	  permeability	  
experiments,	  an	  8	  cm	  segment	  was	  isolated	  starting	  at	  2	  cm	  distal	  to	  the	  ligament	  of	  
Treitz.	  For	  ileum	  permeability	  a	  6	  cm	  segment	  was	  isolated	  1	  cm	  proximal	  of	  the	  
ceacum.	  For	  the	  colon,	  a	  segment	  of	  4	  cm	  was	  isolated	  starting	  at	  1	  cm	  distal	  to	  the	  
ceacum.	  All	  experiments	  were	  performed	  at	  pH	  6.5,	  and	  with	  0.01	  mM	  cefadroxil.	  	  
 
  63 
Analytical	  Method	  
The	  samples	  from	  the	  in-­‐situ	  perfusion	  experiments	  were	  assayed	  by	  High	  
Performance	  Liquid	  Chromatography	  (HPLC)	  using	  a	  Waters	  616	  pump,	  a	  Waters	  
717	  auto-­‐sampler,	  and	  a	  photodiodode	  array	  UV	  detector	  (Waters	  2487	  dual	  λ	  
absorbance).	  The	  column	  used	  was	  a	  Waters	  ODS-­‐3	  column	  (2.50*4.6mm),	  the	  
injection	  volume	  was	  20	  µL,	  the	  flow	  rate	  1	  mL/min,	  and	  the	  detection	  wavelength	  
265	  nm.	  The	  isocratic	  mobile	  phase	  was	  a	  mixture	  of	  90:10	  %	  v/v	  of	  
aqueous/organic	  phase.	  The	  aqueous	  phase	  consisted	  of	  0.01%	  trifluoroacetic	  acid	  
(TFA)	  in	  water,	  and	  the	  organic	  phase	  of	  0.01%	  of	  TFA	  in	  acetonitrile.	  The	  perfusion	  
samples	  were	  centrifuged	  at	  11000x	  g	  for	  10	  minutes	  and	  the	  supernatant	  was	  used	  
for	  the	  HPLC	  measurements.	  The	  calibration	  graphs	  for	  the	  cefadroxil	  standards	  
were	  linear	  over	  the	  concentration	  ranges	  of	  0.001	  to	  25	  mM,	  and	  the	  retention	  time	  
for	  cefadroxil	  was	  11	  minutes.	  	  
Data	  Analysis	  
The	  effective	  permeability	  (Peff)	  of	  cefadroxil	  was	  calculated	  according	  to	  the	  
complete	  radial	  mixing	  model	  (parallel	  tube)	  described	  by	  [36]	  [37]	  as	  follow:	  
Peff =
−Q ln Cout Cin( )
2πRL 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (3.1)	  
where	  Q	  is	  the	  perfusion	  rate,	  Cin	  and	  Cout	  are	  the	  concentrations	  of	  drug	  
coming	  into	  the	  intestinal	  segment	  and	  coming	  out	  of	  it	  (corrected	  for	  water	  flux),	  
and	  R	  and	  L	  are	  the	  radius	  and	  the	  length	  of	  the	  intestinal	  segment,	  respectively.	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Then,	  the	  Cin	  and	  Peff	  values	  used	  to	  obtain	  the	  steady-­‐state	  flux	  through	  the	  
epithelial	  membrane	  J:	  
	  
J = Cin ⋅Peff
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (3.2)	  
The	  apparent	  Michaelis-­‐Menten	  parameters	  V’max	  and	  K’m	  were	  calculated,	  
using	  the	  following	  formula:	  	  
J = V 'max ⋅C in
K 'm+Cin 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (3.3)	  
The	  problem	  of	  using	  this	  method	  is	  that	  it	  overestimates	  value	  of	  the	  K’m,	  
because	  it	  doesn’t	  take	  into	  account	  the	  permeability	  of	  cefadroxil	  through	  the	  
unstirred	  water	  layer	  present	  in	  the	  small	  intestine.	  Though,	  it	  became	  necessary	  to	  
separate	  the	  permeability	  of	  cefadroxil	  through	  the	  aqueous	  layer	  (Paq),	  from	  the	  
permeability	  of	  it	  through	  the	  intestinal	  wall	  (Pw)	  using	  the	  method	  described	  by	  [23,	  
24,	  38].	  The	  following	  formula	  is	  used	  to	  calculate	  Pw:	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (3.4)	  
Then,	  the	  boundary	  layer	  approach	  was	  used	  to	  calculate	  the	  aqueous	  
permeability	  (Paq),	  and	  therefore	  the	  wall	  permeability,	  according	  to:	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (3.5)	  
where	  A	  is	  a	  unitless	  constant	  (A	  =	  2.50	  Gz	  +	  1.125),	  R	  is	  the	  radius,	  D	  is	  the	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ratio	  of	  the	  mean	  residence	  time	  of	  a	  fluid	  in	  the	  intestine	  (tres	  =	  πR2L/Q)	  to	  the	  
mean	  radial	  diffusion	  time	  of	  a	  solute	  (tdiff	  =	  2R2/D)	  and	  is	  calculated	  according	  to:	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (3.6)	  
Once	  the	  aqueous	  and	  the	  wall	  and	  aqueous	  permeability	  were	  calculated,	  
the	  concentration	  of	  drug	  at	  the	  surface	  of	  the	  epithelial	  membrane	  (Cw)	  was	  
calculated	  as:	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (3.7)	  
Then	  the	  intrinsic	  parameters	  Km	  and	  Vmax	  were	  be	  subsequently	  found	  with	  
the	  following	  equation:	  
J = Vmax ⋅C w
Km +Cw 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (3.8)	  
In	  addition	  the	  data	  was	  also	  fitted	  to	  a	  more	  complex	  model	  that	  included	  
both	  a	  saturable	  and	  a	  non-­‐saturable	  (passive	  diffusion)	  component	  with	  the	  three	  
following	  parameters	  Km,	  Vmax	  and	  Pm.	  Since	  Pm	  had	  no	  significant	  difference	  from	  
zero,	  and	  the	  fitting	  of	  the	  data	  did	  not	  improved,	  we	  decided	  to	  use	  the	  model	  with	  
only	  saturable	  process,	  as	  described	  in	  equation	  3.8.	  
Statistical	  Analysis	  
The	  data	  are	  presented	  as	  mean	   	  standard	  error	  (SE),	  where	  n=3-­‐8.	  In	  order	  
to	  determine	  statistically	  significant	  differences	  between	  groups,	  one-­‐way	  analysis	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and	  a	  p<0.05	  was	  considered	  statistically	  significant.	  To	  test	  the	  quality	  of	  the	  fit	  of	  
the	  linear	  models,	  the	  residual	  plots	  were	  visually	  inspected,	  and	  the	  coefficient	  of	  
determination	  (R2)	  and	  the	  standard	  error	  of	  the	  residuals	  were	  evaluated	  as	  well.	  
All	  statistical	  analyses	  were	  performed	  with	  Prism	  v5.0.	  A	  p-­‐value	  below	  0.05	  was	  
considered	  statistically	  significant.	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Results	  
Stability	  of	  Cefadroxil	  	  
Cefadroxil	  was	  not	  metabolized	  during	  the	  in	  situ	  intestinal	  permeability	  
studies.	  Figure	  3.1	  shows	  chromatograms	  of	  blank	  perfusion	  buffer,	  cefadroxil	  
dissolved	  in	  perfusion	  buffer,	  the	  mouse	  jejunal	  perfusate,	  and	  the	  exiting	  perfusate	  
containing	  working	  solution	  (10	  µM	  cefadroxil	  in	  buffer)	  in	  the	  jejunum	  of	  mice.	  
Concentration-­‐Dependency	  Studies	  
To	  understand	  the	  kinetics	  of	  the	  transport	  in	  the	  jejunum,	  various	  
concentrations	  of	  this	  antibiotic	  were	  used	  (0.005,	  0.01,	  0.1,	  1,	  5,	  10	  and	  25	  mM)	  in	  
wild-­‐type	  mice.	  Figure	  3.2	  shows	  that	  the	  flux	  of	  cefadroxil	  has	  a	  saturable	  
component	  to	  it,	  and	  the	  data	  was	  fitted	  to	  the	  model	  described	  by	  equation	  3,	  the	  
apparent	  Michaelis	  Menten	  parameters	  V’max	  and	  K’m	  for	  cefadroxil	  in	  the	  jejunum	  
were	  4.75	  nmol/cm2/sec	  and	  3.83	  mM,	  respectively	  (R2=0.89)	  (See	  Table	  3.1).	  	  
Then,	  using	  the	  boundary	  layer	  approach,	  the	  aqueous	  permeability	  (Paq)	  of	  
cefadroxil	  was	  calculated	  as	  8.91*10-­‐3	  cm/sec.	  Subsequently,	  the	  concentrations	  of	  
cefadroxil	  at	  the	  intestinal	  wall	  (Cw)	  and	  the	  wall	  permeability	  of	  cefadroxil	  (Pw)	  
were	  also	  calculated,	  and	  the	  data	  was	  fitted	  again	  to	  equation	  3.3.	  The	  resulting	  
intrinsic	  Vmax	  and	  Km	  were	  4.48	  nmol/cm2/s	  and	  2.8	  mM,	  respectively	  (R2=0.90)	  
(See	  Table	  3.2).	  These	  results	  show	  that	  cefadroxil	  has	  low	  affinity	  for	  the	  
transporter	  (high	  Km)	  and	  high	  Vmax,	  and	  are	  similar	  to	  the	  results	  obtained	  by	  Sinko	  
et	  al	  [23,	  24],	  and	  Sanchez-­‐Pico	  et	  al	  [27]	  in	  rat	  jejunum.	  Similar	  to	  Sinko’s	  results	  
[23,	  24],	  our	  results	  also	  fit	  the	  simplest	  model	  (without	  the	  passive	  diffusion	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component)	  better,	  and	  it	  is	  consistent	  with	  the	  previously	  described	  characteristics	  
of	  PEPT1	  transport	  of	  amino-­‐cephalosporins	  [39].	  	  
To	   see	   if	   one	   or	   more	   transporters	   were	   in	   charge	   of	   the	   transport	   of	  
cefadroxil,	   the	   data	  was	   linearized	   using	  Woolf–Eadie–Augustinsson–Hofstee	   plot.	  
As	   seen	   in	   Figure	  3.4	   the	   curve	  has	   only	   one	   slope,	  which	   indicates	   that	   only	   one	  
transporter	  is	  responsible	  for	  it.	  	  	  
Regional	  Permeability	  Studies	  
To	  determine	  if	  the	  is	  a	  difference	  in	  functionality	  of	  PEPT1	  along	  the	  small	  
intestine	  and	  colon,	  the	  effective	  permeability	  of	  cefadroxil	  was	  measured	  in	  all	  4	  
intestinal	  segments	  of	  the	  intestine	  both	  wild-­‐type	  and	  PEPT1	  knockout	  mice.	  As	  
shown	  in	  Figure	  3.6	  the	  effective	  permeability	  of	  cefadroxil	  is	  significantly	  higher	  in	  
the	  duodenum,	  jejunum	  and	  ileum	  of	  wild-­‐type	  mice,	  when	  compared	  to	  the	  
duodenum,	  jejunum,	  and	  ileum	  of	  PEPT1	  knockout	  mice.	  The	  effective	  permeability	  
of	  cefadroxil	  in	  knockout	  mice	  is	  about	  2%	  in	  the	  duodenum,	  10%	  in	  the	  jejunum	  
and	  5%	  in	  the	  ileum,	  of	  the	  wild-­‐type	  mice.	  There	  is	  no	  significant	  difference	  in	  the	  
effective	  permeability	  of	  cefadroxil	  in	  the	  colon	  of	  both	  genotypes.	  Also,	  the	  effective	  
permeability	  of	  cefadroxil	  in	  wild-­‐type	  mice	  is	  significantly	  higher	  in	  the	  duodenum,	  
jejunum	  and	  ileum,	  that	  in	  the	  colon.	  There	  is	  no	  statistically	  significant	  difference	  in	  
the	  effective	  permeability	  of	  cefadroxil	  for	  the	  four	  intestinal	  segments	  in	  PEPT1	  
knockout	  mice.	  Table	  3.3	  shows	  the	  mean	  values	  and	  standard	  error	  for	  the	  effective	  
permeability	  in	  all	  4	  segments	  of	  both	  wild-­‐type	  and	  PEPT1	  knockout	  mice.	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  pH-­‐Dependent	  Studies	  
The	  jejunal	  effective	  permeability	  of	  cefadroxil	  was	  evaluated	  at	  different	  
relevant	  physiological	  pH	  values	  (from	  pH	  5.5	  to	  7.5).	  This	  was	  generated	  by	  mixing	  
different	  ratios	  of	  10	  mM	  HEPES/TRIS	  and	  10	  mM	  MES/TRIS,	  keeping	  the	  
osmolarity	  of	  the	  buffer	  constant.	  	  All	  experiments	  were	  done	  with	  0.01	  mM	  of	  
cefadroxil.	  As	  observed	  in	  Figure	  3.7	  the	  optimal	  uptake	  of	  cefadroxil	  occurs	  at	  pH	  6.	  
Though	  there	  is	  no	  statistical	  significant	  difference	  on	  the	  effective	  permeability	  of	  
cefadroxil	  at	  different	  pH	  values	  when	  compared	  to	  the	  control	  with	  a	  pH	  of	  7.5.	  
Following	  these	  experiments,	  the	  effect	  of	  dimethyl-­‐amiloride	  (DMA),	  an	  inhibitor	  of	  
proton/sodium	  exchanger	  the	  apical	  membrane,	  was	  co-­‐administered	  to	  see	  if	  the	  
increase	  in	  the	  pH	  at	  the	  apical	  membrane	  had	  an	  effect	  on	  the	  permeability	  of	  
cefadroxil.	  Results	  show	  that	  a	  direct	  inhibition	  of	  the	  proton	  exchanger,	  and	  
therefore	  an	  increase	  in	  the	  pH	  at	  the	  apical	  membrane	  significantly	  decreased	  the	  
effective	  permeability	  of	  cefadroxil.	  	  
Substrate	  Specificity	  Studies	  
Different	  molecules	  were	  used	  to	  evaluate	  their	  effect	  on	  the	  jejunal	  
permeability	  of	  cefadroxil.	  Substrates	  for	  PEPT1	  and	  other	  transporters	  were	  used,	  
including	  amino	  acids,	  such	  as	  L-­‐histidine	  and	  glycine,	  dipeptides	  such	  as	  Gly-­‐Sar	  
and	  Gly-­‐Pro,	  p-­‐aminohippuric	  acid	  (PHA)	  an	  organic	  anion	  transporter	  inhibitor,	  
and	  n-­‐methyl-­‐nicotine-­‐amide	  (NMN),	  an	  organic	  cation	  transporter	  inhibitor.	  
Cephalexin,	  a	  first	  generation	  α-­‐amino-­‐cephalosporin,	  and	  cephalothin,	  a	  first	  
generation	  cephalosporin	  that	  lacks	  the	  α-­‐amino	  group,	  were	  also	  used.	  All	  
compounds	  were	  used	  at	  a	  concentration	  of	  25	  mM	  and	  the	  experiments	  were	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performed	  at	  a	  pH	  of	  6.5.	  Figure	  3.7	  shows	  that	  the	  jejunal	  effective	  permeability	  of	  
cefadroxil	  was	  significantly	  decreased	  with	  the	  addition	  of	  Gly-­‐Sar	  and	  Gly-­‐Pro,	  
which	  indicates	  that	  this	  antibiotic	  is	  transported	  by	  a	  peptide	  transporter	  in	  the	  
jejunum,	  such	  as	  PEPT1,	  capable	  of	  transporting	  dipeptides.	  On	  the	  other	  hand,	  no	  
significant	  effect	  was	  seen	  when	  L-­‐Histidine	  and	  glycine	  were	  added	  to	  the	  perfusate	  
solution.	  This	  indicates	  that	  cefadroxil	  is	  not	  taken	  up	  by	  the	  peptide/histidine	  
transporters	  (PHT1/PHT2),	  or	  by	  those	  L-­‐histidine	  and	  glycine	  transporters	  that	  
could	  be	  present	  in	  the	  mouse	  jejunum	  such	  as	  the	  B0+	  transporters,	  GLYT1,	  LAT1	  
and	  ASCT2	  [40].	  The	  addition	  of	  a	  high	  concentration	  of	  cephalexin,	  another	  first	  
generation	  amino-­‐cephalosporin,	  caused	  a	  significant	  decrease	  in	  the	  effective	  
permeability	  of	  cefadroxil.	  Which	  indicates	  that	  both	  of	  these	  amino	  cephalosporins	  
are	  transported	  by	  the	  same	  system	  in	  the	  mouse	  jejunum.	  The	  concomitant	  
administration	  of	  high	  concentration	  of	  cephalothin,	  a	  cephalosporin	  that	  doesn’t	  
contain	  the	  alpha	  amino	  group	  and	  therefore	  is	  not	  a	  substrate	  for	  PEPT1,	  did	  not	  
affect	  the	  effective	  permeability	  of	  cefadroxil.	  The	  administration	  of	  p-­‐
aminohippuric	  acid	  didn’t	  cause	  a	  significant	  reduction	  in	  the	  effective	  permeability	  
of	  cefadroxil,	  nor	  did	  the	  addition	  of	  1-­‐methyl	  nicotinamide.	  These	  results	  indicate	  
that	  neither	  the	  organic	  anion	  transporters,	  nor	  the	  organic	  cation	  ones,	  are	  
significantly	  involved	  in	  the	  uptake	  of	  cefadroxil	  from	  the	  mouse	  jejunum.	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Discussion	  
The	  work	  disclosed	  in	  this	  paper	  demonstrates	  and	  quantifies	  for	  the	  first	  
time	  the	  importance	  of	  PEPT1	  in	  the	  absorption	  of	  cefadroxil	  in	  the	  small	  intestine	  
and	  in	  the	  colon.	  	  The	  results	  of	  the	  performed	  perfusion	  experiments	  and	  the	  
preliminary	  in	  vivo	  ones	  gave	  important	  and	  novel	  information	  about	  the	  uptake	  of	  
cefadroxil	  in	  mice.	  We	  found	  that:	  1)	  Cefadroxil	  permeability	  in	  the	  small	  intestine	  is	  
a	  carrier	  mediated	  process	  that	  is	  concentration	  dependent	  and	  is	  driven	  mainly	  by	  
one	  transporter,	  PEPT1.	  2)	  The	  effective	  permeability	  (Peff)	  values	  for	  cefadroxil	  in	  
wild-­‐type	  mice	  are	  at	  least	  10	  fold	  higher	  in	  the	  small	  in	  the	  small	  intestine	  and	  
there	  is	  no	  significant	  difference	  in	  colon	  for	  both	  species.	  3)	  A	  Km	  of	  3.83	  mM	  in	  the	  
jejunum	  indicates	  that	  the	  transporter	  has	  low	  affinity	  for	  cefadroxil.	  4)	  That	  the	  
change	  of	  bulk	  in	  the	  pH	  doesn’t	  significantly	  affect	  the	  effective	  permeability	  of	  
cefadroxil	  in	  mice	  jejunum,	  but	  the	  actual	  blockage	  of	  the	  proton-­‐sodium	  exchanger	  
actually	  does	  affect	  the	  Peff	  of	  cefadroxil.	  	  	  
Using	  PEPT1	  knockout	  mice	  that	  were	  previously	  developed	  by	  Hu	  et	  al	  [13]	  
we	  demonstrated	  that	  PEPT1	  is	  the	  most	  important	  transporter	  in	  the	  uptake	  of	  
cefadroxil	  from	  the	  small	  intestine	  in	  mice.	  Permeability	  data	  obtained	  in	  mice	  is	  of	  
great	  importance	  and	  could	  be	  very	  relevant	  in	  clinical	  research,	  since	  it	  could	  be	  
used	  to	  predict	  in	  someway	  the	  behavior	  of	  PEPT1	  substrates	  when	  administered	  to	  
humans.	  Although	  it	  has	  been	  shown	  before	  that	  permeability	  data	  obtained	  using	  
perfusion	  experiments	  in	  rats	  correlates	  with	  the	  fraction	  absorbed	  in	  humans	  for	  
drugs	  that	  passively	  diffuse	  through	  the	  membranes,	  for	  drugs	  that	  use	  transporters	  
it	  might	  not	  be	  the	  case.	  Mice	  have	  been	  shown	  to	  have	  a	  very	  similar	  gene	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expression	  pattern	  to	  humans	  for	  PEPT1	  and	  other	  transporters	  in	  the	  small	  
intestine,	  while	  in	  rats	  the	  expression	  of	  PEPT1	  has	  been	  shown	  to	  be	  significantly	  
higher	  [41].	  But	  not	  only	  the	  expression	  pattern	  between	  mice	  and	  human	  is	  very	  
similar,	  there	  is	  also	  a	  high	  homology	  (83%	  amino	  acid	  identity)	  between	  the	  
structures	  of	  the	  human	  PEPT1	  and	  the	  mouse	  PEPT1	  as	  shown	  by	  Fei	  et	  al	  [42].	  The	  
use	  of	  mice	  also	  allows	  the	  testing	  of	  different	  conditions	  that	  could	  be	  difficult	  or	  
sometimes	  impossible	  to	  perform	  in	  humans,	  such	  as	  testing	  the	  permeability	  of	  
drugs	  in	  distal	  segments	  of	  the	  small	  intestine	  and	  colon,	  or	  the	  use	  of	  really	  high	  
concentrations	  of	  potentially	  toxic	  drugs.	  We	  chose	  this	  in	  situ	  single	  pass	  intestinal	  
perfusion	  technique	  over	  other	  in	  vitro	  and	  in	  situ	  methods,	  because	  it	  resembles	  
more	  accurately	  in	  vivo	  conditions,	  such	  as	  intact	  blood	  supply.	  	  
Cefadroxil	  was	  chosen	  as	  the	  model	  drug,	  given	  its	  good	  stability	  [23,	  29]	  and	  
well-­‐known	  properties,	  in	  the	  mist	  of	  understanding	  the	  importance	  of	  PEPT1	  in	  the	  
absorption	  of	  therapeutically	  relevant	  compounds.	  Since	  cefadroxil	  has	  a	  chemical	  
structure	  that	  highly	  resembles	  that	  of	  a	  peptide,	  it	  is	  a	  substrate	  for	  peptide	  
transporters	  (PEPT1	  and	  PEPT2).	  A	  plethora	  of	  studies	  have	  demonstrated	  how	  
cefadroxil	  can	  inhibit	  the	  uptake	  of	  Gly-­‐Sar	  in	  different	  systems,	  such	  as	  Caco-­‐2	  cells	  
[15],	  cells	  expressing	  PEPT1	  [28,	  43],	  Oocytes	  expressing	  PEPT1	  [14,	  26],	  mice	  [8].	  
[26].	  Very	  few	  studies	  have	  actually	  described	  the	  kinetics	  and	  other	  characteristics	  
of	  its	  transport	  in	  the	  small	  intestine	  [23,	  24,	  44].	  And	  definitely	  none	  have	  yet	  
calculated	  the	  importance	  of	  this	  PEPT1	  in	  the	  absorption	  of	  cefadroxil.	  PEPT1	  has	  
been	  described	  in	  the	  literature	  as	  a	  low	  affinity	  transporter,	  which	  means	  that	  it	  
has	  low	  affinity	  for	  its	  substrates	  of	  its	  substrates	  with	  Km	  values	  in	  the	  lower	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millimolar	  range	  (0.2-­‐10	  mM)[2].	  In	  our	  studies	  we	  measured	  both	  the	  apparent	  
(K’m	  =3.8	  mM)	  and	  the	  intrinsic	  Km	  for	  cefadroxil	  (Km	  =2.8	  mM),	  and	  we	  found	  that	  
they	  are	  in	  the	  range	  of	  PEPT1	  and	  are	  also	  consistent	  to	  the	  Km	  values	  for	  cefadroxil	  
previously	  reported	  by	  Sinko	  and	  Amidon	  in	  rat	  jejunum	  (Km=	  5.9	  mM)	  [24],	  6.6	  by	  
Sanchez-­‐Picó	  [27],	  and	  by	  Wenzel	  et	  al,	  in	  oocytes	  transfected	  with	  rabbit	  intestinal	  
PEPT1	  (Km=	  1.1mM)	  [14,	  26].	  	  
To	  measure	  the	  actual	  relevance	  of	  PEPT1	  in	  the	  uptake	  of	  cefadroxil,	  we	  
compared	  wild-­‐type	  vs	  knockout	  mice.	  These	  experiments	  showed	  that	  PEPT1	  is	  
extremely	  important	  for	  the	  absorption	  of	  cefadroxil	  from	  the	  small	  intestine,	  since	  
the	  effective	  permeability	  of	  cefadroxil	  in	  is	  significantly	  lower	  (10%	  or	  less)	  in	  the	  
duodenum,	  jejunum	  and	  ileum	  of	  PEPT1	  knockout	  mice.	  Cefadroxil	  transport	  is	  
minimal	  in	  colon,	  where	  there	  is	  no	  expression	  of	  PEPT1,	  and	  as	  expected	  both	  wild-­‐
type	  and	  PEPT1	  knockout	  mice	  have	  very	  similar	  values.	  
The	  concentration	  of	  cefadroxil	  used	  in	  our	  perfusion	  experiments	  ranged	  
from	  0.005	  mM	  to	  25	  mM.	  This	  range	  of	  concentrations	  allows	  good	  estimation	  of	  
the	  Km	  and	  Vmax	  for	  PEPT1,	  since	  full	  saturation	  is	  achieved.	  When	  cefadroxil	  is	  
administered	  to	  patients	  it	  is	  given	  in	  doses	  of	  250,	  500	  or	  1000	  mg,	  once	  or	  twice	  
daily.	  Since	  the	  volume	  of	  the	  small	  intestine	  in	  fasted	  patients	  has	  been	  established	  
to	  be	  between	  50	  and	  1100	  mL,	  and	  on	  average	  500	  mL,	  the	  concentrations	  of	  
cefadroxil	  approximately	  translate	  to	  values	  between	  0.5	  and	  50	  mM.	  Our	  
experiments	  therefore	  are	  carried	  out	  at	  a	  range	  of	  concentrations	  that	  fall	  below	  
and	  above	  the	  ones	  present	  in	  the	  jejunum	  in	  humans	  after	  the	  administration	  of	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cefadroxil,	  thus	  allowing	  us	  to	  understand	  more	  accurately	  the	  behavior	  of	  
cefadroxil	  [45].	  	  
As	  seen	  before	  with	  Gly-­‐Sar	  in	  previously	  reported	  in	  situ	  experiments	  [8],	  
the	  change	  in	  bulk	  pH	  has	  no	  significant	  effect	  on	  the	  effective	  permeability	  of	  
cefadroxil	  in	  the	  small	  intestine.	  The	  effect	  of	  pH	  in	  the	  uptake	  of	  cefadroxil	  has	  been	  
previously	  described	  in	  vitro	  systems,	  such	  as	  Caco-­‐2	  cells	  and	  Oocytes	  transfected	  
with	  rabbit	  PEPT1	  [26],	  but	  not	  in	  animal	  models.	  In	  Oocytes,	  Wenzel	  et	  al	  showed	  
that	  the	  uptake	  of	  cefadroxil	  in	  Caco-­‐2	  cells	  is	  optimum	  between	  pH	  6	  and	  6.5,	  and	  
when	  was	  plotted	  against	  the	  apical	  pH	  it	  displayed	  a	  bell-­‐shape	  curve.	  They	  also	  
showed	  that	  in	  Oocytes	  expressing	  PEPT1,	  the	  cefadroxil-­‐mediated	  inward	  current	  
is	  at	  its	  maximum	  at	  pH	  6.5	  (-­‐60mV)	  and	  it	  decreases	  to	  half	  at	  it	  at	  pH	  5.5	  [26].	  The	  
lack	  of	  significant	  difference	  observed	  in	  situ	  and	  in	  vivo	  can	  be	  explained	  by	  the	  
presence	  of	  an	  acidic	  microclimate	  layer	  in	  the	  apical	  membrane	  of	  the	  intestinal	  
epithelial	  cells.	  This	  layer,	  formed	  by	  mucus	  and	  proton	  secretion	  (by	  transporters)	  
at	  the	  brush	  border	  membrane,	  creates	  an	  environment	  that	  is	  highly	  resistant	  to	  pH	  
changes	  in	  the	  bulk	  of	  the	  intestine	  [46,	  47].	  In	  order	  to	  actually	  affect	  the	  pH	  at	  the	  
apical	  membrane	  we	  used	  DMA,	  an	  inhibitor	  of	  the	  sodium-­‐proton	  exchanger	  at	  the	  
apical	  membrane	  of	  the	  enterocytes.	  	  
To	  fully	  confirm	  that	  PEPT1	  was	  the	  main	  transporter	  responsible	  for	  the	  
absorption	  cefadroxil	  different	  compounds,	  high	  doses	  of	  known	  substrates	  and	  
non-­‐substrates	  of	  PEPT1	  were	  perfused	  concomitantly	  with	  cefadroxil.	  When	  
known	  substrates	  of	  PEPT1	  were	  used	  at	  high	  concentrations,	  such	  as	  Gly-­‐Sar,	  Gly-­‐
Pro,	  and	  cephalexin,	  the	  effective	  permeability	  of	  cefadroxil	  was	  significantly	  
 
  75 
reduced,	  which	  confirms	  that	  cefadroxil	  is	  a	  PEPT1	  substrate.	  On	  the	  other	  hand	  the	  
lack	  of	  effect	  on	  the	  effective	  seen	  on	  the	  effective	  permeability	  of	  cefadroxil	  when	  
non-­‐PEPT1	  substrates,	  such	  as	  the	  amino	  acids	  glycine	  and	  l-­‐histidine,	  the	  organic	  
base	  TEA,	  the	  organic	  acid	  PAH	  and	  the	  non-­‐amino-­‐cephalosporin	  cephalothin,	  were	  
given	  at	  high	  concentrations,	  indicates	  that	  cefadroxil	  is	  transported	  mainly	  by	  
PEPT1	  and	  not	  by	  other	  transporters	  in	  the	  small	  intestine.	  
In	  conclusion	  we	  have	  extensively	  characterized	  the	  PEPT1-­‐mediated	  uptake	  
of	  cefadroxil	  and	  the	  factors	  that	  affect	  it.	  We	  shown	  that	  it	  is	  a	  saturable	  process	  
and	  demonstrated	  that	  in	  the	  duodenum,	  jejunum	  and	  ileum	  it	  represents	  at	  least	  
the	  90%	  of	  the	  uptake	  of	  cefadroxil	  in	  situ.	  We	  have	  also	  shown	  that	  even	  though	  the	  
change	  in	  the	  bulk	  pH	  has	  no	  effect	  on	  the	  uptake	  of	  cefadroxil,	  the	  increase	  in	  the	  
pH	  by	  the	  actual	  depletion	  of	  protons	  at	  the	  apical	  membrane	  (caused	  by	  DMA)	  does	  
in	  fact	  decrease	  the	  uptake	  of	  cefadroxil.	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Tables	  
	  
PARAMETER	   VALUE	  
V’max	  (nmol/cm2/s)	   4.8	  
K’m(mM)	   3.8	  
R2	   0.894	  
Std	  Error	  Vmax’	  (nmol/cm2/sec)	   0.4	  
Std	  Error	  K’m	  (mM)	   1.2	  
Table	  3.1.	  Apparent	  Michaelis-­‐Menten	  parameters	  of	  cefadroxil	  in	  the	  jejunum	  of	  wild-­‐type	  
mice.	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PARAMETER	   VALUE	  
Paq	  (cm/s)	   8.9*10-­‐3	  
Vmax	  (nmol/cm2/s)	  	   4.5	  
Km	  (mM)	   2.1	  
R2	   0.898	  
Std	  Error	  Vmax	  (nmol/cm2/sec)	   0.3	  
Std	  Error	  Km	  (mM)	   0.6	  
Table	  3.2.	  Intrinsic	  Michaelis-­‐Menten	  parameters,	  and	  aqueous	  permeability	  (Paq)	  of	  
cefadroxil	  in	  the	  jejunum	  of	  wild-­‐type	  mice.	  	   	  
 




Cefadroxil	  Peff	  (cm/s	   i 	  10	  -­‐	  4)	  
Wild	  Type	   PEPT1	  Knockout	  
Duodenum	   0.493	  ±	  0.153	  
	  
0.003	  ±	  0.017	  
Jejunum	   0.809	  ±	  0.075	   0.009	  ±	  0.053	  
Ileum	   0.881	  ±	  0.177	  
	  
0.042	  ±	  0.023	  
Colon	   0.063	  ±	  0.089	   0.031	  ±	  0.052	  
	  
Table	  3.3.	  Effective	  permeability	  values	  of	  cefadroxil	  for	  the	  different	  segments	  of	  the	  
intestine	  in	  wild-­‐type	  and	  PEPT1	  knockout	  mice.	  Data	  are	  expressed	  as	  mean	  ±	  S.E.	  (n=4-­‐8).	  
	   	  
 








	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  
	  





Figure	  3.1.	  Chromatographs	  of	  A)	  Blank	  buffer,	  B)	  10uM	  cefadroxil	  in	  buffer,	  C)	  Mouse	  
jejunal	  perfusate	  and	  D)	  jejunal	  perfusate	  with	  10	  μM	  cefadroxil.	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Figure	  3.2.	  Concentration-­‐dependent	  flux	  of	  cefadroxil	  (0.01-­‐25	  mM)	  in	  the	  jejunum	  of	  wild	  
type	  mice.	  Cin	  is	  the	  concentration	  of	  cefadroxil	  in	  the	  perfusion	  buffer.	  All	  studies	  were	  done	  
at	  pH	  6.5.	  Values	  are	  expressed	  as	  mean	  ±	  S.E.	  (n=4-­‐8).	  
	   	  
 
  84 
	  
Figure	  3.3	  Concentration-­‐dependent	  flux	  of	  cefadroxil	  (0.01-­‐25	  mM)	  in	  the	  jejunum	  of	  wild	  
type	  mice.	  Cw	  is	  the	  calculated	  concentration	  of	  cefadroxil	  at	  the	  intestinal	  wall.	  All	  studies	  
were	  done	  at	  pH	  6.5.	  Values	  are	  expressed	  as	  mean	  ±	  S.E.	  (n=4-­‐8).	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Figure	  3.4.	  Woolf–Eadie–Augustinsson–Hofstee	  plot.	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Figure	  3.5.	  Effective	  permeability	  (Peff)	  of	  10	  µM	  cefadroxil	  in	  the	  jejunum	  of	  wild	  type	  (WT)	  
and	  PEPT1	  knockout	  (KO)	  mice.	  ***	  p<0.005	  Values	  are	  expressed	  as	  mean	  ±	  S.E.	  (n=4-­‐8).	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Figure	  3.6.	  Effective	  permeability	  (Peff)	  of	  10	  µM	  cefadroxil	  in	  the	  different	  intestinal	  
segments	  of	  wild	  type	  (WT)	  and	  PEPT1	  knockout	  (KO)	  mice.	  Studies	  were	  done	  at	  pH	  6.5.	  
Data	  are	  expressed	  as	  mean	  ±	  S.E.	  (n=4-­‐8).	  Same	  letters	  represent	  no	  statistically	  significant	  
difference,	  while	  different	  letters	  mean	  that	  there	  is	  a	  significant	  difference.	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Figure	  3.7.	  A)	  Effect	  of	  bulk	  pH	  on	  the	  effective	  permeability	  (Peff)	  of	  cefadroxil	  (10	  µM)	  in	  
the	  jejunum	  of	  wild	  type	  mice.	  Data	  are	  expressed	  as	  Mean	  ±	  S.E.	  (n=4-­‐8).	  B)	  Effect	  of	  
dimethyl-­‐amiloride	  (DMA)	  on	  the	  effective	  permeability	  of	  cefadroxil	  in	  the	  jejunum	  of	  wild-­‐
type	  mice	  at	  pH=	  6.5.	  Data	  are	  expressed	  as	  mean	  ±	  S.E.	  (n=4-­‐8).	  **	  p<	  0.01.	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Figure	  3.8.	  Effect	  of	  potential	  inhibitors	  on	  the	  effective	  permeability	  (Peff)	  of	  cefadroxil	  in	  
the	  jejunum	  of	  wild	  type	  mice.	  Data	  are	  presented	  as	  mean	  ±	  S.E.	  (n=4-­‐8).	  	  **	  p<	  0.01	  and	  ***	  
p<	  0.005.	  Concentration	  of	  cefadroxil	  is	  10	  μM	  and	  concentration	  of	  inhibitors	  is	  25	  mM.	  
	   	  
 





	  ORAL	  ABSORPTION,	  TISSUE	  DISTRIBUTION,	  AND	  DISPOSITION	  OF	  
CEFADROXIL	  IN	  WILD-­‐TYPE	  AND	  PEPT1	  KNOCKOUT	  MICE	  
	  
Abstract	  
Although	  cefadroxil	  is	  known	  to	  be	  a	  PEPT1	  substrate,	  the	  relative	  
importance	  of	  this	  transporter	  in	  the	  intestinal	  absorption	  of	  cefadroxil,	  an	  amino-­‐
cephalosporin	  antibiotic,	  is	  unknown.	  Therefore,	  the	  aim	  of	  this	  study	  was	  to	  
determine	  the	  contribution	  of	  PEPT1	  in	  the	  absorption,	  tissue	  distribution,	  and	  
disposition	  of	  cefadroxil	  under	  in	  vivo	  conditions.	  The	  pharmacokinetics	  of	  3H-­‐
cefadroxil	  was	  studied	  in	  wild-­‐type	  and	  PEPT1	  knockout	  mice	  after	  both	  oral	  (44.5,	  
89.1,	  178	  and	  356	  nmol/g)	  and	  intravenous	  (44.5	  nmol/g)	  bolus	  administrations.	  
Oral	  doses	  were	  scaled	  according	  to	  surface	  area	  using	  the	  four	  most	  prescribed	  
human	  doses,	  and	  were	  given	  by	  oral	  gavage.	  After	  harvesting	  serial	  blood	  samples	  
over	  120	  min,	  plasma	  concentrations	  of	  radioactive	  cefadroxil	  were	  measured	  using	  
a	  dual-­‐channel	  liquid	  scintillation	  counter.	  Pharmacokinetic	  parameters	  were	  
determined	  using	  a	  non-­‐compartmental	  analysis	  of	  the	  plasma	  concentration-­‐time	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profiles.	  The	  Cmax	  and	  AUC0-­‐120	  values	  of	  cefadroxil	  across	  all	  4	  oral	  doses	  were	  
statistically	  and	  substantially	  lower	  for	  the	  PEPT1	  knockout	  mice,	  as	  compared	  to	  
wild-­‐type	  animals.	  However,	  dose-­‐corrected	  Cmax	  and	  AUC0-­‐120	  estimates	  were	  not	  
different	  between	  treatments	  for	  each	  genotype.	  Likewise,	  analysis	  of	  the	  
intravenous	  data	  showed	  there	  was	  no	  significant	  difference	  in	  cefadroxil	  
disposition	  between	  wild-­‐type	  and	  PEPT1	  knockout	  mice.	  These	  findings	  
demonstrate	  that	  PEPT1	  ablation	  has	  a	  substantial	  effect	  on	  cefadroxil	  absorption,	  
reducing	  its	  systemic	  exposure	  by	  8-­‐	  to	  10-­‐fold.	  Moreover,	  cefadroxil	  exhibits	  an	  
“apparent”	  linearity	  over	  the	  44.5	  -­‐	  356	  nmol/g	  dose	  range.	  The	  tissue	  distribution	  
experiments	  showed	  that	  PEPT1	  was	  only	  important	  for	  the	  uptake	  of	  cefadroxil	  
into	  the	  enterocytes	  of	  the	  small	  intestine,	  but	  not	  for	  the	  uptake	  of	  cefadroxil	  into	  
other	  tissues	  of	  the	  body.	  Finally,	  the	  disposition	  of	  cefadroxil	  by	  non-­‐PEPT1	  
processes	  is	  not	  different	  between	  genotypes	  given	  its	  virtually	  superimposable	  
plasma	  profiles	  after	  intravenous	  dosing.	  	  
Key	  Words	  
Oral	  absorption,	  Tissue	  Distribution,	  Disposition,	  PEPT1,	  Cefadroxil,	  Preclinical	  
Pharmacokinetics,	  Absorption	  Analysis.	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Introduction	  
PEPT1	  is	  a	  peptide	  transporter	  member	  of	  the	  SLC15	  family.	  This	  family	  is	  
constituted	  by	  4	  members:	  PEPT1,	  PEPT2,	  PHT1	  and	  PHT2.	  All	  these	  proteins	  
transport	  di-­‐	  and	  tri-­‐peptides,	  across	  different	  membranes	  in	  the	  body,	  using	  an	  
electrochemical	  proton	  gradient	  [1,	  2].	  While	  PEPT1	  and	  PEPT2	  can	  only	  move	  di-­‐	  
and	  tri-­‐peptides,	  PHT1	  and	  PHT2	  can	  move	  also	  the	  amino	  acid	  histidine	  [3].	  	  
Besides	  di-­‐	  and	  tri-­‐peptides,	  peptide	  transporters	  can	  also	  carry	  peptide-­‐like	  
molecules	  with	  important	  pharmacological	  activity	  such	  as	  the	  antiviral	  drug	  
(valacyclovir),	  angiotensin	  converting	  enzyme	  inhibitors	  (captopril),	  the	  anticancer	  
agent	  bestatin	  and	  amino-­‐cephalosporins	  such	  as	  cefadroxil.	  
Cefadroxil	  is	  a	  broad-­‐spectrum	  first	  generation	  amino-­‐cephalosporin	  used	  to	  
treat	  skin,	  upper	  respiratory,	  and	  urinary	  tract	  infections,	  caused	  by	  both	  gram-­‐
positive	  and	  gram-­‐negative	  bacteria	  [4,	  5].	  	  Cefadroxil	  has	  a	  very	  high	  bioavailability	  
in	  rats	  and	  humans	  (68	  and	  89	  %	  respectively),	  no	  significant	  metabolism,	  and	  is	  
excreted	  almost	  completely	  in	  the	  urine	  [4,	  6].	  	  
Several	  transporters	  are	  involved	  in	  the	  transport	  of	  cefadroxil	  across	  
membranes	  of	  different	  tissues	  in	  the	  body.	  	  This	  amino-­‐cephalosporin	  has	  been	  
shown	  to	  be	  a	  substrate	  of	  PEPT1	  in	  different	  system	  such	  as	  Caco-­‐2	  cells,	  oocytes,	  
rats,	  and	  mice	  [7-­‐10].	  In	  previous	  studies,	  our	  group	  showed	  that	  PEPT1	  is	  the	  
principal	  transporter	  involved	  in	  the	  permeation	  of	  cefadroxil	  from	  the	  small	  
intestine	  into	  the	  blood	  stream.	  	  This	  transporter	  is	  expressed	  in	  the	  small	  intestine,	  
but	  not	  in	  the	  in	  stomach	  or	  colon.	  Using	  single	  pass	  intestinal	  perfusion,	  a	  widely	  
used	  in	  situ	  technique,	  in	  wild	  type	  and	  PEPT1	  knockout	  mice,	  we	  showed	  that	  90	  %	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of	  the	  effective	  permeability	  of	  cefadroxil	  in	  the	  jejunum	  is	  due	  to	  PEPT1.	  PEPT2,	  
another	  peptide	  transporter	  expressed	  mainly	  in	  the	  kidney	  and	  choroid	  plexus,	  has	  
also	  been	  proven	  to	  play	  a	  major	  role	  in	  the	  transport	  of	  cefadroxil	  [7,	  11-­‐14].	  	  In	  the	  
kidney,	  even	  though	  both	  PEPT1	  and	  PEPT2	  are	  present	  at	  the	  brush	  border	  
membrane	  of	  the	  epithelial	  cells	  in	  the	  proximal	  tubule,	  PEPT2	  is	  responsible	  for	  
most	  of	  the	  re-­‐absorption	  of	  cefadroxil	  back	  into	  the	  blood	  [11]	  [15].	  	  In	  the	  choroid	  
plexus	  epithelium,	  PEPT2	  is	  in	  charged	  of	  the	  efflux	  of	  cefadroxil	  from	  the	  CSF	  
(cerebrospinal	  fluid)	  into	  the	  cells,	  limiting	  the	  exposure	  of	  cefadroxil	  in	  the	  CSF	  
[13].	  	  At	  pH	  7.4	  (pH	  of	  the	  blood)	  almost	  50%	  of	  cefadroxil	  molecules	  are	  negatively	  
charged,	  while	  the	  other	  50%	  are	  present	  as	  a	  zwitterions.	  This	  condition	  makes	  
cefadroxil	  a	  good	  substrate	  for	  the	  organic	  anion	  transporters	  present	  in	  the	  body.	  	  
In	  the	  kidney,	  cefadroxil	  is	  proven	  to	  be	  actively	  secreted	  into	  the	  urine	  by	  the	  
organic	  anion	  transporters	  1	  (hOAT1),	  2	  (hOAT2),	  and	  3	  (hOAT3)	  in	  humans,	  and	  in	  
rats	  by	  the	  rOAT2	  [16-­‐18].	  Since	  so	  many	  different	  transporters	  can	  play	  a	  role	  in	  
the	  absorption	  of	  cefadroxil	  in	  vivo,	  we	  decided	  to	  use	  the	  previously	  designed	  
PEPT1	  knockout	  mice[19]	  and	  compare	  it	  to	  the	  wild-­‐type	  mice,	  to	  quantify	  the	  
actual	  contribution	  of	  PEPT1	  into	  the	  absorption,	  tissue	  distribution,	  and	  disposition	  
of	  cefadroxil	  in	  vivo.	  	  
Cefadroxil,	  as	  well	  as	  other	  first	  generation	  amino-­‐cephalosporins,	  is	  usually	  
prescribed	  as	  an	  initial	  empiric	  medication	  to	  treat	  a	  wide	  variety	  of	  community	  
acquired	  infections,	  such	  as	  skin,	  respiratory	  and	  urinary	  tract	  infections,	  because	  of	  
its	  broad	  spectrum	  and	  low	  toxicity.	  Understanding	  the	  pharmacokinetics	  of	  
cefadroxil	  and	  other	  antibiotics	  is	  important,	  since	  it	  plays	  an	  important	  role	  in	  the	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efficacy	  of	  the	  treatment.	  Our	  main	  goals	  with	  this	  project	  are	  1)	  to	  quantify	  the	  role	  
of	  PEPT1	  in	  the	  absorption	  and	  disposition	  of	  cefadroxil,	  and	  2)	  to	  determine	  the	  
role	  of	  PEPT1	  in	  the	  tissue	  distribution	  of	  cefadroxil.	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Methods	  
Materials	  	  
3H-­‐Cefadroxil	  (0.8	  Ci/mmol)	  and	  14C-­‐dextran-­‐carboxyl	  70.000	  (1.1	  mCi/g)	  
were	  obtained	  from	  Moravek	  Biochemicals	  and	  Radiochemicals	  (Brea,	  CA).	  Hyamine	  
hydroxide	  was	  purchased	  at	  ICN	  radiochemicals	  (Irvine,	  CA).	  All	  other	  chemicals	  
were	  purchased	  from	  Sigma.	  (St.	  Louis,	  MO).	  
Animals	  	  
All	  studies	  were	  done	  in	  6-­‐8	  week	  old	  gender-­‐matched	  wild	  type	  (PEPT1+/+)	  
and	  PEPT1	  knockout	  	  (PEPT1-­‐/-­‐)	  mice.	  The	  animals	  were	  kept	  in	  a	  temperature-­‐
controlled	  room	  with	  12-­‐hour	  light,	  12-­‐hour	  dark	  cycle,	  and	  had	  standard	  diet	  and	  
water	  ad	  libitum.	  All	  of	  the	  procedures	  were	  approved	  by	  the	  University	  of	  Michigan	  
Committee	  on	  Use	  and	  Care	  of	  Animals	  (UCUCA),	  and	  were	  carried	  out	  in	  
accordance	  with	  the	  Guide	  for	  Use	  of	  Laboratory	  Animals	  as	  adopted	  and	  
promulgated	  by	  the	  US	  National	  Institutes	  of	  Health	  (NIH	  publication	  No.	  85-­‐23,	  
revised	  in	  1985).	  
Oral	  Administration	  of	  Cefadroxil	  
Gender-­‐matched	  wild	  type	  (PEPT1+/+)	  and	  PEPT1	  knockout	  (PEPT1-­‐/-­‐)	  mice	  
were	  fasted	  14	  hours	  before	  the	  beginning	  of	  the	  experiment.	  Cefadroxil	  was	  
dissolved	  in	  200-­‐250	  µL	  of	  water	  and	  administered	  to	  the	  mice	  using	  a	  20G	  oral	  
gavage	  needle	  at	  the	  following	  doses.	  Doses	  were	  scaled	  down	  from	  human	  relevant	  
doses	  using	  a	  surface	  area	  adjustment.	  For	  all	  doses	  0.5	  µCi/	  gram	  of	  body	  weight	  of	  
radiolabeled	  cefadroxil	  (3H-­‐cefadroxil)	  were	  administered.	  Plasma	  was	  harvested	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from	  blood	  samples	  (15	  -­‐	  20	  µL)	  that	  were	  collected	  by	  tail	  nicks	  at	  the	  following	  
times:	  5,	  10,	  15,	  20,	  30,	  45,	  60,	  90,	  and	  120	  minutes	  after	  oral	  dosing.	  The	  blood	  was	  
collected	  using	  a	  PCR	  tube	  containing	  1	  µl	  of	  7.5%	  EDTA	  and	  centrifuged	  at	  3300	  rfc	  
for	  3	  minutes.	  Then,	  5	  µL	  of	  plasma	  were	  collected	  and	  placed	  in	  a	  scintillation	  vial	  
with	  6	  mL	  of	  CytoScint	  scintillation	  fluid	  (MP	  Biomedicals,	  Solon,	  OH).	  	  The	  
radioactivity	  in	  the	  sample	  was	  measured	  using	  dual	  channel	  Scintillation	  Counter	  
(Beckman	  LS	  6000	  SC;	  Beckman	  Coulter	  Inc.,	  Fullerton,	  CA).	  	  Mice	  had	  free	  access	  to	  
water	  during	  the	  whole	  experiment.	  
Systemic	  Administration	  of	  Cefadroxil	  
Gender-­‐matched	  wild	  type	  (PEPT1+/+)	  and	  PEPT1	  knockout	  (PEPT1-­‐/-­‐)	  mice	  
were	  injected	  with	  cefadroxil	  dissolved	  in	  saline	  solution	  via	  the	  tail	  vein	  using	  a	  
27G	  needle.	  The	  dose	  used	  was	  44.5	  nmol/g	  and	  it	  was	  scaled	  down	  from	  the	  lowest	  
human	  relevant	  dose.	  0.5	  µCi/	  gram	  of	  body	  weight	  of	  radiolabeled	  cefadroxil	  (3H-­‐
cefadroxil)	  were	  administered.	  Plasma	  was	  harvested	  from	  blood	  samples	  (15-­‐20	  
µL)	  that	  were	  collected	  by	  tail	  nicks	  at	  the	  following	  times:	  0.5,	  2,	  5,	  15,	  30,	  45,	  60,	  
90,	  and	  120	  minutes	  after	  I.V.	  dosing.	  The	  blood	  was	  collected	  using	  a	  PCR	  tube	  
containing	  1	  µl	  of	  7.5%	  EDTA	  and	  centrifuged	  at	  3300	  rfc	  for	  3	  minutes.	  Then,	  5	  µL	  
of	  plasma	  were	  collected	  and	  placed	  in	  a	  scintillation	  vial	  with	  6	  mL	  of	  CytoScint	  
scintillation	  fluid	  (MP	  Biomedicals,	  Solon,	  OH).	  	  The	  radioactivity	  in	  the	  sample	  was	  
measured	  using	  dual	  channel	  Scintillation	  Counter	  (Beckman	  LS	  6000	  SC;	  Beckman	  
Coulter	  Inc.,	  Fullerton,	  CA).	  	  Mice	  had	  free	  access	  to	  water	  during	  the	  total	  duration	  
of	  the	  experiment.	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Tissue	  Distribution	  after	  Oral	  Administration	  of	  Cefadroxil	  
Gender-­‐matched	  wild	  type	  (PEPT1+/+)	  and	  PEPT1	  knockout	  (PEPT1-­‐/-­‐)	  mice	  
were	  fasted	  14	  hours	  before	  the	  beginning	  of	  the	  experiment.	  Cefadroxil	  was	  
dissolved	  in	  water	  and	  administered	  to	  the	  mice	  using	  a	  20G	  oral	  gavage	  needle	  at	  
178.2	  nmol/g.	  After	  15	  minutes,	  100	  μL	  of	  14C-­‐Dextran	  70.000	  were	  injected	  via	  the	  
tail	  vein,	  and	  5	  minutes	  later	  the	  animal	  was	  euthanized.	  Whole	  blood	  and	  tissues	  
were	  collected	  and	  incubated	  overnight	  with	  330	  μL	  of	  Hyamine	  Hydroxide	  at	  37°C.	  
Then,	  40	  μL	  of	  Hydrogen	  Peroxide	  30%	  were	  added,	  followed	  by	  of	  6	  mL	  of	  
CytoScint	  scintillation	  fluid	  (MP	  Biomedicals,	  Solon,	  OH).	  	  The	  radioactivity	  in	  the	  
sample	  was	  measured	  using	  dual	  channel	  Scintillation	  Counter	  (Beckman	  LS	  6000	  
SC;	  Beckman	  Coulter	  Inc.,	  Fullerton,	  CA).	  	  	  
Data	  Analysis	  	  
The	  plasma	  concentration-­‐time	  profiles	  of	  cefadroxil	  in	  both	  genotypes	  were	  
analyzed	  using	  non-­‐compartment	  analysis	  with	  Phoenix	  (Pharsight,	  Mountain	  View,	  
CA),	  and	  parameters	  	  
Tissue	  concentrations	  of	  cefadroxil	  was	  calculated	  as:	  	  
Ctiss,	  corr	  =	  Ctiss-­‐DS*Cb	  
where	  Ctiss,	  corr	  is	  the	  corrected	  concentration	  of	  Cefadroxil	  in	  each	  tissue	  (in	  nmol/g	  
of	  wet	  tissue,	  DS	  is	  the	  vascular	  volume	  in	  the	  tissue	  (in	  mL/g)	  calculated	  using	  14C-­‐
dextran,	  and	  Cb	  is	  the	  concentration	  of	  cefadroxil	  in	  the	  blood.	  
Statistical	  Analysis	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All	  the	  data	  are	  reported	  as	  mean	  ±	  SE.	  To	  test	  for	  statistically	  significant	  
differences	  between	  wild-­‐type	  and	  PEPT1	  knockout	  mice	  a	  t-­‐test	  was	  performed.	  An	  
ANOVA	  was	  used	  to	  test	  for	  statistical	  differences	  between	  multiple	  treatments	  
followed	  either	  by	  a	  Dunnett’s	  test	  for	  pairwise	  comparisons	  with	  the	  control	  group,	  
or	  a	  Tukey	  test	  for	  multiple	  comparisons.	  To	  test	  the	  quality	  of	  the	  fit	  of	  the	  linear	  
models,	  the	  residual	  plots	  were	  visually	  inspected,	  and	  the	  coefficient	  of	  
determination	  (R2)	  and	  the	  standard	  error	  of	  the	  residuals	  were	  evaluated	  as	  well.	  
All	  statistical	  analyses	  were	  performed	  with	  Prism	  v5.0.	  A	  p-­‐value	  below	  0.05	  was	  
considered	  statistically	  significant.	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Results	  
Oral	  Administration	  of	  Cefadroxil	  
As	  seen	  in	  figure	  4.1	  (A-­‐D),	  the	  average	  plasma	  concentration-­‐time	  profiles	  of	  
cefadroxil	  in	  wild-­‐type	  mice	  are	  significantly	  different	  than	  the	  knockout	  ones.	  For	  
wild-­‐type	  mice	  the	  concentration	  of	  cefadroxil	  raises	  really	  fast	  after	  oral	  
administration,	  has	  a	  Tmax	  at	  around	  20	  minutes,	  and	  then	  it	  decreases	  rapidly	  with	  
time.	  Instead	  for	  the	  knockout	  mice,	  the	  concentration	  tends	  to	  increase	  slower	  and	  
plateau	  out	  at	  around	  60	  minutes	  (Figure	  4.1).	  Since	  the	  concentration	  of	  cefadroxil	  
in	  the	  knockout	  mice	  doesn’t	  decrease	  (stays	  at	  the	  same	  level	  until	  the	  end	  of	  the	  
experiments)	  it	  was	  impossible	  to	  determine	  the	  half-­‐life	  and	  Tmax	  of	  cefadroxil.	  
The	  AUC	  and	  Cmax	  for	  each	  genotype	  at	  each	  dose	  are	  shown	  in	  Table	  4.1,	  as	  well	  as	  
the	  ratios	  between	  them.	  The	  Cmax	  of	  cefadroxil	  in	  wild-­‐type	  mice	  is	  at	  least	  16-­‐fold	  
higher	  than	  the	  Cmax	  in	  PEPT1	  knockout	  animals.	  Likewise,	  the	  AUC	  is	  significantly	  
reduced	  in	  the	  PEPT1	  knockout	  mice	  compared	  to	  the	  wild-­‐type	  mice	  (8-­‐	  to	  10-­‐fold	  
lower).	  One	  can	  see	  that	  the	  ratios	  of	  AUCwt/AUCko	  are	  between	  9	  and	  11,	  which	  
means	  that	  most	  of	  the	  cefadroxil	  (~90%)	  is	  being	  absorbed	  through	  PEPT1.	  These	  
results	  are	  comparable	  to	  the	  previously	  obtained	  results	  from	  in	  situ	  experiments.	  	  
To	  test	  for	  saturation	  of	  the	  cefadroxil	  transport,	  the	  Cmax	  and	  AUC	  for	  the	  4	  
doses	  were	  compared	  using	  linear	  regression	  analysis	  and	  ANOVA	  of	  the	  dose	  
corrected	  pharmacokinetic	  parameter.	  As	  seen	  in	  both	  figures	  4.3	  and	  4.4,	  both	  the	  
Cmax	  and	  the	  AUC	  are	  linear	  with	  the	  dose	  and	  the	  dose	  corrected	  parameters	  are	  not	  
different	  for	  the	  4	  doses.	  This	  means	  that	  cefadroxil	  pharmacokinetics	  exhibit	  an	  
apparent	  linearity	  after	  oral	  administration	  over	  the	  44.5	  -­‐	  356	  nmol/g	  range.	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To	  better	  understand	  the	  differences	  between	  the	  absorption	  process	  and	  
absorption	  rates	  of	  cefadroxil	  in	  wild	  type	  and	  PEPT1	  knockout	  mice	  we	  performed	  
a	  partial	  AUC	  analysis.	  In	  this	  analysis,	  the	  partial	  cumulative	  AUC’s	  were	  plotted	  
versus	  time	  after	  4	  oral	  doses	  from	  0	  to	  120.	  Then	  the	  initial	  slopes,	  from	  10-­‐30	  
minutes,	  were	  compared	  between	  wild	  type	  and	  PEPT1	  knockout	  mice.	  Both	  
genotypes	  show	  a	  single	  slope	  from	  10	  to	  30	  minutes.	  The	  linear	  regression	  analysis	  
showed	  that	  the	  knockout	  mice	  slopes	  were	  significant	  slower	  than	  the	  wild	  type	  
ones.	  A	  two-­‐way	  ANOVA	  of	  the	  initial	  dose-­‐corrected	  slopes	  of	  the	  partial	  AUC’s	  
between	  10-­‐30	  minutes,	  shows	  that	  there	  is	  a	  significant	  difference	  between	  wild-­‐
type	  and	  PEPT1	  knockout	  mice,	  but	  not	  difference	  for	  the	  doses	  in	  each	  of	  the	  
genotypes.	  As	  shown	  in	  table	  4.2	  the	  initial	  slope	  (10-­‐30	  minutes)	  was	  around	  25	  
times	  slower	  than	  the	  PEPT1	  knockout	  mice.	  	  
Systemic	  Administration	  of	  Cefadroxil	  
After	  intravenous	  injection	  of	  cefadroxil,	  both	  genotypes	  have	  very	  similar	  
disposition	  profiles,	  almost	  superimposable	  (Fig	  4.6).	  This	  phenomenon	  indicates	  
that	  this	  antibiotic	  is	  cleared	  from	  the	  body	  through	  the	  same	  mechanisms	  in	  both	  
genotypes,	  and	  PEPT1	  is	  not	  significantly	  involved	  in	  its	  clearance.	  Since	  we	  know	  
that	  cefadroxil	  is	  not	  metabolized	  in	  the	  body	  and	  is	  mainly	  eliminated	  by	  the	  kidney,	  
we	  can	  assume	  that	  other	  processes	  or	  transporters,	  different	  than	  PEPT1,	  are	  in	  
charge	  of	  its	  disposition.	  These	  results	  are	  in	  accordance	  with	  the	  previously	  
reported	  data,	  which	  showed	  that	  PEPT2	  is	  in	  charge	  of	  95%	  of	  the	  reabsorption	  of	  
cefadroxil	  in	  the	  kidney,	  while	  PEPT1	  is	  in	  charge	  of	  only	  5%	  of	  its	  reabsorption	  [11].	  
As	  seen	  in	  table	  4.3,	  there	  is	  no	  significant	  difference	  in	  pharmacokinetic	  parameters	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such	  as	  clearance,	  AUC,	  and	  half-­‐life	  between	  genotypes	  after	  systemic	  
administration	  of	  this	  amino-­‐cephalosporin.	  
Tissue	  Distribution	  of	  Cefadroxil	  
The	  tissue	  distribution	  of	  cefadroxil	  was	  performed	  20	  minutes	  after	  oral	  
dosing.	  This	  particular	  time	  was	  chosen	  given	  its	  proximity	  to	  the	  Tmax	  observed	  
when	  cefadroxil	  was	  administered	  orally	  to	  wild-­‐type	  mice.	  Evidently,	  there	  are	  
significant	  differences	  in	  concentration	  values	  in	  different	  tissue	  for	  the	  two	  
genotypes	  as	  seen	  in	  figure	  4.7.	  But	  is	  important	  to	  note	  that	  the	  concentration	  of	  
cefadroxil	  in	  blood	  is	  also	  significantly	  higher	  (12-­‐fold)	  in	  the	  wild-­‐type	  mice	  
compared	  to	  the	  PEPT1	  knockout	  mice	  as	  seen	  in	  figure	  4.7.	  In	  order	  to	  capture	  the	  
actual	  difference	  between	  the	  tissues,	  and	  not	  the	  difference	  because	  of	  drug	  
absorption,	  we	  normalized	  the	  concentration	  of	  cefadroxil	  in	  the	  tissue	  by	  the	  
concentration	  of	  cefadroxil	  in	  the	  blood.	  Once	  the	  data	  was	  normalized	  by	  the	  
concentration	  of	  cefadroxil	  in	  blood	  (Figure	  4.8),	  the	  difference	  in	  the	  cefadroxil	  
concentration	  in	  the	  other	  tissues	  for	  both	  genotypes	  disappears.	  This	  shows	  that	  
the	  initially	  observed	  difference	  in	  tissue	  concentration	  was	  due	  to	  differences	  in	  
drug	  absorption,	  and	  not	  because	  of	  PEPT1	  functionality	  in	  the	  other	  tissues.	  
	  In	  figure	  4.9,	  one	  can	  see	  the	  difference	  in	  the	  cefadroxil	  concentrations	  in	  
different	  segments	  of	  the	  gastrointestinal	  tract	  after	  20	  minutes	  of	  drug	  
administration.	  The	  highest	  concentration	  in	  wild-­‐type	  mice	  is	  present	  in	  the	  
duodenum,	  and	  is	  significantly	  higher	  than	  the	  concentration	  of	  cefadroxil	  in	  the	  
duodenum	  of	  the	  PEPT1	  knockout	  mice.	  	  It	  is	  also	  significantly	  higher	  than	  the	  
concentration	  of	  cefadroxil	  in	  the	  stomach,	  jejunum,	  ileum	  and	  colon	  of	  the	  wild-­‐
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type	  mice.	  There	  was	  no	  difference	  between	  the	  stomach,	  the	  jejunum,	  the	  ileum	  and	  
the	  colon	  for	  both	  genotypes.	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Discussion	  
This	  work	  presents	  new	  findings	  on	  the	  in	  vivo	  oral	  absorption,	  tissue	  
distribution	  and	  disposition	  of	  cefadroxil	  in	  mice.	  We	  reported	  for	  the	  first	  time	  that	  
1)	  the	  deletion	  of	  PEPT1	  reduces	  by	  90%	  the	  systemic	  exposure	  of	  cefadroxil	  after	  
its	  oral	  administration.	  Likewise,	  2)	  the	  Cmax	  of	  cefadroxil	  is	  significantly	  lower	  in	  the	  
PEPT1	  knockout	  mice.	  Also,	  we	  showed	  that	  3)	  there	  is	  an	  apparent	  linearity	  in	  the	  
Cmax	  and	  AUC	  for	  the	  4	  clinically	  relevant	  doses	  administered.	  Moreover,	  we	  found	  
out	  that	  5)	  the	  systemic	  exposure	  of	  cefadroxil	  is	  not	  affected	  by	  PEPT1	  erasure	  
after	  intravenous	  administration,	  and	  finally,	  6)	  that	  the	  distribution	  into	  tissues	  
depends	  majorly	  on	  the	  actual	  concentration	  of	  cefadroxil	  in	  blood,	  and	  not	  on	  
expression	  of	  PEPT1	  in	  them.	  	  
The	  reduction	  of	  the	  exposure	  of	  cefadroxil	  in	  vivo	  by	  approximately	  90%,	  for	  
the	  4	  doses	  used,	  in	  the	  PEPT1	  knockout	  mice	  correlates	  extremely	  well	  with	  our	  
previous	  results	  from	  the	  in	  situ	  studies	  in	  mice.	  In	  the	  previously	  performed	  single	  
pass	  intestinal	  perfusion	  experiments	  we	  demonstrated	  that	  the	  ablation	  of	  PEPT1	  
reduces	  the	  effective	  permeability	  (Peff)	  of	  cefadroxil	  also	  by	  90%.	  Unsurprisingly,	  
these	  results	  are	  consistent	  because	  the	  amount	  of	  drug	  absorbed	  in	  vivo	  after	  oral	  
administration	  depends	  directly	  on	  its	  membrane	  permeability,	  and	  other	  factors	  
such	  as	  the	  drug	  concentration	  in	  the	  intestinal	  lumen,	  the	  pH,	  and	  the	  transit	  time	  
[20,	  21].	  Our	  results	  show	  that	  the	  absorption	  of	  cefadroxil	  in	  wild-­‐type	  mice	  is	  quite	  
fast,	  displaying	  a	  Tmax	  at	  approximately	  20	  minutes.	  Therefore	  we	  can	  suggest	  that	  
the	  absorption	  of	  cefadroxil	  is	  happening	  mostly	  in	  the	  upper	  portion	  of	  the	  GI	  tract.	  
Since	  we	  know	  that	  cefadroxil	  isn’t	  absorbed	  in	  the	  stomach,	  because	  there	  is	  no	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PEPT1	  present	  in	  this	  organ,	  we	  can	  suggests	  that	  the	  absorption	  happens	  mostly	  in	  
the	  upper	  segment	  of	  the	  small	  intestine,	  probably	  in	  the	  duodenum	  and	  upper	  
jejunum.	  This	  hypothesis	  in	  then	  confirmed	  with	  the	  results	  of	  the	  tissue	  
distribution	  experiments,	  which	  showed	  that	  the	  highest	  concentration	  of	  cefadroxil	  
along	  the	  gastrointestinal	  tract	  after	  20	  minutes	  occurred	  in	  the	  duodenum	  of	  wild-­‐
type	  mice.	  We	  can	  hypothesize	  then,	  that	  the	  absorption	  of	  cefadroxil	  in	  the	  small	  
intestine	  is	  driven	  mostly	  by	  the	  concentration	  of	  drug	  in	  the	  lumen,	  because	  it	  
would	  be	  the	  concentration	  of	  drug	  in	  the	  lumen	  the	  only	  factor	  that	  significantly	  
changes	  in	  the	  small	  intestine	  of	  these	  mice.	  McConnell	  et	  al	  showed	  that	  the	  pH	  
along	  the	  gastrointestinal	  tract	  of	  fasted	  mice	  remains	  very	  similar,	  between	  4	  and	  5,	  
so	  we	  can	  conclude	  that	  this	  would	  not	  have	  a	  direct	  impact	  in	  the	  differences	  of	  
cefadroxil	  observed	  in	  the	  small	  intestine	  of	  wild-­‐type	  mice.	  Similarly,	  we	  have	  
shown	  in	  our	  previous	  experiments	  that	  there	  was	  no	  significant	  difference	  in	  the	  
effective	  permeability	  of	  cefadroxil	  in	  the	  3	  segments	  of	  the	  small	  intestine	  
(duodenum,	  jejunum,	  and	  ileum),	  so	  it	  can	  be	  assumed	  that	  this	  is	  not	  the	  cause	  of	  
the	  different	  concentrations	  along	  the	  gastrointestinal	  tract.	  	  
On	  the	  other	  hand,	  for	  the	  PEPT1	  knockout	  mice	  one	  can	  see	  a	  significantly	  
lower	  Cmax	  and	  AUC0-­‐120,	  and	  also	  a	  very	  slow	  absorption	  of	  cefadroxil.	  In	  the	  wild-­‐
type	  mice	  the	  plasma	  concentration	  of	  cefadroxil	  increases	  very	  fast,	  and	  probably	  
the	  luminal	  concentration	  of	  cefadroxil	  also	  decreases	  very	  fast	  as	  the	  drug	  gets	  
absorbed	  along	  the	  small	  intestine.	  	  In	  the	  knockout	  mice	  something	  different	  
happens,	  the	  plasma	  concentration	  of	  cefadroxil	  increases	  very	  slowly	  and	  reaches	  a	  
plateau	  at	  a	  later	  time.	  This	  is	  probably	  because	  the	  drug	  isn’t	  being	  absorbed	  in	  the	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upper	  segments	  of	  the	  small	  intestine	  so	  high	  concentrations	  of	  it	  reach	  the	  lumen	  of	  
the	  lower	  segments	  causing	  an	  increase	  in	  the	  driving	  force	  for	  passive	  diffusion.	  
In	  preliminary	  studies	  of	  the	  pharmacokinetics	  of	  cefadroxil	  in	  wild-­‐type	  
mice,	  Buck	  et	  al	  showed	  that	  the	  Cmax	  of	  cefadroxil	  occurs	  around	  30	  minutes	  after	  
oral	  administration	  and	  that	  it	  is	  linear	  with	  the	  dose,	  between	  25	  mg/kg	  and	  200	  
mg/kg	  (68.9	  and	  550	  nmol/g)[4].	  Our	  results	  are	  very	  similar	  to	  these	  ones.	  Though	  
their	  Tmax	  is	  at	  30	  minutes	  and	  not	  20	  like	  ours,	  we	  believe	  that	  ours	  is	  more	  
accurate	  because	  they	  report	  only	  1	  data	  point	  before	  the	  Tmax,	  while	  we	  sampled	  3	  
times	  (at	  5,	  10,	  and	  15	  minutes)	  before	  it	  [4]	  .	  	  
Though	  we	  observed	  a	  dose-­‐proportional	  increase	  of	  the	  AUC0-­‐120	  and	  Cmax,	  
and	  no	  change	  in	  the	  clearance	  of	  cefadroxil,	  we	  know	  that	  its	  intestinal	  absorption,	  
and	  renal	  secretion	  and	  reabsorption	  are	  handled	  by	  transporters,	  and	  with	  a	  high	  
enough	  dose,	  these	  transporters	  will	  eventually	  be	  saturated	  and	  the	  dose-­‐
proportionality	  in	  the	  Cmax	  and	  AUC	  will	  be	  lost.	  So,	  we	  can	  say	  that	  what	  we	  
observed	  is	  an	  “apparent”	  linearity	  of	  the	  pharmacokinetics	  of	  cefadroxil.	  The	  doses	  
used	  for	  these	  experiments	  were	  scaled	  down	  from	  the	  four	  most	  prescribed	  human	  
doses	  (125,	  250,	  500	  and	  1000	  mg)	  using	  a	  surface	  area	  approach.	  Our	  doses	  of	  
(44.5,	  89.1,	  179	  and	  356	  nmol/g)	  would	  then	  result	  in	  stomach	  concentrations	  of	  1.5,	  
3,	  6,	  and	  12	  mM.	  According	  to	  these	  calculations,	  the	  two	  highest	  doses	  would	  
surpass	  the	  high	  Km	  of	  cefadroxil	  in	  the	  small	  intestine	  (3.8	  in	  the	  bulk	  of	  the	  
intestine,	  2.1	  at	  the	  intestinal	  wall).	  So	  one	  would	  expect	  that	  at	  least	  the	  highest	  
dose	  used	  would	  cause	  a	  saturation	  of	  the	  peptide	  transporter	  in	  the	  small	  intestine,	  
causing	  a	  decrease	  in	  the	  fraction	  absorbed.	  On	  the	  other	  hand,	  an	  increase	  in	  the	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dose,	  and	  subsequently	  in	  the	  plasma	  concentration,	  could	  cause	  a	  saturation	  of	  the	  
active	  reabsorption	  of	  cefadroxil	  by	  PEPT2,	  and	  therefore	  causing	  an	  increase	  in	  the	  
clearance	  and	  a	  lower	  than	  proportional	  increase	  in	  the	  AUC	  and	  Cmax.	  One	  can	  also	  
run	  into	  the	  situation	  where	  the	  active	  secretion	  transporters,	  OAT’s	  are	  saturated	  
and	  then	  the	  clearance	  could	  be	  higher,	  causing	  an	  increase	  in	  the	  dose	  corrected	  
AUC	  and	  Cmax	  of	  cefadroxil.	  	  
In	  the	  literature	  there	  is	  mixed	  information	  about	  the	  linearity	  of	  the	  
pharmacokinetics	  of	  cefadroxil.	  While	  a	  some	  authors	  report	  that	  cefadroxil	  exhibits	  
non-­‐linear	  kinetics	  after	  oral	  administration	  of	  cefadroxil	  in	  rats	  and	  humans	  [22,	  
23],	  others	  show	  that	  cefadroxil	  displays	  a	  dose-­‐proportional	  increase	  of	  AUC	  and	  
Cmax	  and	  a	  dose	  independent	  clearance	  within	  therapeutic	  doses	  in	  mice	  and	  
humans	  [4,	  24].	  Although	  all	  studies	  were	  performed	  under	  similar	  circumstances	  
and	  with	  similar	  doses,	  we	  think	  that	  the	  mixed	  results	  rely	  on	  the	  already	  
mentioned	  complexity	  of	  the	  processes	  involved	  in	  the	  absorption	  and	  elimination	  
in	  the	  kidney	  of	  cefadroxil.	  	  
For	  both	  genotypes,	  the	  tissue	  distribution	  of	  cefadroxil	  is	  not	  different	  after	  
the	  concentration	  of	  cefadroxil	  in	  tissue	  is	  normalized	  for	  the	  blood	  one.	  This	  means	  
that	  after	  cefadroxil	  is	  absorbed	  into,	  PEPT1	  ablation	  has	  no	  effect	  in	  distribution	  of	  
cefadroxil.	  Also,	  one	  can	  observe	  a	  high	  variability	  in	  the	  tissue	  concentration	  values	  
for	  each	  genotype.	  This	  phenomenon	  can	  be	  attributed	  to	  the	  time	  of	  tissue	  
collection	  and/or	  the	  lack	  of	  equilibrium	  between	  drug	  present	  in	  the	  tissue	  and	  in	  
the	  blood.	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Our	  results	  show	  that	  after	  intravenous	  administration	  of	  cefadroxil	  the	  
exposure	  and	  disposition	  of	  this	  antibiotic	  is	  the	  same	  for	  both	  genotypes,	  
concluding	  that	  the	  ablation	  of	  PEPT1	  doesn’t	  affect	  the	  elimination	  of	  cefadroxil.	  
This	  is	  in	  agreement	  with	  previous	  studies	  from	  our	  group	  that	  showed	  that	  PEPT1	  
accounted	  only	  for	  5%	  of	  the	  reabsorption	  of	  cefadroxil	  in	  the	  kidney,	  while	  PEPT2	  
accounted	  for	  95%	  of	  it	  in	  wild-­‐type	  mice	  [11].	  Also	  our	  group	  showed	  that	  
cefadroxil	  is	  not	  significantly	  metabolized	  in	  the	  mice,	  and	  almost	  90%	  of	  it	  can	  be	  
recovered	  intact	  in	  the	  urine	  after	  24	  hours	  [11].	  Therefore,	  we	  can	  conclude	  that	  
the	  clear	  differences	  observed	  in	  both	  genotypes	  after	  oral	  administration	  can	  be	  
attributed	  to	  differences	  in	  the	  absorption	  process,	  and	  not	  to	  the	  tissue	  distribution,	  
metabolism,	  or	  elimination	  of	  cefadroxil	  in	  mice.	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Figures	  
	  
Figure	  4.1.	  Plasma	  concentration-­‐time	  profiles	  of	  cefadroxil	  in	  wild-­‐type	  (WT)	  and	  PEPT1	  
knockout	  (KO)	  mice	  after	  oral	  dosing	  of	  A)	  44.5	  nmol/g,	  and	  B)	  89.1	  nmol/g,	  C)	  178	  nmol/g,	  
and	  D)	  356	  nmol/g.	  Data	  are	  presented	  as	  mean	  ±	  S.E.	  (n=6).	  	  	  
 
  109 
	   	  
Figure	  4.2.	  Cumulative	  partial	  area	  under	  the	  plasma	  concentration-­‐time	  (AUC)	  vs	  time	  of	  
cefadroxil	  after	  oral	  dosing	  of	  A)	  44.5nmol/g,	  B)	  89.1nmol/g,	  C)	  178	  nmol/g	  and	  D)	  356	  
nmol/g.	  Data	  are	  presented	  as	  mean	  ±	  S.E.	  (n=6-­‐8).	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Figure	  4.3.	  Dose-­‐corrected	  initial	  slope	  of	  the	  cumulative	  partial	  AUC	  of	  3H-­‐cefadroxil	  from	  
0-­‐30	  minutes	  in	  wild-­‐type	  and	  PEPT1	  knockout	  mice.	  Data	  are	  presented	  as	  mean	  ±	  S.E.	  
(n=6-­‐8).	  ***	  p<0.005.	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Figure	  4.4.	  A)	  AUC0-­‐120	  vs	  dose	  after	  4	  oral	  doses	  of	  3H-­‐cefadroxil	  in	  wild-­‐type	  and	  PEPT1	  
knockout	  mice.	  B)	  Cmax	  vs	  dose	  for	  4	  oral	  doses	  of	  3H-­‐cefadroxil	  in	  wild-­‐type	  mice	  and	  PEPT1	  
knockout	  mice.	  Data	  are	  expressed	  as	  mean	  ±	  S.E.	  (n=6-­‐8).	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Figure	  4.5.	  A)	  Dose	  corrected	  AUC0-­‐120	  for	  4	  oral	  doses	  of	  3H-­‐cefadroxil	  and	  B)	  Dose	  
corrected	  Cmax	  after	  4	  oral	  doses	  of	  3H-­‐cefadroxil	  in	  wild-­‐type	  and	  PEPT1	  knockout	  mice.	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Figure	  4.6.	  Tissue	  distribution	  of	  cefadroxil	  in	  wild-­‐type	  (WT)	  and	  PEPT1	  (KO)	  knockout	  
mice	  20	  minutes	  after	  oral	  dosing	  of	  178	  nmol/g	  3H-­‐cefadroxil.	  Data	  are	  presented	  as	  mean	  
±	  S.E.	  (n=6),	  *	  p	  <0.05,	  **	  p	  <0.01,	  ***p	  <	  0.005.	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Figure	  4.7.	  Blood	  corrected	  tissue	  distribution	  of	  cefadroxil	  in	  wild-­‐type	  (WT)	  and	  PEPT1	  
knockout	  (KO)	  mice	  20	  minutes	  after	  oral	  dosing	  of	  178	  nmol/g	  of	  3H-­‐cefadroxil.	  Data	  are	  
presented	  as	  mean	  ±	  SE	  (n=6).	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Figure	  4.8.	  Tissue	  distribution	  of	  cefadroxil	  in	  the	  gastrointestinal	  tract	  of	  wild-­‐type	  (WT)	  
and	  PEPT1	  knockout	  (KO)	  mice	  20	  minutes	  after	  oral	  dosing	  of	  178	  nmol/g	  of	  3H-­‐cefadroxil.	  
Data	  are	  presented	  as	  mean	  ±	  SE	  (n=6).	  *p	  <	  0.05.	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Figure	  4.9.	  Plasma	  concentration-­‐time	  profiles	  in	  wild-­‐type	  (WT)	  and	  PEPT1	  knockout	  (KO)	  
mice	  after	  intravenous	  dosing	  of	  44.5nmol/g	  of	  3H-­‐cefadroxil.	  Data	  are	  presented	  as	  mean	  ±	  
S.E.	  (n=6-­‐8).	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Tables	  
Dose	  (nmol/g)	   Wild-­‐type	   PEPT1	  KO	   WT/KO	  
AUC	  0-­‐120	  (min	  *	  μM)	  	  
44.5	   2041	  ±	  145	   176	  ±	  22	   11.6	  
89.1	   3166	  ±	  340	   279	  ±	  19	   11.3	  
178	   6032	  ±	  608	   634	  ±	  42	   9.5	  
356	   15063	  ±	  733	   1634	  ±	  281	   9.2	  
Cmax	  (μM)	  	  
44.5	   36.6	  ±	  3.6	   2.0	  ±	  0.3	   18.3	  
89.1	   77.4	  ±	  6.4	   2.9	  ±	  0.2	   26.7	  
178	   125	  ±	  14	   8.9	  ±	  0.9	   14.0	  
356	   300	  ±	  16	   19.6	  ±	  3.6	   15.3	  
Table	  4.1.	  Pharmacokinetic	  parameters	  of	  cefadroxil	  in	  wild-­‐type	  and	  knockout	  mice	  after	  
oral	  administration	  of	  3H-­‐cefadroxil.	  Data	  are	  presented	  as	  mean	  ±	  S.E.	  (n=6-­‐8).	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Dose	  (nmol/g)	  
Wild-­‐type	   PEPT1	  KO	   WT/KO	  
Initial	  Slope	  
44.5	   30.5	  ±	  2.7	   1.18	  ±	  0.1	   25.9	  
89.1	   62.9	  ±	  6.1	   2.00	  ±	  0.2	   31.5	  
178	   109	  ±	  11	   5.79	  ±	  0.9	   18.8	  
356	   267	  ±	  22	   12.8	  ±	  2.8	   20.9	  
Table	  4.2.	  Initial	  slopes	  (10-­‐30	  min)	  of	  dose-­‐corrected	  partial	  AUC	  versus	  time	  plots	  of	  of	  
3H-­‐cefadroxil	  in	  wild-­‐type	  and	  PEPT1	  knockout	  mice.	  Data	  are	  presented	  as	  mean	  ±	  S.E.	  
(n=6-­‐8).	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Parameter	   Wild-­‐type	   PEPT1	  Knockout	  
AUC	  0-­‐120	  (min	  *	  μM)	   3224	  ±	  312	   3363	  ±	  488	  
Cl	  (mL/min)	   0.29	  ±	  0.03	   0.29	  ±	  0.03	  
MRT	  0-­‐inf	  (min)	   27.0	  ±	  1.9	   27.2	  ±	  1.6	  
Half-­‐life	  (min)	   32.6	  ±	  1.9	   27.2	  ±	  2.5	  
Vdss	  (mL)	   10.8	  ±	  1.2	   10.0	  ±	  2.0	  
Table	  4.3.	  Pharmacokinetic	  parameters	  of	  3H-­‐cefadroxil	  after	  intravenous	  administration	  of	  
44.5nmol/g	  of	  cefadroxil	  to	  wild-­‐type	  and	  PEPT1	  knockout	  mice.	  Data	  are	  presented	  as	  
mean	  ±	  S.E.	  (n=6-­‐8).	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CHAPTER	  5	  	  
IN	  SILICO	  PREDICTIONS	  OF	  THE	  ABSORPTION	  AND	  




The	  aim	  of	  this	  study	  was	  to	  retrospectively	  model	  the	  absorption	  and	  
pharmacokinetics	  of	  cefadroxil	  in	  mice,	  using	  the	  advanced	  compartmental	  
absorption	  and	  transit	  model	  (ACAT)	  built	  within	  Gastroplus®.	  The	  ACAT	  model	  
was	  used	  to	  explain	  mechanistically	  the	  plasma	  concentration-­‐time	  profiles	  of	  
cefadroxil	  in	  mice	  after	  oral	  administration	  of	  escalating	  doses	  of	  the	  antibiotic	  (44.5,	  
89.1,	  178	  and	  356	  nmol/g.)	  The	  Peff	  and	  Km	  values	  obtained	  in	  the	  in	  situ	  perfusion	  
experiments,	  along	  with	  the	  in	  vivo	  disposition	  parameters	  of	  cefadroxil	  in	  mice,	  
were	  used	  as	  input	  parameters	  in	  the	  model.	  A	  parameter	  sensitivity	  analysis	  was	  
performed	  in	  order	  to	  determine	  the	  sensitivity	  of	  the	  AUC0-­‐120	  and	  Cmax	  to	  changes	  
in	  the	  experimental	  input	  parameters.	  In	  the	  knockout	  mice,	  a	  fairly	  good	  prediction	  
of	  plasma	  concentration-­‐time	  profiles	  was	  obtained.	  In	  the	  wild-­‐type	  mice,	  the	  
observed	  plasma	  concentration-­‐time	  profiles	  for	  the	  lowest	  2	  doses	  were	  fairly	  well	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reproduced,	  and	  the	  Cmax	  and	  AUC0-­‐120	  were	  comparable	  with	  those	  obtained	  in	  vivo.	  
However,	  the	  model	  under-­‐predicted	  the	  Cmax	  and	  AUC0-­‐120	  of	  the	  highest	  2	  doses,	  
perhaps	  because	  of	  PEPT1	  saturation	  in	  the	  small	  intestine.	  It	  is	  important	  to	  note	  
that	  cefadroxil	  undergoes	  both	  active	  tubular	  secretion	  and	  reabsorption,	  and	  the	  
clearance	  changes	  constantly	  at	  a	  given	  dose.	  Therefore,	  we	  hypothesize	  that	  the	  
observed	  linearity	  in	  Cmax	  and	  AUC0-­‐120	  could	  be	  an	  “apparent”	  linearity	  caused	  by	  a	  
simultaneous	  decrease	  in	  the	  fraction	  absorbed	  (due	  to	  saturation	  of	  PEPT1)	  and	  a	  
decrease	  in	  clearance	  (saturation	  of	  OATs).	  Although	  the	  ACAT	  model	  has	  been	  
proven	  a	  good	  tool	  to	  predict	  absorption	  and	  pharmacokinetics	  during	  for	  the	  first	  
two	  doses,	  for	  the	  latter	  two	  doses	  it	  becomes	  necessary	  to	  connect	  the	  ACAT	  model	  
to	  a	  new	  PBPK	  model	  that	  includes	  several	  non-­‐linear	  processes	  for	  the	  disposition	  
of	  cefadroxil.	  	  
Key	  Words	  
ACAT	  model,	  Cefadroxil,	  Absorption,	  PEPT1,	  Knockout	  mice,	  Modeling	  and	  
Simulation.	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Introduction	  
The	  past	  few	  decades	  have	  seen	  important	  changes	  in	  the	  practice	  of	  drug	  
development,	  shifting	  from	  empirical	  towards	  more	  mechanistic	  and	  model-­‐based	  
approaches.	  These	  systematic	  methods	  of	  drug	  development	  have	  benefited	  
immensely	  from	  model	  building	  software	  and	  computational	  tools.	  	  The	  design	  of	  in	  
silico	  predictive	  tools	  has	  expanded	  considerably	  in	  the	  pharmaceutical	  research	  
world,	  where	  it	  has	  helped	  immensely	  in	  go/no-­‐go	  decisions	  and	  reducing	  cost	  and	  
time	  of	  first	  in	  human	  trials.	  Despite	  most	  of	  the	  modeling	  in	  the	  pharmaceutical	  
industry	  occurring	  in	  the	  clinical	  phases	  of	  drug	  development,	  more	  of	  it	  is	  starting	  
to	  be	  done	  in	  early	  stages	  of	  drug	  discovery,	  formulation,	  and	  preclinical	  research	  
[1-­‐3].	  	  
The	  accurate	  prediction	  of	  a	  drug’s	  pharmacokinetics	  and	  absorption	  
behavior	  from	  in	  vitro	  and	  preclinical	  data	  is	  crucial	  in	  reducing	  time	  and	  money	  in	  
drug	  development	  and	  drug	  discovery	  settings.	  Moreover,	  the	  early	  prediction	  of	  
ADME	  properties	  can	  aid	  in	  the	  selection	  of	  the	  best	  candidates	  for	  development,	  
resulting	  in	  a	  faster	  progression	  into	  phase	  I	  clinical	  studies	  by	  eliminating	  
compounds	  with	  poor	  pharmacokinetic	  properties	  earlier	  on	  in	  the	  development	  
process	  [3].	  	  
Oral	  administration	  is	  the	  major	  and	  preferred	  route	  of	  drug	  delivery	  due	  to	  
its	  convenience,	  safety,	  low	  cost,	  and	  patient	  compliance.	  However,	  predicting	  the	  
absorption	  behavior	  and	  pharmacokinetics	  of	  orally	  administered	  drugs	  is	  not	  an	  
easy	  task.	  Predicting	  drug	  absorption	  and	  pharmacokinetics	  is	  challenging	  due	  to	  
the	  complexity	  of	  the	  physical,	  physiological	  and	  biochemical	  processes	  involved	  in	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the	  GI	  tract	  such	  as	  drug	  release	  and	  dissolution,	  precipitation,	  absorption	  and	  efflux	  
transporters,	  metabolism,	  and	  others	  [3-­‐5].	  	  
The	  prediction	  of	  a	  drug’s	  absorption	  rate	  and	  extent	  is	  benefitted	  immensely	  
from	  understanding	  what	  factors	  play	  important	  roles	  in	  drug	  absorption.	  Some	  of	  
the	  key	  ones	  are:	  	  1)	  the	  physicochemical	  characteristics	  of	  the	  drug,	  2)	  the	  anatomy	  
and	  physiology	  of	  the	  gastrointestinal	  tract,	  and	  3)	  the	  dosage	  form.	  Since	  the	  mid	  
1990’s	  a	  few	  research	  groups	  have	  tried	  to	  integrate	  their	  knowledge	  about	  all	  these	  
phenomena,	  which	  resulted	  in	  the	  development	  of	  different	  dynamic	  models	  that	  
allow	  the	  prediction	  of	  the	  extent	  and	  rate	  of	  drug	  absorption	  in	  the	  GI	  tract	  [4].	  
Some	  of	  these	  prediction	  models	  include	  the	  dispersion	  model,	  the	  mixing	  tank	  
model,	  the	  compartmental	  absorption	  and	  transit	  model	  (CAT),	  the	  advanced	  
dissolution	  and	  absorption	  and	  metabolism	  model	  (ADAM),	  the	  Grass	  model,	  the	  
gastrointestinal	  transit	  and	  absorption	  (GITA)	  model,	  and	  the	  advanced	  
compartmental	  absorption	  and	  transit	  (ACAT)	  model	  [4].	  
The	  CAT	  or	  compartmental	  absorption	  and	  transit	  model,	  developed	  by	  
Amidon	  and	  Yu,	  divides	  the	  GI	  tract	  into	  7	  compartments	  and	  describes	  the	  
transport	  of	  drug	  through	  them	  by	  a	  series	  of	  differential	  equations.	  The	  CAT	  model	  
can	  be	  used	  to	  predict	  passive	  absorption	  and/or	  saturable	  absorption,	  drug	  
degradation	  in	  the	  intestine,	  and	  drug	  pharmacokinetics.	  The	  caveats	  of	  this	  model	  
include	  its	  inability	  to	  predict	  absorption	  from	  the	  stomach	  and	  colon,	  and	  inability	  
to	  predict	  the	  permeability	  of	  compounds	  based	  on	  their	  chemical	  structure	  [4,	  6]	  
[7].	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The	  ADAM	  (advanced	  dissolution	  absorption	  and	  metabolism)	  model	  used	  by	  
SimCyp®	  is	  based	  on	  the	  CAT	  model.	  It	  uses	  solubility,	  permeability,	  
gastrointestinal	  transit	  times	  and	  surface	  area,	  enzyme	  distribution,	  and	  blood	  flow	  
to	  predict	  the	  extent	  and	  rate	  of	  absorption	  of	  drugs.	  Though	  this	  model	  is	  really	  
useful	  in	  the	  prediction	  of	  enzymatic	  related	  processes	  such	  as	  drug-­‐drug	  
interactions	  and	  metabolism,	  its	  limitations	  include	  the	  lack	  of	  prediction	  of	  
absorption	  in	  the	  stomach	  and	  colon,	  and	  the	  inability	  to	  predict	  intestinal	  
transporter	  related	  drug-­‐drug	  interactions	  [8]	  [9].	  	  
The	  Grass	  model,	  developed	  by	  Grass	  et	  al	  [10,	  11],	  is	  a	  multicomponent	  
physiologically	  based	  model	  used	  to	  predict	  drug	  absorption.	  It	  is	  an	  easy	  to	  use	  
model	  that	  incorporates	  solubility,	  permeability	  and	  surface	  area	  data	  to	  predict	  
drug	  absorption.	  However,	  its	  biggest	  limitation	  is	  that	  it	  does	  not	  incorporate	  first-­‐
pass	  metabolism	  or	  active	  transport	  processes.	  	  
The	  GITA	  model,	  developed	  by	  Kimura	  et	  al	  [12-­‐15],	  divides	  the	  intestine	  into	  
8	  segments	  and	  calculates	  the	  absorption	  rate	  coefficient	  for	  each	  of	  them.	  The	  GITA	  
model	  can	  predict	  a	  first-­‐pass	  effect,	  but	  unfortunately	  is	  unable	  to	  incorporate	  
active	  transport	  into	  the	  simulations	  and	  predictions.	  
The	  ACAT	  model	  used	  in	  Gastroplus®	  was	  developed	  by	  Simulations	  Plus	  
and	  divides	  the	  gastrointestinal	  tract	  into	  9	  compartments,	  all	  of	  which	  can	  have	  
absorption	  occurring	  from	  them.	  The	  ACAT	  defines	  one	  compartment	  for	  stomach,	  
one	  for	  the	  duodenum,	  2	  compartments	  for	  the	  jejunum,	  3	  for	  the	  ileum,	  1	  for	  the	  
ceacum,	  and	  1	  compartment	  for	  the	  ascending	  colon.	  The	  above	  9	  compartments	  are	  
then	  sub-­‐divided	  into	  the	  following	  4	  sub-­‐compartments:	  unreleased	  drug,	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undissolved	  drug,	  dissolved	  drug,	  and	  the	  enterocyte.	  The	  disintegration,	  dissolution,	  
permeation	  and	  gastrointestinal	  transit	  of	  drug	  between	  all	  of	  these	  compartments	  
and	  sub-­‐compartments	  are	  described	  by	  a	  series	  of	  differential	  equations,	  including	  
linear	  and	  non-­‐linear	  processes.	  By	  knowing	  a	  drug’s	  structure	  and	  its	  in	  vitro	  (or	  in	  
situ)	  affinity	  for	  the	  transporter,	  one	  can	  predict	  the	  fraction	  absorbed	  and	  
bioavailability	  of	  the	  compound	  in	  preclinical	  and	  clinical	  settings,	  if	  it	  interacts	  with	  
food	  or	  other	  drugs	  and	  its	  tissue	  distribution	  and	  disposition.	  
Among	  other	  qualities,	  Gastroplus	  can	  simulate	  changes	  of	  pH	  along	  the	  
gastrointestinal	  tract,	  which	  may	  affect	  the	  solubility	  and	  permeability	  of	  ionizable	  
molecules	  such	  as	  cefadroxil.	  Gastroplus®	  also	  takes	  into	  account	  changes	  in	  
volume	  of	  fluid	  in	  the	  small	  intestine	  and	  colon,	  which	  can	  affect	  the	  concentration	  
of	  drug	  in	  the	  GI	  tract	  and,	  therefore	  its	  uptake	  velocity	  by	  transporters	  and/or	  its	  
propensity	  to	  precipitate.	  Moreover,	  it	  takes	  into	  account	  the	  surface	  area	  in	  the	  
small	  intestine	  and	  how	  it	  changes	  along	  the	  GI	  tract	  in	  order	  to	  get	  a	  better	  
prediction	  of	  the	  permeability.	  Gastroplus	  has	  a	  module	  called	  ADMET™	  predictor,	  
which	  can	  predict	  the	  effective	  permeability	  of	  a	  drug	  molecule,	  based	  on	  its	  
chemical	  structure.	  Not	  only	  can	  it	  predict	  drug	  permeability,	  it	  can	  also	  predict	  
other	  properties,	  including	  ionization	  constants,	  diffusion	  coefficient,	  solubility,	  
supersaturation	  ratio,	  logP,	  logD,	  fraction	  of	  drug	  unbound	  in	  plasma,	  and	  blood	  to	  
plasma	  ratio.	  	  
Cefadroxil	  (Figure	  5.1)	  is	  a	  first	  generation	  amino-­‐cephalosporin	  used	  to	  
treat	  skin,	  upper	  respiratory	  tract	  and	  urinary	  tract	  infections	  caused	  by	  both	  gram	  
positive	  and	  negative	  bacteria.	  It	  was	  chosen	  as	  a	  model	  drug	  because	  of	  its	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metabolic	  and	  chemical	  stability,	  and	  its	  commercial	  availability	  as	  a	  radiolabeled	  
drug.	  Although	  cefadroxil	  absorption	  is	  primarily	  due	  to	  PEPT1-­‐mediated	  transport,	  
it	  has	  been	  shown	  to	  have	  apparent	  linear	  AUC0-­‐120	  and	  Cmax	  values	  with	  increasing	  
doses	  in	  humans	  and	  in	  mice.	  The	  antibiotic	  has	  a	  molecular	  weight	  of	  363,	  an	  
intrinsic	  solubility	  of	  17.4	  mg/mL,	  and	  a	  logD4.96	  of	  -­‐2.41.	  It	  has	  three	  ionization	  
constants	  (pka’s)	  at	  2.70,	  7.22,	  and	  9.62.	  Cefadroxil	  has	  high	  permeability	  and	  
excellent	  oral	  bioavailability	  (~90%	  in	  humans).	  It	  also	  has	  high	  solubility	  and	  a	  low	  
drug	  dose	  number	  (Do=	  maximum	  dose	  strength	  (mg)/lowest	  solubility	  (mg/mL)	  
/250	  mL	  =	  0.23)	  of	  ≤	  1,	  and	  its	  absorption	  is	  not	  affected	  by	  food	  intake.	  Cefadroxil	  
chemical	  degradation	  is	  marginal	  at	  physiological	  pH,	  with	  lower	  degradation	  rate	  
constants	  in	  more	  acidic	  environment.	  Also,	  cefadroxil	  is	  metabolically	  stable	  and	  
almost	  all	  of	  it	  is	  excreted	  unchanged	  in	  the	  urine	  [16].	  	  
PEPT1	  a	  member	  of	  the	  solute	  carrier	  (SLC)	  superfamily	  of	  transporters	  is	  
present	  in	  the	  apical	  membrane	  of	  the	  enterocytes	  of	  the	  duodenum,	  jejunum,	  and	  
ileum,	  but	  not	  in	  the	  stomach	  or	  colon.	  Our	  group	  previously	  published	  mRNA	  levels	  
and	  protein	  expression	  patterns	  in	  both	  wild	  type	  and	  PEPT1	  knockout	  mice	  [17,	  
18].	  Expression	  levels	  of	  PEPT1	  in	  mouse	  are	  similar	  along	  regions	  of	  the	  small	  
intestine,	  but	  significantly	  higher	  than	  in	  colon	  [17].	  Also,	  our	  previous	  studies	  in	  
wild-­‐type	  and	  PEPT1	  knockout	  mice	  showed	  that	  the	  major	  site	  of	  cefadroxil	  
absorption	  after	  oral	  administration	  is	  the	  small	  intestine	  (Chapter	  3	  and	  Chapter	  4).	  
Likewise,	  we	  showed	  that	  PEPT1	  is	  the	  most	  important	  absorption	  pathway	  for	  
cefadroxil,	  accounting	  for	  over	  90	  %	  of	  the	  uptake	  of	  this	  antibiotic	  in	  the	  small	  
intestine	  during	  in	  situ	  perfusion	  studies.	  Previous	  studies	  showed	  that	  in	  the	  kidney,	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cefadroxil	  is	  primarily	  reabsorbed	  from	  the	  renal	  tubules	  by	  PEPT2	  expressed	  on	  
the	  apical	  membrane	  of	  the	  renal	  epithelial	  cells[16],	  and	  secreted	  by	  organic	  anion	  
transporters	  at	  the	  basolateral	  membrane	  of	  the	  renal	  epithelial	  cells	  (more	  
information	  and	  references	  in	  Table	  1).	  
In	  this	  chapter	  our	  main	  objectives	  are	  to	  integrate,	  using	  the	  ACAT	  built	  
within	  Gastroplus®,	  the	  acquired	  knowledge	  about	  PEPT1	  functionality	  and	  the	  
physiological	  and	  physicochemical	  properties	  of	  cefadroxil,	  and	  to	  retrospectively	  
model	  the	  extent	  and	  rate	  of	  absorption	  and	  pharmacokinetics	  of	  this	  antibiotic	  in	  
mice.	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Material	  And	  Methods	  
Simulations	  
All	  simulations	  were	  run	  on	  a	  Dell	  Dimension	  5150	  computer	  using	  
GastroPlus®	  software	  (version	  8.0.002,	  Simulations	  Plus,	  Inc,	  Lancaster,	  CA).	  The	  
ACAT	  model	  was	  to	  predict	  the	  rate	  and	  extent	  of	  absorption	  of	  cefadroxil	  (Figure	  1)	  
from	  the	  gastrointestinal	  tract.	  	  
ACAT	  model	  
The	  advanced	  compartmental	  absorption	  and	  transit	  (ACAT)	  model	  
numerically	  integrates	  a	  set	  of	  over	  80	  differential	  equations	  that	  describe	  different	  
processes	  with	  linear	  and	  non-­‐linear	  kinetics,	  occurring	  after	  drug	  administration.	  
These	  processes	  include:	  disintegration,	  dissolution,	  precipitation,	  absorption,	  
exsorption,	  excretion,	  degradation,	  metabolism	  (in	  gut	  and	  liver),	  distribution,	  and	  
clearance	  (renal	  and	  non-­‐renal).	  The	  ACAT	  model	  divides	  the	  gastrointestinal	  into	  a	  
set	  of	  9	  compartments:	  stomach,	  duodenum,	  jejunum	  1,	  jejunum	  2,	  ileum	  1,	  ileum	  2,	  
ileum	  3,	  ceacum,	  and	  ascending	  colon.	  Each	  of	  these	  compartments	  is	  divided	  into	  4	  
sub-­‐compartments,	  based	  on	  the	  state	  of	  the	  drug:	  unreleased,	  undissolved,	  
dissolved,	  and	  enterocyte	  [19].	  	  
In	  this	  project,	  the	  ACAT	  model	  was	  used	  to	  simulate	  retrospectively	  the	  rate	  
and	  extend	  of	  absorption	  and	  pharmacokinetics	  of	  four	  oral	  doses	  of	  cefadroxil	  
administered	  to	  mice.	  The	  four	  doses	  of	  cefadroxil	  (Table	  5.10)	  were	  administered	  
in	  solution	  to	  both	  wild-­‐type	  and	  PEPT1	  knockout	  mice	  as	  described	  below.	  A	  
schematic	  representation	  of	  the	  tailored	  ACAT	  model	  used	  in	  this	  project	  is	  shown	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in	  Figure	  5.2.	  The	  tissue	  expression	  levels	  of	  PEPT1	  used	  in	  the	  simulations	  of	  wild-­‐
type	  mice	  were	  extracted	  and/or	  adapted	  from	  the	  literature,	  based	  on	  RNA	  and	  
protein	  levels	  in	  mice	  and	  in	  humans	  (Table	  5.2).	  All	  PEPT1	  expression	  levels	  are	  
relative	  values	  based	  on	  the	  expression	  of	  PEPT1	  transporter	  in	  the	  ileum.	  	  
ACAT	  Model	  Assumptions	  
The	  following	  assumptions	  were	  made	  in	  order	  to	  model	  the	  absorption	  of	  
cefadroxil	  in	  mice	  using	  GastroPlus®:	  1)	  there	  is	  no	  degradation	  of	  cefadroxil	  in	  the	  
gastrointestinal	  tract;	  2)	  all	  transit	  through	  the	  gastrointestinal	  tract	  are	  first-­‐order	  
processes;	  3)	  there	  is	  no	  absorption	  of	  cefadroxil	  in	  the	  stomach;	  4)	  the	  disposition	  
of	  cefadroxil	  is	  the	  same	  in	  both	  wild-­‐type	  and	  PEPT1	  knockout	  mice	  and	  follows	  
linear	  kinetics	  (i.e.	  no	  saturation	  is	  present);	  and	  5)	  in	  wild-­‐type	  mice,	  PEPT1	  is	  the	  
only	  transporter	  responsible	  for	  the	  absorption	  of	  cefadroxil	  into	  the	  enterocyte	  and	  
it	  is	  only	  expressed	  in	  the	  apical	  membrane	  of	  the	  small	  intestine.	  	  
Cefadroxil	  
Cefadroxil	  is	  a	  polar	  ampholyte	  with	  medium-­‐high	  solubility	  in	  water	  and	  
low	  passive	  permeability.	  It	  has	  been	  shown	  by	  in	  situ	  perfusion	  that	  at	  least	  90%	  of	  
its	  transport	  in	  the	  small	  intestine	  of	  mice	  is	  dependent	  on	  PEPT1,	  with	  an	  apparent	  
Km	  of	  3.8	  mM.	  	  Cefadroxil	  has	  3	  pKa’s,	  two	  acidic	  ones	  at	  2.7	  and	  9.62,	  and	  one	  basic	  
pKa	  at	  7.22.	  More	  information	  about	  its	  properties	  can	  be	  found	  in	  Table	  5.3	  and	  
Table	  5.4.	  Cefadroxil	  has	  been	  found	  to	  have	  negligible	  metabolism	  in	  the	  small	  
intestine	  and	  plasma.	  Cefadroxil	  has	  also	  been	  reported	  to	  have	  very	  low	  luminal	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degradation	  in	  different	  species,	  especially	  at	  low	  pH.	  After	  intravenous	  
administration	  to	  mice,	  98%	  of	  cefadroxil	  is	  found	  intact	  in	  urine	  after	  24	  hours	  [16].	  
Animal	  Studies	  with	  Cefadroxil	  
All	   in	  vivo	   and	   in	  situ	   studies	  were	  done	   in	   8-­‐10	  week	  old	   gender-­‐matched	  
wild-­‐type	  (PEPT1+/+)	  and	  PEPT1	  knockout	  (PEPT1-­‐/-­‐)	  mice.	  The	  animals	  were	  kept	  
in	   a	   temperature-­‐controlled	   room	  with	  12-­‐hour	   light	   and	  dark	   cycles,	   and	  given	  a	  
standard	   diet	   and	   water	   ad	   libitum.	   All	   of	   the	   procedures	   were	   approved	   by	   the	  
University	  of	  Michigan	  Committee	  on	  Use	  and	  Care	  of	  Animals	  (UCUCA),	  and	  were	  
carried	  out	  in	  accordance	  with	  the	  Guide	  for	  Use	  of	  Laboratory	  Animals	  as	  adopted	  
and	  promulgated	  by	  the	  US	  National	  Institutes	  of	  Health	  (NIH	  publication	  No.	  85-­‐23,	  
revised	  in	  1985).	  
The	   permeability	   of	   cefadroxil	   in	   the	   small	   intestine	   and	   colon	   (Peff)	   was	  
determined	  according	  to	  the	  procedures	  described	  in	  Chapter	  3.	  Briefly,	  mice	  were	  
anesthetized,	   and	   their	   duodenum,	   jejunum,	   ileum,	   and	   colon	   were	   isolated	   and	  
perfused	  with	  ascending	  concentrations	  of	   cefadroxil	   (0.001	   -­‐	  25	  mM)	  at	  a	   rate	  of	  
0.1	  mL/min,	  pH	  of	  6.5.	  The	  samples	  were	  collected	  at	  steady	  state	  (after	  ~	  30	  min)	  
and	   were	   analyzed	   by	   high	   performance	   liquid	   chromatography	   coupled	   to	   an	  
ultraviolet	   detector.	   The	   effective	   permeability	   (Peff,	   cm/sec)	   of	   cefadroxil	   was	  
calculated	  with	  the	  following	  formula:	  
	  
Peff = −Q ln(Co /Cin)
2πRL 	  	   	  (5.1)	  
where	  Q	  is	  the	  perfusion	  rate	  (ml/sec),	  Cout	  is	  the	  water	  flux-­‐corrected	  concentration	  
of	  cefadroxil	  coming	  out	  of	  the	  perfused	  segment	  (µg/mL),	  Cin	  is	  the	  input	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concentration	  of	  cefadroxil	  (µg/mL),	  and	  R	  and	  L	  are	  the	  radius	  and	  length	  of	  the	  
perfused	  segment	  (cm),	  respectively.	  	  
The	   plasma	   concentration-­‐time	   profiles	   of	   cefadroxil	   in	  mice	   used	   in	   these	  
simulations	   were	   determined	   in	   our	   laboratory	   with	   standard	   procedures	   as	  
described	   in	   Chapter	   4.	   Briefly,	   all	   studies	   were	   done	   in	   8-­‐10	   week	   old	   gender-­‐
matched	  wild-­‐type	  (PEPT1+/+)	  and	  PEPT1	  knockout	  	  (PEPT1-­‐/-­‐)	  mice.	  Cefadroxil	  was	  
dosed	  via	  oral	   gavage	   (0.323,	  0.646,	  1.292,	  2.584	  mg)	  or	   tail-­‐vein	   injection	   (0.323	  
mg),	   and	   the	   plasma	   was	   harvested	   after	   serial	   blood	   sampling,	   from	   0	   and	   120	  
minutes.	   The	   radioactivity	   in	   plasma	   was	   measured	   using	   a	   dual	   channel	   liquid	  
scintillation	   counter.	   The	   pharmacokinetic	   values	   of	   cefadroxil	   after	   intravenous	  
administration	  were	  fitted	  using	  WinNonlin,	  and	  the	  goodness	  of	   fit	  was	  evaluated	  
by	  visual	  inspection	  of	  the	  predicted	  values	  and	  residual	  plots.	  	  
Absorption	  Models	  and	  Gastrointestinal	  Physiology	  
GastroPlus®	  defines	  absorption	  as	  the	  movement	  of	  drug	  from	  the	  intestinal	  
lumen	  into	  the	  enterocyte,	  and	  calculates	  the	  absorption	  rate	  constant	  as	  a	  product	  
of	  the	  effective	  permeability	  of	  the	  drug	  and	  the	  absorption	  scale	  factor,	  according	  to	  
the	  following	  formula	  
𝑘𝑎 = 𝑃!""   𝛼	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (5.2)	  
where	  Peff	  is	  the	  effective	  permeability	  and	  α	  is	  the	  absorption	  scale	  factor	  
(ASF)	  for	  each	  intestinal	  segment.	  The	  absorption	  scale	  factor	  is	  used	  to	  scale	  
regional	  permeability	  to	  the	  absorption	  rate	  constant	  and	  is	  defined	  as	  the	  ratio	  of	  
the	  volume	  of	  the	  intestinal	  segment	  and	  its	  surface	  area,	  as	  seen	  in	  the	  formula:	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  (5.3)	  




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (5.4)	  
Gastroplus	  has	  different	  models	  to	  calculate	  and	  scale	  the	  absorption	  scale	  
factor	  (ASF)	  for	  different	  segments	  of	  the	  intestine,	  according	  to	  differences	  in	  
surface	  area	  and	  width	  of	  the	  tight	  junctions.	  The	  8	  different	  models	  were	  compared	  
based	  on	  their	  sum	  of	  squares	  errors	  and	  the	  differences	  between	  the	  predicted	  and	  
observed	  plasma-­‐concentration	  time	  profiles	  and	  pharmacokinetic	  parameters.	  	  
Parameter	  Sensitivity	  Analysis	  
Initially,	  a	  parameter	  sensitivity	  analysis	  (PSA)	  was	  performed	  using	  data	  for	  
the	  lowest	  dose	  of	  cefadroxil	  (44.5nmol/g)	  in	  knockout	  mice,	  thus	  providing	  an	  
understanding	  of	  the	  sensitivity	  of	  the	  predicted	  Cmax	  and	  AUC0-­‐120	  of	  cefadroxil	  to	  
several	  input	  properties	  including	  effective	  permeability	  (Peff),	  clearance	  (Cl),	  
volume	  of	  distribution	  in	  the	  central	  compartment	  (Vc),	  and	  the	  distribution	  micro-­‐	  
rate	  constants	  (K12,	  K21).	  	  
Subsequently,	  a	  second	  parameter	  sensitivity	  analysis	  was	  performed	  using	  
data	  for	  lowest	  dose	  of	  cefadroxil	  (44.5	  nmol/g)	  in	  the	  wild-­‐type	  mice.	  In	  this	  
analysis,	  we	  tested	  the	  sensitivity	  of	  the	  predicted	  Cmax	  and	  AUC0-­‐120	  to	  changes	  in	  
the	  previously	  mentioned	  pharmacokinetic	  parameters,	  and	  in	  the	  PEPT1	  affinity	  
constant	  (Km),	  and	  maximum	  transport	  rate	  constant	  (Vmax).	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Optimization	  
The	  optimization	  function	  in	  GastroPlus®	  was	  used	  to	  calibrate	  the	  model	  by	  
minimizing	  the	  objective	  function	  (error	  function)	  of	  different	  model	  parameters	  
specified	  by	  the	  user	  in	  order	  to	  get	  a	  better	  prediction	  of	  the	  AUC0-­‐120	  and	  Cmax,	  
These	  optimizations	  were	  performed	  in	  the	  training	  data	  sets	  which	  were	  the	  lowest	  
dose	  (44.5	  nmol/g)	  in	  both	  wild-­‐type	  and	  PEPT1	  knockout	  mice.	  The	  parameters	  
that	  were	  optimized	  were	  Vmax	  for	  PEPT1	  in	  the	  wild-­‐type	  mice,	  since	  the	  value	  
obtained	  in	  the	  in	  situ	  perfusion	  experiments	  cannot	  be	  directly	  scaled	  to	  the	  in	  vivo	  
value	  in	  the	  simulations.	  In	  addition	  to	  Vmax,	  some	  pharmacokinetics	  parameters	  
obtained	  after	  intravenous	  administration	  of	  cefadroxil	  in	  mice	  were	  optimized	  such	  
as	  clearance,	  volume	  of	  distribution	  in	  the	  central	  compartment,	  and	  the	  
distribution	  rate	  constants.	  
Simulation	  Strategy	  
The	  following	  strategy	  was	  followed	  for	  the	  retrospective	  simulation	  of	  the	  
absorption	  of	  cefadroxil	  in	  mice:	  
1. Development	  of	  an	  absorption	  model	  using	  the	  lowest	  dose	  of	  cefadroxil	  
(44.5	  nmol/g)	  in	  PEPT1	  knockout	  mice	  (training	  set	  A).	  
2. Parameter	  sensitivity	  analysis	  and	  model	  optimization	  for	  training	  set	  A	  .	  
3. Development	  of	  an	  absorption	  model	  using	  the	  lowest	  dose	  (44.5	  nmol/g)	  
in	  wild-­‐type	  mice	  (training	  set	  B).	  
4. Parameter	  sensitivity	  analysis	  and	  model	  optimization	  of	  training	  set	  B.	  
5. 	  Simulation	  of	  absorption	  and	  pharmacokinetics	  of	  cefadroxil	  in	  wild-­‐type	  
and	  PEPT1	  knockout	  mice	  for	  3	  higher	  doses	  (89.1,	  178,	  and	  356	  nmol/g).	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6. Evaluation	  of	  the	  quality	  of	  the	  simulations,	  as	  judged	  by:	  1)	  an	  evaluation	  
of	  the	  coefficient	  of	  determination	  R2	  and	  the	  sum	  of	  squares	  of	  error	  
(SSE),	  2)	  a	  visual	  inspection	  of	  the	  plasma	  concentration-­‐time	  profiles,	  
and	  finally	  3)	  a	  comparison	  of	  the	  observed	  and	  the	  predicted	  
pharmacokinetic	  parameters	  Cmax,	  and	  AUC0-­‐120.	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Results	  
Disposition	  of	  Cefadroxil	  
The	  plasma	  concentration-­‐time	  data	  obtained	  after	  the	  intravenous	  
administration	  of	  cefadroxil	  in	  wild-­‐type	  and	  PEPT1	  knockout	  mice,	  were	  fitted	  
using	  a	  two-­‐compartment	  model	  with	  a	  weighting	  factor	  of	  1/Y2.	  This	  model	  was	  
chosen	  because	  it	  had	  the	  lowest	  Akaike	  Information	  Criterion	  (AIC),	  the	  lowest	  
Schwartz	  Bayesian	  Criterion	  (SBC),	  the	  lowest	  R2,	  and	  produced	  the	  best	  estimates	  
for	  the	  parameters	  and	  standard	  errors.	  Since	  there	  were	  no	  significant	  differences	  
between	  wild-­‐type	  and	  PEPT1	  knockout	  mice,	  the	  data	  were	  pooled	  together	  and	  
the	  average	  values	  of	  the	  pharmacokinetic	  parameters	  were	  used	  for	  the	  model.	  The	  
clearance	  (Cl),	  volume	  of	  distribution	  in	  the	  central	  compartment	  (Vc),	  and	  
peripheral	  compartment	  distribution	  micro-­‐	  rate	  constants	  (K12	  and	  K21)	  obtained	  
in	  the	  fitting	  with	  WinNonlin®	  are	  shown	  in	  Table	  5.5.	  	  
Parameter	  Sensitivity	  Analyses	  (PSA)	  
The	  parameter	  sensitivity	  analyses	  performed	  in	  the	  in	  the	  PEPT1	  knockout	  
mice	  show	  that	  clearance	  and	  effective	  permeability	  are	  the	  two	  parameters	  that	  
most	  affected	  the	  Cmax	  of	  cefadroxil,	  followed	  by	  k12	  and	  the	  volume	  of	  distribution	  
in	  the	  central	  compartment.	  As	  shown	  in	  Figure	  5.3	  A	  for	  knockout	  mice,	  when	  the	  
effective	  permeability	  (Peff)	  of	  cefadroxil	  was	  increased	  by	  two	  orders	  of	  magnitude,	  
the	  Cmax	  changed	  from	  0.23	  to	  1.53	  μg/mL	  (~7-­‐fold	  increase).	  In	  contrast,	  when	  the	  
clearance	  was	  increased	  by	  two	  orders	  of	  magnitude,	  the	  Cmax	  decreased	  from	  2.15	  
 
  138 
to	  0.07	  μg	  /mL	  (30-­‐fold	  difference).	  Similarly,	  when	  Vc	  and	  K12	  increased	  by	  2	  orders	  
of	  magnitude,	  the	  Cmax	  decreased	  by	  2	  fold.	  
For	  wild-­‐type	  mice,	  the	  Cmax	  was	  found	  to	  be	  sensitive	  to	  changes	  in	  volume	  
of	  distribution	  in	  the	  central	  compartment	  (Vc),	  Vmax,	  Km,	  clearance	  (CL)	  and	  the	  
distribution	  micro-­‐rate	  constant	  (K12)	  as	  seen	  in	  Figure	  5.3	  B.	  When	  the	  volume	  of	  
distribution	  in	  the	  central	  compartment	  was	  increased	  by	  2	  orders	  of	  magnitude,	  
the	  Cmax	  decreased	  from	  52	  to	  4.2	  μg	  /mL	  (~13-­‐fold	  difference).	  When	  the	  Vmax	  
increased	  by	  2	  orders	  of	  magnitude,	  the	  Cmax	  increased	  from	  12	  to	  44	  μg/mL	  (4-­‐fold	  
difference).	  	  When	  the	  Km	  increased	  by	  2	  orders	  of	  magnitude,	  the	  Cmax	  decreased	  
from	  41	  to	  11	  μg	  /mL	  (4-­‐fold	  difference).	  When	  the	  clearance	  increased	  by	  2	  orders	  
of	  magnitude,	  the	  Cmax	  decreased	  from	  37	  to	  6.5	  μg	  /mL	  (~5-­‐fold	  difference).	  When	  
the	  k12	  increased	  by	  2	  orders	  of	  magnitude,	  the	  Cmax	  decreased	  from	  28	  to	  10	  μg	  
/mL	  (~3-­‐fold	  difference).	  
As	  seen	  in	  Figure	  5.4	  A,	  the	  AUC0-­‐120	  for	  PEPT1	  knockout	  mice	  was	  most	  
affected	  by	  the	  effective	  permeability	  (Peff),	  the	  clearance	  (CL),	  and	  the	  volume	  of	  
distribution	  in	  the	  central	  compartment	  (Vc).	  When	  the	  effective	  permeability	  was	  
increased	  by	  2	  orders	  of	  magnitude,	  the	  AUC0-­‐120	  increased	  from	  378	  to	  16,636	  μg	  
/mL*	  hr	  (~44-­‐fold).	  When	  the	  clearance	  was	  increased	  by	  2	  orders	  of	  magnitude,	  
the	  AUC0-­‐120	  decreased	  from	  2236	  to	  34	  μg/mL*	  hr	  (~65-­‐fold).	  When	  the	  volume	  of	  
distribution	  in	  the	  central	  compartment	  was	  increased	  by	  2	  orders	  of	  magnitude,	  
the	  AUC0-­‐120	  decreased	  from	  1477	  to	  626	  μg	  /mL*	  hr	  (~2-­‐fold).	  	  
As	  seen	  in	  Figure	  5.4	  B,	  the	  predicted	  AUC0-­‐120	  in	  wild-­‐type	  mice	  was	  the	  
most	  sensitive	  to	  changes	  in	  clearance	  (CL)	  and	  volume	  of	  distribution	  in	  the	  central	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compartment	  (Vc).	  When	  the	  clearance	  increased	  by	  2	  orders	  of	  magnitude,	  the	  
AUC0-­‐120	  decreased	  from	  51,000	  to	  17,700	  μg	  /mL*	  hr	  (~3-­‐fold	  difference).	  When	  
the	  volume	  of	  distribution	  in	  the	  central	  compartment	  was	  increased	  by	  2	  orders	  of	  
magnitude,	  the	  AUC0-­‐120	  decreased	  from	  17,000	  to	  6,400	  μg	  /mL*	  hr	  (~2.5-­‐fold	  
difference).	  	  
Optimization	  
The	  first	  optimization	  step	  was	  performed	  with	  the	  first	  dose	  in	  the	  knockout	  
mice	  data.	  The	  results	  are	  listed	  on	  Table	  5.5.	  The	  optimized	  parameters	  in	  the	  
knockout	  mice	  were	  CL,	  K12,	  K21,	  and	  Vc.	  In	  the	  wild-­‐type	  mice,	  Vmax	  was	  also	  
optimized.	  These	  values	  are	  also	  shown	  on	  Table	  5.5.	  	  
Simulation	  of	  Cefadroxil	  Absorption	  and	  Pharmacokinetics	  
Figure	  5.5	  shows	  the	  results	  for	  the	  simulation	  of	  cefadroxil	  plasma	  
concentration	  profiles	  in	  PEPT1	  knockout	  mice	  after	  oral	  administration	  of	  44.5	  
nmol/g	  (0.323	  mg),	  89.1	  nmol/g	  (0.646mg),	  178	  nmol/g	  (1.292	  mg),	  and	  356	  
nmol/g	  (2.584	  mg).	  	  All	  4	  doses	  were	  simulated	  using	  the	  same	  optimized	  
parameters	  listed	  in	  Table	  5.5.	  All	  the	  simulated	  curves	  are	  within	  the	  range	  of	  
individually	  observed	  data.	  Table	  5.6	  shows	  that	  the	  simulated	  Cmax	  and	  AUC0-­‐120	  
values	  are	  very	  similar	  to	  the	  experimental	  ones,	  and	  that	  all	  simulations	  had	  a	  R2	  
higher	  than	  0.6.	  	  
Figure	  5.6	  shows	  the	  results	  for	  the	  simulation	  of	  cefadroxil	  plasma	  
concentration	  time	  profiles	  in	  wild-­‐type	  mice.	  When	  all	  doses	  were	  simulated	  using	  
the	  same	  input	  pharmacokinetic	  parameters,	  only	  the	  plasma	  concentration-­‐time	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profiles	  for	  the	  first	  2	  doses	  looked	  similar	  to	  the	  observed	  profiles.	  The	  simulations	  
of	  the	  3rd	  and	  4th	  doses	  significantly	  under	  predicted	  the	  profiles,	  which	  may	  be	  due	  
to	  saturation	  of	  the	  PEPT1	  transporter	  in	  the	  small	  intestine.	  We	  tested	  4	  different	  
gastrointestinal	  tract	  distributions	  of	  PEPT1	  based	  on	  the	  literature	  and	  previously	  
obtained	  results	  in	  our	  research	  group.	  No	  matter	  which	  distribution	  was	  used,	  the	  
simulation	  always	  predicted	  saturation	  of	  the	  2	  highest	  doses,	  with	  lower	  Cmax	  and	  
AUC0-­‐120	  values	  and	  a	  shift	  to	  the	  right	  for	  the	  Tmax.	   	  
Figure	  5.7	  shows	  the	  estimated	  percent	  of	  cefadroxil	  dose	  absorbed	  in	  each	  
of	  the	  segments	  of	  the	  gastrointestinal	  tract	  in	  the	  PEPT1	  knockout	  mice.	  For	  all	  four	  
doses,	  the	  total	  percent	  absorbed	  was	  about	  13	  %,	  which	  is	  very	  close	  to	  the	  
systemic	  exposure	  obtained	  in	  the	  in	  vivo	  experiments	  in	  Chapter	  4.	  Similarly,	  the	  
absorption	  of	  cefadroxil	  was	  lower	  and	  fairly	  consistent	  for	  each	  segment	  along	  the	  
GI	  tract	  for	  all	  4	  doses.	  Given	  that	  PEPT1	  is	  absent	  in	  these	  mice,	  higher	  amounts	  
(and	  concentrations)	  of	  cefadroxil	  are	  available	  for	  absorption	  at	  each	  segment	  
along	  the	  GI,	  from	  the	  duodenum	  to	  the	  lower	  colon.	  Furthermore,	  results	  of	  the	  
simulation	  show	  that	  cefadroxil	  is	  mostly	  absorbed	  via	  transcellular	  passive	  
diffusion	  in	  the	  PEPT1	  knockout	  mice	  and	  very	  little	  drug	  is	  absorbed	  through	  
paracellular	  diffusion	  (<10%).	  	  
Figure	  5.8	  shows	  the	  estimated	  percent	  of	  cefadroxil	  dose	  absorbed	  in	  
different	  segments	  of	  the	  GI	  tract	  of	  wild-­‐type	  mice	  for	  the	  four	  doses.	  The	  results	  
show	  that	  most	  of	  this	  antibiotic	  is	  absorbed	  in	  the	  early	  segments	  of	  the	  small	  
intestine,	  especially	  the	  duodenum	  and	  jejunum.	  At	  the	  lower	  doses,	  about	  80	  %	  of	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cefadroxil	  gets	  absorbed	  in	  the	  first	  2	  hours	  while,	  at	  higher	  doses,	  PEPT1	  gets	  
saturated	  and	  less	  drug	  is	  absorbed	  from	  the	  GI	  tract	  (<	  80%).	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Discussion	  
This	  work	  presents	  a	  new	  example	  in	  which	  in	  silico	  models	  can	  be	  useful	  in	  
the	  analysis	  and	  prediction	  of	  peptide/mimetic	  absorption	  in	  genetically	  modified	  
animals.	  Although	  this	  model	  is	  based	  on	  previously	  acquired	  data,	  we	  believe	  it	  
could	  be	  useful	  in	  understanding	  the	  role	  of	  PEPT1	  in	  the	  absorption	  of	  drugs	  and	  
the	  impact	  on	  the	  variability	  of	  this	  transporter	  in	  drug	  concentrations	  in	  the	  body.	  
Possibly,	  it	  could	  also	  help	  predict	  the	  outcomes	  of	  PEPT1	  substrates	  in	  other	  
preclinical	  species	  and	  in	  humans.	  	  
In	  this	  project	  we	  predicted	  retrospectively	  the	  importance	  of	  PEPT1	  in	  the	  
rate	  and	  extent	  of	  cefadroxil	  absorption	  in	  mice,	  by	  integrating	  information	  acquired	  
from	  our	  own	  in	  situ	  and	  in	  vivo	  experiments	  with	  data	  collected	  from	  the	  literature.	  
We	  were	  able	  to	  establish	  a	  model	  that	  predicted	  the	  effect	  of	  PEPT1	  on	  the	  
absorption	  and	  pharmacokinetics	  of	  cefadroxil	  using	  the	  ACAT	  model	  built	  into	  
Gastroplus®.	  	  In	  our	  model,	  we	  successfully	  simulated	  the	  rate	  and	  extent	  of	  
absorption	  of	  4	  clinically	  relevant	  doses	  of	  cefadroxil	  in	  PEPT1	  knockout	  mice	  and	  
the	  2	  lower	  doses	  in	  wild-­‐type	  mice.	  
From	  our	  point	  of	  view	  the	  model	  revealed	  the	  following	  important	  findings	  
1)	  PEPT1	  has	  an	  important	  effect	  on	  the	  absorption	  rate	  and	  extent	  of	  cefadroxil,	  
and	  it	  is	  responsible	  for	  about	  90%	  of	  the	  drug	  absorbed	  in	  wild-­‐type	  mice;	  2)	  in	  
wild-­‐type	  mice,	  the	  absorption	  of	  cefadroxil	  occurs	  mostly	  in	  the	  proximal	  segments	  
of	  the	  small	  intestine;	  3)	  in	  PEPT1	  knockout	  mice,	  most	  of	  the	  drug	  is	  absorbed	  via	  
passive	  transcellular	  diffusion,	  and	  this	  process	  is	  evenly	  distributed	  along	  the	  GI	  
tract	  (i.e.	  duodenum	  to	  colon);	  4)	  paracellular	  absorption	  plays	  a	  minor	  role	  in	  the	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permeability	  of	  cefadroxil	  in	  both	  genotypes;	  and	  5)	  the	  model	  predicts	  saturation	  
of	  PEPT1	  at	  the	  2	  highest	  doses	  in	  wild-­‐type	  mice.	  	  
Given	  the	  inter-­‐subject	  variability	  that	  is	  usually	  observed	  in	  oral	  absorption,	  
a	  parameter	  sensitivity	  analysis	  was	  performed	  in	  order	  to	  study	  the	  effect	  of	  
intravenous	  input	  parameters	  on	  the	  predicted	  AUC0-­‐120	  and	  Cmax	  of	  cefadroxil	  in	  
both	  wild-­‐type	  and	  PEPT1	  knockout	  mice.	  For	  the	  knockout	  mice	  the	  effective	  
permeability	  and	  clearance	  had	  the	  most	  influence	  on	  the	  Cmax	  and	  AUC0-­‐120	  of	  
cefadroxil.	  For	  the	  wild-­‐type	  mice,	  the	  input	  parameters	  with	  the	  most	  impact	  on	  
Cmax	  and	  AUC0-­‐120	  were	  the	  clearance	  and	  the	  Vmax	  and	  Km	  of	  PEPT1.	  	  
A	  parameter	  optimization	  was	  performed	  on	  those	  input	  variables	  that	  
showed	  to	  have	  an	  important	  effect	  on	  the	  AUC0-­‐120	  and	  Cmax	  of	  cefadroxil	  in	  both	  
genotypes,	  which	  in	  this	  case	  were	  the	  volume	  of	  distribution	  in	  the	  central	  
compartment,	  clearance,	  and	  K12	  and	  K21.	  As	  mentioned	  previously,	  the	  values	  of	  the	  
optimized	  parameters	  were	  similar	  to	  the	  fitted	  ones,	  with	  a	  maximum	  2-­‐fold	  
difference	  between	  them.	  Although	  the	  sensitivity	  analysis	  revealed	  that	  the	  jejunal	  
effective	  permeability	  (Peff)	  had	  a	  big	  effect	  on	  the	  AUC0-­‐120	  and	  Cmax	  in	  knockout	  
mice,	  we	  decided	  not	  to	  optimize	  it	  given	  the	  good	  results	  that	  were	  obtained	  in	  the	  
knockout	  mice	  simulations.	  For	  wild-­‐type	  mice,	  in	  addition	  to	  the	  already	  optimized	  
intravenous	  pharmacokinetic	  parameters,	  we	  optimized	  the	  Vmax	  value	  of	  PEPT1	  
obtained	  from	  our	  in	  situ	  experiments.	  In	  Gastroplus,	  this	  parameter	  is	  intended	  to	  
be	  from	  in	  vitro	  experiments	  and	  not	  from	  in	  situ	  perfusion	  experiments,	  like	  it	  is	  in	  
this	  particular	  case.	  
 
  144 
The	  ACAT	  model	  was	  very	  useful	  in	  predicting	  the	  plasma	  concentration-­‐
time	  profiles	  of	  cefadroxil	  in	  knockout	  mice.	  The	  simulated	  plasma	  concentration-­‐
time	  curves	  were	  very	  similar	  to	  the	  experimental	  ones,	  and	  the	  R2	  values	  were	  high	  
enough	  suggesting	  the	  prediction	  was	  reliable.	  When	  analyzing	  the	  shape	  of	  the	  
curves,	  the	  plateau	  of	  the	  curves	  and	  Tmax	  suggest	  that	  the	  absorption	  of	  cefadroxil	  
happens	  very	  slowly	  relative	  to	  the	  wild-­‐type	  mice,	  and	  the	  absorption	  can	  be	  
explained	  by	  flip-­‐flop	  kinetics	  (i.e.	  absorption	  is	  slow	  compared	  to	  elimination).	  
Results	  of	  the	  simulation	  show	  that	  the	  regional	  absorption	  pattern	  of	  cefadroxil	  in	  
knockout	  mice	  is	  fairly	  uniform	  along	  the	  gastrointestinal	  tract.	  The	  percent	  of	  drug	  
absorbed	  is	  similar	  along	  the	  different	  segments	  of	  the	  gastrointestinal	  tract	  and,	  
given	  the	  long	  residence	  time	  in	  the	  intestines,	  absorption	  occurs	  passively	  in	  all	  
regions	  including	  the	  colon.	  	  
The	  simulated	  values	  for	  percent	  dose	  absorbed	  of	  cefadroxil	  were	  very	  
similar	  to	  the	  experimental	  values	  observed	  for	  knockout	  mice.	  The	  simulations	  
predict	  that	  13%	  of	  the	  orally	  administered	  cefadroxil	  dose	  is	  absorbed	  in	  the	  first	  2	  
hours	  after	  dosing.	  Our	  in	  vivo	  results	  also	  show	  similar	  percentages,	  around	  14%,	  
for	  the	  relative	  systemic	  exposure	  of	  cefadroxil	  for	  this	  genotype.	  For	  the	  lower	  oral	  
doses	  in	  wild-­‐type	  mice,	  the	  simulated	  values	  for	  percent	  dose	  absorbed	  of	  
cefadroxil	  were	  around	  80%.	  This	  again,	  is	  very	  similar	  to	  the	  78	  %	  relative	  
systemic	  exposure	  observed	  in	  the	  in	  vivo	  experiments	  in	  this	  genotype	  described	  in	  
Chapter	  4.	  The	  agreement	  between	  the	  simulated	  and	  experimental	  results	  gives	  us	  
confidence	  in	  the	  correctness	  of	  our	  model.	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For	  wild-­‐type	  mice,	  the	  simulations	  results	  of	  the	  lower	  2	  doses	  (0.323	  and	  
0.646	  mg)	  look	  similar	  to	  the	  experimental	  plasma	  concentration-­‐time	  profiles.	  The	  
regional	  absorption	  results	  show	  that	  most	  of	  the	  absorption	  occurs	  in	  the	  upper	  
regions	  of	  the	  gastrointestinal	  tract,	  in	  particular	  in	  the	  duodenum	  and	  jejunum.	  In	  
knockout	  mice	  the	  lack	  of	  PEPT1	  results	  in	  higher	  absorption	  of	  cefadroxil	  in	  the	  
later	  part	  of	  the	  intestinal	  segments.	  This	  compensatory	  effect	  has	  been	  observed	  
and	  described	  previously	  [20],	  in	  which	  passive	  diffusion	  becomes	  more	  important	  
in	  lower	  segments	  of	  the	  gastrointestinal	  tract	  when	  PEPT1	  is	  not	  present	  in	  the	  
small	  intestine.	  
While	  the	  experimental	  data	  showed	  no	  change	  in	  the	  dose-­‐corrected	  	  	  	  	  
AUC0-­‐120	  and	  Cmax	  for	  the	  4	  doses,	  the	  model	  predicts	  saturation	  of	  the	  PEPT1-­‐
mediated	  absorption	  of	  cefadroxil	  in	  the	  small	  intestine.	  To	  better	  understand	  this	  
phenomenon,	  we	  calculated	  what	  the	  concentrations	  of	  cefadroxil	  in	  the	  mouse	  
small	  intestine	  would	  be	  for	  the	  four	  different	  doses	  and	  compared	  it	  with	  the	  Km	  
obtained	  from	  in	  situ	  experiments.	  As	  seen	  on	  Table	  5.10,	  the	  calculated	  small	  
intestinal	  concentrations	  of	  cefadroxil	  in	  the	  mouse	  for	  the	  2	  highest	  doses	  are	  well	  
above	  the	  Km	  of	  3.8	  mM	  (at	  least	  2-­‐fold	  higher),	  indicating	  that	  saturation	  of	  the	  
PEPT1-­‐related	  transport	  may	  be	  occurring	  at	  these	  doses.	  	  
Still,	  this	  lack	  of	  fit	  of	  our	  model	  in	  wild-­‐type	  mice	  prompted	  us	  to	  start	  
thinking	  about	  the	  potential	  of	  having	  inaccurate	  input	  parameters	  in	  our	  model.	  
For	  example,	  it	  is	  possible	  that	  the	  Km	  we	  measured	  in	  the	  perfusion	  experiments	  
may	  not	  be	  directly	  translatable	  to	  the	  in	  vivo	  setting.	  It	  is	  also	  possible	  that	  the	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actual	  concentrations	  of	  drug	  available	  for	  PEPT1	  at	  the	  apical	  membranes	  of	  
enterocytes	  was	  lower	  than	  the	  calculated	  concentrations.	  
We	  believe	  our	  in	  situ	  Km	  value	  of	  3.8	  mM	  is	  correct	  and	  similar	  to	  what	  has	  
been	  reported	  by	  other	  authors.	  For	  example,	  Sinko	  et	  al	  reported	  a	  Km	  value	  of	  5.8	  
mM	  for	  cefadroxil	  in	  rat	  perfusion	  experiments	  [21,	  22],	  and	  Wenzel	  et	  al	  [23]	  
reported	  a	  Km	  of	  1.1	  mM	  for	  cefadroxil	  in	  Xenopus	  oocytes	  transfected	  with	  PEPT1.	  
However,	  in	  vitro	  and	  in	  situ	  conditions	  do	  not	  necessarily	  reflect	  what	  happens	  in	  
vivo	  and	  the	  Km	  estimate	  may	  not	  be	  extrapolated	  directly	  to	  in	  vivo	  conditions.	  This	  
value	  of	  3.8	  mM	  was	  measured	  in	  the	  jejunum	  of	  wild-­‐type	  mice	  using	  a	  cefadroxil	  
perfusion	  rate	  of	  0.1	  ml/min.	  However,	  if	  one	  uses	  allometric	  scaling	  to	  calculate	  the	  
intestinal	  flow	  rate	  (Q)	  in	  mice	  from	  the	  human	  value	  (2-­‐3mL/min)	  using	  the	  











	  	   (5.1)	  
the	  resulting	  value	  would	  be	  approximately	  0.01	  mL/min.	  Thus,	  in	  vivo	  
perfusion	  rate	  is	  actually	  10	  times	  lower	  than	  the	  perfusion	  rate	  of	  0.1	  mL/min	  used	  
in	  the	  in	  situ	  experiments,	  which	  could	  result	  in	  an	  in	  situ	  Km	  value	  that	  is	  
significantly	  different	  than	  the	  in	  vivo	  one.	  This	  is	  because,	  according	  to	  Johnson	  et	  al	  
[47],	  a	  high	  perfusion	  rate	  decreases	  the	  resistance	  of	  the	  aqueous	  layer	  to	  the	  
diffusion	  of	  drug	  from	  the	  bulk	  fluid	  towards	  the	  wall	  of	  the	  intestine.	  A	  lower	  
resistance	  results	  in	  a	  lower	  Graetz	  number.	  This	  would	  in	  turn	  result	  in	  higher	  
carrier	  permeability	  and	  a	  lower	  Km.	  In	  summary,	  a	  high	  perfusion	  rate	  might	  cause	  
an	  under-­‐prediction	  of	  the	  Km	  for	  the	  transporter,	  and	  therefore	  predict	  saturation	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at	  higher	  doses.	  To	  see	  what	  would	  happen	  in	  to	  our	  simulations	  using	  a	  higher	  Km,	  
we	  developed	  a	  model	  with	  a	  Km	  of	  35	  mM,	  which	  is	  10-­‐fold	  higher	  than	  our	  in	  situ	  
experimental	  value.	  By	  using	  this	  artificial	  Km,	  no	  under-­‐predictions	  of	  the	  AUC0-­‐120	  
Tmax	  ,	  or	  Cmax	  occurred,	  and	  really	  good	  correlations	  were	  observed	  for	  all	  4	  doses	  
(Table	  5.12).	  	  
As	  mentioned	  earlier,	  another	  reason	  why	  the	  model	  may	  not	  fit	  the	  
experimental	  results	  could	  be	  that	  the	  actual	  concentrations	  of	  cefadroxil	  available	  
for	  PEPT1	  at	  the	  membrane	  surface	  are	  significantly	  lower	  than	  the	  concentrations	  
of	  cefadroxil	  in	  the	  bulk	  fluid	  of	  the	  intestinal	  segment.	  This	  happens	  because	  the	  
drug	  has	  to	  diffuse	  from	  the	  middle	  of	  the	  tube	  towards	  the	  intestinal	  wall,	  creating	  
a	  gradient	  with	  higher	  concentrations	  of	  drug	  in	  the	  middle	  than	  at	  the	  wall,	  
especially	  in	  the	  presence	  of	  a	  mucous	  layer	  barrier.	  In	  that	  case	  the	  concentration	  
of	  cefadroxil	  at	  the	  apical	  membrane	  could	  be	  lower	  than	  the	  Km,	  which	  would	  mean	  
no	  saturation	  of	  this	  transport	  process.	  	  
Another	  possible	  hypothesis	  could	  be	  that	  the	  saturation	  of	  PEPT1	  is	  being	  
masked	  in	  vivo	  by	  other	  processes,	  and	  we	  believe	  that	  a	  decrease	  of	  cefadroxil	  
clearance	  in	  the	  kidney	  is	  one	  of	  the	  responsible	  mechanisms.	  Cefadroxil,	  as	  
previously	  described,	  is	  actively	  secreted	  in	  the	  kidney	  by	  the	  organic	  anion	  
transporters,	  OAT1,	  OAT3,	  and	  OAT4	  [24]	  [25,	  26].	  With	  a	  cefadroxil	  plasma	  
concentration	  level	  above	  the	  Km	  of	  these	  transporters,	  the	  active	  secretion	  of	  the	  
antibiotic	  would	  become	  saturated	  and	  the	  clearance	  would	  decrease	  significantly	  
with	  increasing	  doses.	  Therefore,	  the	  dose	  corrected	  area	  under	  the	  curve	  (AUC/D)	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would	  not	  change	  significantly	  if	  both	  the	  fraction	  absorbed	  (F)	  and	  clearance	  (Cl)	  





Cl 	  	   (5.2)	  
We	  believe	  that	  contradicting	  results	  on	  the	  pharmacokinetics	  of	  cefadroxil	  
are	  the	  result	  of	  competing	  saturable	  processes	  such	  as	  active	  tubular	  secretion	  and	  
reabsorption	  in	  the	  kidney,	  and	  PEPT1-­‐mediated	  absorption	  in	  the	  intestine.	  While	  
one	  paper	  describes	  the	  linear	  pharmacokinetics	  of	  cefadroxil	  in	  mice	  after	  oral	  
administration	  of	  the	  antibiotic,	  in	  rats	  and	  humans	  there	  is	  significant	  controversy	  
on	  the	  linearity	  of	  the	  pharmacokinetics	  of	  cefadroxil.	  Granero	  et	  al	  [27]	  showed	  in	  
their	  renal	  excretion	  experiments	  with	  rats,	  that	  the	  clearance	  of	  cefadroxil	  first	  
increases	  with	  an	  increase	  in	  infusion	  rate,	  but	  then	  decreases	  at	  even	  higher	  
infusion	  rates.	  They	  hypothesized,	  that	  the	  initial	  increase	  in	  clearance	  was	  related	  
to	  a	  saturation	  of	  the	  active	  reabsorption	  of	  cefadroxil,	  and	  that	  at	  even	  higher	  doses	  
there	  was	  saturation	  of	  active	  secretion	  mechanisms.	  Several	  years	  later,	  when	  more	  
sophisticated	  molecular	  techniques	  became	  available,	  Shen	  et	  al	  [16]	  demonstrated	  
that	  reabsorption	  of	  cefadroxil	  in	  the	  kidney	  was	  primarily	  dependent	  on	  the	  
peptide	  transporter	  2	  (PEPT2)	  [16,	  28].	  The	  authors	  confirmed	  the	  expression	  of	  
PEPT2	  on	  the	  apical	  membrane	  of	  renal	  epithelial	  cells,	  specifically	  in	  the	  S2	  and	  S3	  
segments	  of	  the	  proximal	  tubules	  of	  kidney	  [28,	  29].	  Their	  experiments	  
demonstrated	  that,	  at	  their	  highest	  dose,	  the	  clearance	  of	  cefadroxil	  in	  wild-­‐type	  
mice	  increased	  due	  to	  saturation	  of	  PEPT2.	  On	  the	  other	  hand,	  in	  their	  PEPT2	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knockout	  mice	  experiments,	  the	  clearance	  of	  cefadroxil	  decreased	  significantly	  with	  
the	  increasing	  dose,	  indicating	  saturation	  of	  active	  secretion	  [16].	  
Another	  strategy	  to	  better	  fit	  the	  observed	  results	  would	  be	  to	  couple	  the	  
ACAT	  model	  to	  a	  physiologically-­‐based	  pharmacokinetic	  model	  (PBPK),	  instead	  of	  
the	  2-­‐compartment	  model	  used	  in	  this	  project.	  The	  PBPK	  model	  allows	  the	  addition	  
of	  saturable	  clearance	  mechanisms	  in	  the	  kidney,	  such	  as	  the	  reabsorption	  and	  
secretion	  by	  PEPT2	  and	  OAT	  transporters,	  respectively.	  Several	  papers	  have	  already	  
shown	  the	  benefit	  of	  coupling	  a	  PBPK	  model	  to	  the	  ACAT	  model	  in	  Gastroplus®.	  
These	  models	  have	  been	  shown	  superior	  at	  predicting	  the	  pharmacokinetics	  of	  
drugs,	  especially	  of	  those	  drugs	  that	  are	  subject	  to	  active	  transport,	  metabolism	  and	  
convoluted	  pharmacokinetics[30,	  31].	  	  
Additionally,	  a	  recent	  publication	  by	  De	  Waart	  et	  al	  [32]	  suggests	  that	  
MRP3/MRP4,	  expressed	  on	  the	  basolateral	  membrane	  of	  the	  enterocytes,	  could	  be	  
involved	  in	  the	  transport	  of	  cefadroxil	  from	  the	  enterocyte	  into	  the	  blood.	  The	  
authors	  show	  that	  the	  in	  vitro	  Km	  values	  of	  these	  transporters	  are	  2.5	  and	  0.25	  mM	  
for	  MRP3/4,	  respectively	  [32].	  Most	  likely,	  the	  concentration	  of	  cefadroxil	  in	  the	  
enterocyte	  is	  higher	  than	  the	  Km	  of	  these	  transporters	  at	  the	  doses	  of	  drug	  
administered.	  This	  means	  that	  these	  transporters	  would	  also	  be	  saturated,	  and	  
increasing	  concentrations	  of	  drug	  would	  not	  have	  an	  effect	  on	  the	  uptake	  velocity	  
and	  transfer	  rate	  into	  the	  blood.	  These	  processes	  could	  be	  a	  rate-­‐limiting	  step	  in	  the	  
absorption	  of	  cefadroxil,	  and	  in	  conjunction	  with	  the	  decrease	  in	  clearance,	  a	  reason	  
why	  we	  are	  unable	  see	  the	  non-­‐linearity	  in	  vivo.	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In	  their	  paper,	  Bolger	  et	  al	  [33]	  use	  different	  PEPT1	  protein	  expression	  
patterns	  in	  the	  human	  gastrointestinal	  tract,	  and	  found	  that	  the	  distribution	  by	  
Herrera-­‐Ruiz	  et	  al	  [34]	  gave	  them	  the	  best	  results.	  Though,	  the	  PEPT1	  distributions	  
used	  by	  the	  authors	  were	  based	  on	  RNA	  levels	  and	  not	  protein	  levels.	  RNA	  levels	  are	  
not	  always	  predictive	  of	  protein	  levels.	  For	  example,	  RT-­‐PCR	  shows	  PEPT1	  RNA	  
expression	  in	  the	  colon	  of	  wild-­‐type	  mice,	  though	  western-­‐blot	  experiments	  show	  
no	  presence	  of	  this	  transporter	  protein	  in	  this	  tissue.	  In	  this	  project	  we	  examined	  
different	  physiological	  distributions	  of	  PEPT1,	  including	  the	  3	  human	  distributions	  
tested	  by	  Bolger	  et	  al,	  and	  mouse	  PEPT1	  protein	  distribution	  from	  our	  lab.	  	  From	  all	  
the	  compared	  distributions	  we	  got	  the	  best	  fits	  with	  the	  distribution	  obtained	  in	  our	  
lab	  for	  mouse	  PEPT1	  protein	  levels.	  	  
In	  conclusion,	  this	  study	  illustrated	  the	  ability	  of	  the	  advanced	  
compartmental	  absorption	  and	  transit	  model,	  of	  GastroPlus®,	  to	  simulate	  the	  
absorption	  and	  pharmacokinetics	  of	  cefadroxil.	  With	  the	  ACAT	  model	  we	  were	  able	  
to	  integrate	  our	  experimental	  data	  and	  simulate	  the	  importance	  of	  the	  intestinal	  
PEPT1	  in	  the	  absorption	  of	  cefadroxil	  in	  mice.	  We	  were	  also	  able	  to	  improve	  our	  
understanding	  of	  the	  physicochemical	  and	  biopharmaceutical	  factors	  that	  affect	  the	  
active	  and	  passive	  absorption	  processes	  of	  PEPT1	  substrates,	  and	  the	  resulting	  
concentration	  versus	  time	  profiles.	  The	  use	  of	  Gastroplus	  also	  revealed	  certain	  
pharmacokinetic	  aspects	  that	  were	  not	  accounted	  for	  during	  our	  previous	  in	  vivo	  
and	  in	  situ	  experiments.	  Though	  we	  are	  pleased	  with	  our	  initial	  modeling	  attempts	  
and	  results,	  we	  believe	  at	  least	  3	  different	  issues	  should	  be	  further	  considered	  in	  
order	  to	  improve	  the	  prediction	  of	  plasma	  concentration-­‐time	  profiles	  in	  wild-­‐type	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mice,	  and	  to	  extrapolate	  the	  results	  to	  humans.	  First,	  a	  physiologically-­‐based	  
pharmacokinetic	  model	  should	  be	  incorporated	  into	  the	  ACAT	  model	  to	  take	  into	  
account	  the	  non-­‐saturable	  elimination	  processes	  in	  the	  kidney.	  Second,	  one	  should	  
also	  consider	  that	  even	  at	  higher	  doses	  the	  concentration	  of	  cefadroxil	  at	  the	  apical	  
membrane	  could	  be	  smaller	  than	  the	  Km,	  due	  to	  the	  radial	  diffusion	  gradient	  of	  the	  
drug	  across	  the	  intestinal	  tube.	  And	  finally,	  one	  should	  also	  take	  into	  account	  that	  a	  
higher	  Km	  would	  reflect	  the	  in	  vivo	  situation	  better	  and	  could	  provide	  better	  
predictions,	  given	  that	  the	  actual	  residence	  time	  of	  the	  drug	  in	  the	  intestine	  is	  longer	  
in	  vivo	  than	  in	  the	  in	  situ	  experiments.	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Figures	  
	  
Figure	  5.1.	  Cefadroxil	  monohydrate	  molecular	  structure.	  










Figure	  5.2.	  Diagram	  of	  the	  ACAT	  model	  used	  for	  the	  simulations	  of	  cefadroxil	  in	  wild-­‐type	  
and	  PEPT1	  knockout	  mice.	  S=	  stomach,	  D=	  duodenum,	  J=	  jejunum,	  I=	  ileum,	  C=	  Ceacum,	  and	  
As	  C	  =	  ascending	  colon.	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Figure	  5.3.	  Parameter	  sensitivity	  analysis	  of	  the	  maximum	  concentration	  (Cmax)	  of	  cefadroxil	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Figure	  5.4.	  Parameter	  sensitivity	  analysis	  for	  the	  area	  under	  the	  plasma	  concentration-­‐time	  























































Figure	  5.5.	  Simulation	  results	  in	  PEPT1	  knockout	  mice	  after	  oral	  administration	  of	  44.5,	  
89.1,	  178	  and	  356	  nmol/g	  of	  cefadroxil	  (Doses	  =	  0.323,	  0.646,	  1.292,	  and	  2.582	  mg,	  































































KO	  Mice	  2.584	  mg	  
 





Figure	  5.6.	  Simulation	  results	  in	  Wild-­‐type	  mice	  after	  oral	  administration	  of	  44.5,	  89.1,	  178	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  2.584	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Figure	  5.7.	  Percent	  of	  cefadroxil	  dose	  absorbed	  in	  different	  segments	  of	  the	  gastrointestinal	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Figure	  5.8.	  Percent	  of	  cefadroxil	  dose	  absorbed	  in	  different	  segments	  of	  the	  gastrointestinal	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Tables	  
	  
NAME	   LOCATION	   SYSTEM	  USED	   REFERENCE	  
PEPT1	   Small	  intestine	  
	  
Kidney	  (proximal	  tubule)	  






PEPT2	   Kidney	  (AP)	  
	  
CSF	  
KO	  mice,	  cells,	  BBMV	  
	  
cells,	  KO	  mice	  
[38]	  [28]	  [16]	  [37]	  
	  
[16,	  28,	  37,	  39,	  40]	  
OAT3	   Kidney	  (BL)	   S2	  cells	  (transfected)	   [24]	  [25,	  26]	  
OAT1	   Kidney	  (BL)	   S2	  cells	  (transfected)	   [24-­‐26]	  
OAT2	  (rat)	   Kidney	  (BL)	   S2	  cells	  (transfected)	   [24,	  25]	  
OAT4	  	   Kidney	  (BL)	   S2	  cells	  (transfected)	   [24,	  25]	  
OATP2	   Liver	  rat	  (BL)	   Oocytes	   [41]	  
MRP3/MRP4	   Intestine	  (BL)	   Oocytes	   [32]	  
Table	  5.1.	  Proteins	  involved	  in	  the	  transport	  of	  cefadroxil.	  
	   	  
 
  161 
	  








Duodenum	   3.8	   8.42	   0.72	  
Jejunum	  1	   9.4	   1.48	   0.92	  
Jejunum	  2	   9.4	   1.48	   0.92	  
Ileum	  1	   3.58	   1.00	   1.00	  
Ileum	  2	   3.58	   1.00	   1.00	  
Ileum	  3	   3.58	   1.00	   1.00	  
Ceacum	   0	   0	   0.02	  
Colon	   0	   0	   0.02	  
Table	  5.2.	  PEPT1	  distributions	  tested	  in	  our	  ACAT	  model.	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PROPERTY	   VALUE	   REFERENCE	  
Intrinsic	  Solubility	  (mg/mL)	  	   17.4	   Tsuji	  1983	  [43]	  
	  
pKa	  (37	  °C)	  	  
Acid	  =	  2.70	  
Base	  =	  7.22	  
Acid	  =	  9.62	  
Tsuji	  1983	  [43]	  and	  1981	  [44]	  
Degradation	  (%/h;	  rat	  intestine)	   2.1	   Tsuji	  1980	  [45]	  
Degradation	  T1/2	  	  (h)	  pH=4	  T=37°C	   5.76	   Mariño	  1982	  [46]	  
Degradation	  T1/2	  	  (h)	  pH=7	  T=37°C	   8.6	   Mariño	  1982[46]	  
Intrinsic	  solubility	  (mg/mL)	  
pH=4.96	  
17.5	   Tsuji	  1983	  [43]	  
LogP	   -­‐2.103	   Estimated	  by	  ADMET	  predictor	  
LogD	  (pH=4.8)	   -­‐2.11	   Estimated	  by	  ADMET	  predictor	  
Table	  5.3.	  Physicochemical	  properties	  of	  cefadroxil	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PROPERTY	   VALUE	   REFERENCE	  
Body	  Weight	  (Kg)	   0.02	   Mice	  
In	  situ	  Km	  transporter	  (mg/L)	   1380	   Perfusion	  Experiments	  
Passive	  Jejunal	  Permeability	  (cm/s)	   0.09*10-­‐4	   Perfusion	  Experiments	  
Fu%	  (mice)	   80	   Shen	  2007	  [16]	  
Blood	  to	  plasma	  ratio	   0.92	   Estimated	  by	  ADMET	  predictor	  
Table	  5.4.	  Input	  parameters	  of	  cefadroxil	  for	  ACAT	  model	  in	  mice.	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PARAMETER	   FITTED	  VALUE	   OPTIMIZED	  VALUE	   FITTED/OPTIMIZED	  
Clearance	  (L/h)	   0.018	   0.018	   1	  
Vc	  (L)	   0.2	   0.09	   2.2	  
K12	  (h-­‐1)	   2.841	   3.2207	   0.88	  
K21(h-­‐1)	   3.954	   4.9757	   0.79	  
Table	  5.5.	  Pharmacokinetic	  parameters	  of	  cefadroxil	  in	  wild-­‐type	  and	  PEPT1	  knockout	  mice	  
after	  intravenous	  administration.	  	  
	   	  
 




AUC0-­‐120	  (μg	  *h/mL)	   Cmax	  (μg/mL)	   R2	  
Observed	   Predicted	   Obs/pred	   Observed	   Predicted	   Obs/pred	  
0.323	   1.0611	   1.0369	   1.023	   0.6211	   0.6456	   0.962	   0.929	  
0.646	   1.69	   2.0739	   0.815	   0.979	   1.2	   0.816	   0.788	  
1.292	   3.8917	   4.1478	   0.938	   2.5097	   2.5824	   0.972	   0.609	  
2.584	   9.0541	   8.2955	   1.091	   5.4159	   5.1648	   1.049	   0.750	  
Table	  5.6.	  Simulation	  results	  in	  PEPT1	  knockout	  mice.	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DOSE	  
(mg)	  
AUC0-­‐120	  (μg	  *h/mL)	   Cmax	  (μg/mL)	   R2	  
Observed	   Predicted	   Obs/pred	   Observed	   Predicted	   Obs/pred	  
0.323	   12.332	   13.376	   0.922	   12.014	   14.562	   0.825	   0.823	  
0.646	   19.91	   25.966	   0.767	   24.144	   25.585	   0.944	   0.793	  
1.292	   36.529	   34.03	   1.073	   42.978	   27.789	   1.547	   0.439	  
2.584	   88.336	   54.045	   1.634	   99.753	   40.618	   2.456	   0.378	  
Table	  5.7.	  Simulation	  results	  in	  wild-­‐type	  mice.	  	  
	   	  
 





%	  OF	  TOTAL	  DOSE	  ABSORBED	  IN	  INTESTINES	  BY	  DIFFERENT	  
PATHWAYS	  IN	  WILD-­‐TYPE	  MICE	  
PASSIVE	  	   PEPT1	  	   PARACELLULAR	  
0.323	   2.3	   97.2	   0.5	  
0.646	   8.0	   91.3	   0.8	  
1.292	   16.9	   81.6	   1.6	  
2.584	   22.8	   75.2	   2.1	  
Table	  5.8.	  Contribution	  of	  different	  pathways	  toward	  the	  absorption	  of	  cefadroxil	  in	  wild-­‐
type	  mice.	  Percent	  is	  based	  on	  total	  dose	  absorbed	  of	  cefadroxil.	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DOSE	  
%	  OF	  TOTAL	  DOSE	  ABSORBED	  IN	  INTESTINES	  BY	  DIFFERENT	  
PATHWAYS	  IN	  PEPT1	  KNOCKOUT	  MICE	  
PASSIVE	  	   PEPT1	  	   PARACELLULAR	  
0.323	   91.2	   0.00	   8.8	  
0.646	   91.2	   0.00	   8.8	  
1.292	   91.2	   0.00	   8.8	  
2.584	   91.2	   0.00	   8.8	  
Table	  5.9.	  Contribution	  of	  different	  pathways	  toward	  the	  absorption	  of	  cefadroxil	  in	  PEPT1	  
knockout	  mice.	  Percent	  is	  based	  on	  total	  dose	  absorbed	  of	  cefadroxil.	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DOSE	   SMALL	  INTESTINAL	  CONCENTRATION	  
(mM)	  #	   (mg)	   (nmol/g)	  
1	   0.323	   44.5	   1.62	  –	  2.23	  
2	   0.646	   89.1	   3.24	  –	  4.41	  
3	   1.292	   178	   6.48	  –	  8.91	  
4	   2.584	   356	   12.96	  –	  17.82	  
Table	  5.10.	  Estimated	  concentrations	  of	  cefadroxil	  in	  the	  small	  intestine	  of	  mice.	  (Assumed	  
small	  intestinal	  volumes	  are	  between	  0.4	  and	  0.6	  mL	  and	  mouse	  body	  weight	  =	  0.02	  kg).	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DOSE	  	   DOSE	  (mg)	   STOMACH	  CONCENTRATION	  (mM)	  
1	   125	   1.38	  
2	   250	   2.75	  
3	   500	   5.51	  
4	   1000	   11.02	  
Table	  5.11.	  Estimated	  concentrations	  of	  cefadroxil	  in	  the	  stomach	  of	  humans	  (Assumed	  
stomach	  volume	  of	  250	  mL).	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AUC0-­‐120	  (hr	   	  µg/mL)	   R2	  Dose	  (mg)	   Observed	   Predicted	   Observed/Predicted	  
0.323	   12.33	   12.32	   1.00	   0.779	  
0.646	   19.91	   24.35	   0.82	   0.904	  
1.292	   36.53	   47.65	   0.77	   0.857	  
2.584	   88.34	   91.5	   0.97	   0.913	  
Cmax	  (µg/mL)	   R2	  Dose	  (mg)	   Observed	   Predicted	   Observed/Predicted	  
0.323	   12.01	   13.48	   0.89	   0.779	  
0.646	   24.14	   26.24	   0.92	   0.904	  
1.292	   42.98	   49.93	   0.86	   0.857	  
2.584	   99.75	   91.7	   1.09	   0.913	  
Tmax	  (hr)	   R2	  Dose	  (mg)	   Observed	   Predicted	   Observed/Predicted	  
0.323	   0.33	   0.29	   1.15	   0.779	  
0.646	   0.25	   0.3	   0.83	   0.904	  
1.292	   0.33	   0.32	   1.04	   0.857	  
2.584	   0.33	   0.35	   0.95	   0.913	  
Table	  5.12.	  Results	  of	  ACAT	  simulation	  in	  wild-­‐type	  mice	  using	  a	  Km	  value	  of	  35	  mM.	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